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Abstract 
During these three years, the research was focused on the preparation of pharmaceutical 
solid oral dosage forms with the aim to improve the dissolution behaviors and 
bioavailability of poor soluble drugs, or preparing sustained release systems for water-
soluble drugs. In order to improve the bioavailability of poor soluble drugs, we adopted 
two strategies: 1) the micronization of the drug to increase their surface area, 2) preparing 
solid dispersions (SDs) using hydrophilic carrier. As known in the SDs the drug is 
dispersed or solubilized in an inert excipient or matrix where the active ingredient could 
exist in finely crystalline or amorphous state. When the system is exposed to aqueous 
media, the carrier dissolved and the drug is released as a very fine colloidal particles. This 
greatly reduction in particles size and the following surface area increase, results in an 
improvement of the dissolution rate. 
In addition to bioavailability enhancement, SDs systems were also directed towards the 
development of extender-release dosage forms using lipophilic carriers. For both the 
formulative approaches, we investigated the application of microwave (MW) and 
supercritical fluids (SCF) as preparative methods. In particular, MW ware employed for 
the preparation of solid dispersion either for immediate or sustained release of drugs, while 
SCF were investigated for the micronization and preparation of solid with the aim to 
prepare immediate release systems. Moreover, were investigated the thermodynamic 
aspect involved in the drug processing developing mathematical approaches able to predict 
the best operative conditions. 
Beside the preparation of these systems the physicochemical characterization of the 
compounds were investigated in order to understand the influence of the above 
technologies on the solid state of the materials. The goal of these behaviors was 
investigated trough the dissolution profile.  
From the obtained results these two technologies can be considered innovative and 
promising way to design particles.  
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1. Introduction 
For over half century, pharmaceutical industries interests have been expressed in 
optimizing drug therapy through the design of delivery system. For many years, this 
orbited around incorporating drugs into polymers, which then acted as carriers for 
controlled release, an approach that has been well studied. Over the last few decades, rapid 
developments of pharmaceutical formulations have occurred in this area gaining in the 
design, development, and commercialization of specific (in house) modified-release drug 
delivery systems. This is an exciting and growing area of pharmaceutical research. 
However, a diverse range of technology approaches is associated with the oral 
administration.  
The oral route of drug delivery is typically considered the preferred and most patient-
convenient means of drug administration. Consequently, much effort is directed during 
drug discovery to identify orally active candidates that will provide reproducible and 
effective plasma concentrations in vivo. Unfortunately, about the 40% of new active 
ingredients, including several powerful lipophilic drugs, are characterized by low water 
solubility and the oral administration of these drugs are frequently associated with low 
bioavailability, and lack of proportional dose-therapeutic effect relationship. 
The Noyes-Whitney equation (Eq. 1-1) provides clear indication of parameters that can be 
modified in order to enhance the dissolution rate of poorly soluble drugs:  
  
  
  
        
 
          Eq. 1-1 
Where dC/dt is the dissolution rate, A is the surface area exposed to dissolution medium, D 
is the diffusion coefficient of the drug in solution, Cs is the solubility of the drug, C is the 
drug concentration in the dissolution medium at time t, and h is the thickness of diffusion 
boundary layer. Several parameters in this equation can be adjusted to achieve the 
enhancement of the dissolution rate. For example, increasing either the surface area or 
diffusion coefficient can lead to a higher dissolution rate. Moreover, enhanced drug 
solubility can generate the same effect and the decrease in diffusion boundary layer 
thickness can result in a faster dissolution rate. 
The absorption of an active pharmaceutical ingredient (API) released from the oral dosage 
form depends on two factors: the dissolution of the API in the gastrointestinal tract and its 
 In
tr
o
d
u
ct
io
n
: 
S
o
li
d
 d
is
p
er
si
o
n
 
 9
 
permeability through the mucosa. Based on these two parameters, drugs have been divided 
in four categories, the so called Biopharmaceutical Classification System (BCS) [1].  
 
 
Figure 1.1:Biopharmaceutical Classification System  
In particular, for the second class of compounds, the dissolution in the gastro-intestinal 
lumen is the limiting step of the absorption process [2].  
For this class, several approaches were proposed in order to increase oral bioavailability, 
such as the micronization of the drug, the co-precipitation with hydrophilic polymers or 
non-electrolytes, the formation of inclusion complexes in cyclodextrines, micelles and 
liposomes, or preparing microemulsions and self-emulsifying systems [3- 5].  
Another approach for improving the solubility / dissolution rate of an active belonging to 
class II employs the simplest technology for conveying the principle active in the presence 
of hydrophilic polymers, by preparing solid dispersions (DSs). 
1.1. Solid dispersion 
Typically, the term “solid dispersion” has been utilized to describe a family of dosage 
forms whereby the drug is homogeneously dispersed in an inert matrix, usually with a view 
for enhancing oral bioavailability. More specifically, in the classic review, these systems 
are defined as “the dispersion of one or more active ingredients in an inert carrier matrix at 
solid-state prepared by the melting, solvent or melting-solvent method”, suggesting the 
definition as being a “product formed by converting a fluid drug-carrier combination to the 
solid state”. 
Practically, the carrier has been a water-soluble [6] or water miscible polymers such as 
polyethylene glycol (PEG) [7] or polyvinylpyrrolidone (PVP) [8-10] or low molecular 
weight materials such as sugars or, more recently, carriers with surface activity such as 
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Gelucire ® [11]. In SDs, drug particle size is reduced or a crystalline pure drug is 
converted into amorphous form carrying to an in improvement of drug solubility and 
dissolution profile. 
The promising results of solid dispersion in term of drug solubility and dissolution rate 
enhancement can be attributed to various issues as followed. 
Amorphous vs. crystalline 
New drug candidates enter in the pharmaceutical development process in a crystalline 
state. This tends to ensure a high level of purity and a thermodynamically stable form. By 
introducing thermal and mechanical process, it is possible to lead to full or partial loss of 
crystallinity forming amorphous or disordered crystalline material. Whereas crystals 
exhibit long-range molecular order, the amorphous substances have no long-range order 
but retain the short-range order that is typical of liquids. Many carriers, for example, exist 
in this form, e.g., Crospovidone, Polyvinylpyrrolidone and poly(methyl metacrylate) . 
From a pharmaceutical perspective, the amorphous state is less thermodynamically stable 
than the crystalline one. Consequently, molecules in the amorphous state generally exhibit 
greater chemical instability, enhanced dissolution rates, altered mechanical properties, and 
greater hygroscopicity. [12, 13].  
Normally, in order to dissolve a crystalline drug, energy is required to break up the 
crystalline lattice. This required energy is often considered as a barrier for the drug 
dissolution. In solid molecular dispersions, long-range crystalline structure is absent and 
the drug is dissolved or molecularly dispersed in a polymeric carrier. Here, the drug exists 
in an amorphous state which exhibits a higher kinetic solubility (up to a few orders of 
magnitude) and dissolution rate than that of the crystalline drug [12-13]. The metastable 
nature of amorphous solids leads to instability as reflected by precipitation and/or 
crystallization. As a result, the level of heat and humidity of storage condition is critical in 
preventing the undesirable amorphous-to-crystalline transition. Elevated temperature and 
higher moisture level give rise to higher molecular mobility in amorphous solids leading to 
the formation of corresponding crystals which are thermodynamically more stable [13, 14].  
Amorphous Molecules can exhibit significant molecular motion over timescales of 
pharmaceutical interest both above and below the glass transition temperature (Tg). The 
glass transition temperature is where an amorphous substance changes from a super-cooled 
liquid with relatively low viscosity to an unstable glass with much greater viscosity. 
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Motion in the form of translational and rotational diffusion, which is essential for any 
physical or chemical process, can generally be described in terms of temperature, viscosity, 
and molecular size. It can occur in seconds at and above Tg to months or years below Tg. 
Enhancement of solubility and wettability of poorly soluble drug 
The enhancement in solubility and dissolution rate of poorly soluble drugs is also related to 
the ability of matrix carrier to improve the local solubility and wettability of the drug. For 
example, Van den Mooter G. et al. [15] reported the effect of hydrophilic carriers PEG 600 
and PVP K30 on the solubility of Temazepam; Ahire, B. R. et al. [16] showed the 
improving in solubility of Nevirapine by solid dispersion techniques using PVP K 30. 
Carriers can improve the solubility and wettability of the drug, they also contribute to the 
stabilization of amorphous state of the drug with or without specific interactions with the 
drug and elevating the Tg of the solid dispersion mixtures.  
 
Among the physical modifications, the preparation of solid dispersions has become one of 
the most active areas of research in the pharmaceutical field. Dispersions obtained through 
a fusion process are often called melts, and those obtained by the solvent method are 
frequently referred to as coprecipitates or coevaporates. On the basis of their fast-release 
mechanisms, [17] the solid dispersions are classified into the following six representative 
types: (a) simple eutectic mixtures, (b) solid solutions, (c) glass suspensions, (d) 
amorphous precipitates in crystalline carriers, (e) compounds or complexes, and (f) 
combinations of some of the previous five types.  
Solid dispersion approach is not only used to improve the dissolution behaviors of poorly 
water soluble drugs, but they also find application to mask the drug substances taste and to 
prepare sustained release systems. 
Some methods frequently used for the preparation of solid dispersions are [18]:  
Melting method [18] 
Sekiguchi et al. [19] were the first to use a melting method that consists of melting the drug 
within the carrier. The melted system was cooled pulverized. In the melting process, the 
molecular mobility of carrier is high enough to change the drug’s incorporation [20]. The 
use of high temperatures, and the fact that several drugs can be degraded by the melting 
process, can be a limitation of this method [21]. 
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Hot stage extrusion [18] 
Recently, hot stage extrusion has gained wide acceptance as a SDs preparative method. 
The hot stage extrusion process is highly dependent on the physicochemical properties of 
the compounds and their miscibility in the molten state. Hot stage extrusion consists of the 
extrusion, at high rotational speed, of the drug and carrier, previously mixed, at melting 
temperature for a short time. 
Extrusion then collected after cooling at room temperature and milled [22, 23]. Moreover, 
it was observed that solid dispersions of itraconazole/Intec SP1 prepared by hot-stage 
extrusion presented itraconazole in a fully glassy state, whereas it was only partially glassy 
in solid dispersions prepared by spray drying [20]. 
Melt agglomeration [18] 
Melt agglomeration allows the preparation of solid dispersions in conventional high shear 
mixers. It is prepared by heating a mixture of the drug, carrier and excipients to a 
temperature within or above the melting range of the carrier [24]. It is also possible to 
produce stable solid dispersions by melt agglomeration in a rotary processor [25]. 
Solvent evaporation method [18] 
The solvent evaporation method consists of the solubilization of the drug and carrier in a 
volatile solvent that is later evaporated [26]. In this method, the thermal decomposition of 
drugs or carriers can be prevented, since organic solvent evaporation occurs at low 
temperature. A basic process of preparing solid dispersions of this type consists of 
dissolving the drug and the polymeric carrier in a common solvent, such as ethanol, 
chloroform, mixture of ethanol and dichloromethane. Normally, the resulting films are 
pulverized and milled [27, 28]. 
Spray-drying [18] 
Spray-drying is one of the most commonly used solvent evaporation procedures in the 
production of solid dispersions. It consists of dissolving or suspending the drug and carrier, 
then spraying it into a stream of heated airflow to remove the solvent [20, 29]. Due to the 
large specific surface area offered by the droplets, the solvent rapidly evaporates and the 
solid dispersion is formed within seconds, which may be fast enough to prevent phase 
separation. Van Drooge et al. [30] prepared an alternative solid dispersion by spraying a 
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povidone and diazepam solution into liquid nitrogen, forming a suspension that was then 
lyophilized.  
Freeze-drying [18] 
This process consists of dissolving the drug and carrier in a common solvent, which is 
immersed in liquid nitrogen until the complete frozen. Then, the frozen solution is further 
lyophilized [30]. An important advantage of freeze drying is that the drug is subjected to 
minimal thermal stress during the formation of the solid dispersion. However, the most 
important advantage of freeze drying is that the risk of phase separation is minimized as 
soon as the solution is vitrified. 
Supercritical fluid method [18] 
Supercritical fluid methods are mostly applied with CO2, which is used either as solvent 
for drug and matrix or as an anti-solvent. This aspect will be deeply discussed in chapter 4. 
Co-precipitation method [18] 
Co-precipitation is a recognized technique for increasing the dissolution of poorly water 
soluble drugs, so as to consequently improve bioavailability. In this method non-solvent is 
added drop wise to the drug and carrier solution, under constant stirring. In the course of 
the non-solvent addition, the drug and carrier are co-precipitated to form micro particles. 
At the end, the resulted micro particle suspension is filtered and dried [10, 31]. The 
required quantity of polymer and the drug were mixed and then solvent was added to 
obtain clear solution. The Solution was first dried under vacuum at room temperature and 
kept inside incubator (310 K) for 12 h. Finally it was passed through sieves [32].  
Dropping method [18] 
A solid dispersion of a melted drug carrier mixture is pipetted and then dropped onto a 
plate, where it solidifies into round particles. The size and shape of the particles can be 
influenced by factors such as the viscosity of the melt and the size of the pipette. The 
dropping method does not use organic solvents and, therefore, has none of the problems 
associated with solvent evaporation. This method also avoids the pulverization, sifting and 
compressibility difficulties [33]. 
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1.2. Particle size reduction 
In the last 30 years, particle size reduction technology turned from an exploratory approach 
into a mature commercial drug delivery platform. From micronisation, that means transfer 
of the coarse drug powder to an ultrafine powder with a mean particle size in the range of 
2-5 µm, the recent technology move to the nanonization where the particle size average 
range between 100-1000 nm [34, 35]. The basic principle of the micronisation, and 
expecially in the nanonization, is to increase the dissolution rate of the drugs by increasing 
their surface area. This process includes the intensive techniques like milling [36], freeze 
drying [37] and spray-drying [38] or recrystallizing the particles from solutions and 
sometimes playing (when possible) on the different polymorphic forms [39- 41]. Problems 
with these last traditional methods include the use of large amounts of solvent, solvent 
residues, broad particle size distributions, as well as a thermal and chemical degradation of 
the products.  
Drug nanoparticles can be produced using different technological approaches: 
 
1.2.1. Bottom up process 
This approach refers to the building up of the nano-sized particles from their molecular 
solutions, and is commonly known as precipitation. By changing the condition of the 
system in solution, the molecules start to precipitate in larger formations.  
Nanoparticls 
Combination technology 
-Bottom up + Top Down 
-Top Down + Top Down  
Bottom up techniques 
- Antisolvent precipitation 
process (classic) 
-Advanced  
-Supercritical  
Chemical reactions 
-Polymerization 
-Synthesis 
Top down techniques 
- Wet ball milling 
- Jet milling 
-HPH 
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1.2.1.1. Antisolvent precipitation process (classic) 
The poorly soluble drug is dissolved in a water miscible organic solvent. The precipitation 
is induced by mixing the drug solution with an aqueous phase [42]. 
Antisolvent precipitation process is a promising technique to prepare ultrafine drug 
particles, which is based on the change of supersaturation caused by mixing the solution 
and the antisolvent [43, 44]. In this method, it requires two solvents that are miscible. 
Ideally, the drug must dissolve in the solvent, but not in the antisolvent. Precipitation 
occurs instantaneously by a rapid desolvation of the drug. The key to producing ultrafine 
particles by antisolvent precipitation is to create conditions that favor very rapid particle 
formation and little or no particle growth. The technique presents some advantages, in that 
it is a straightforward method, rapid and easy to perform. This technique has been 
successfully used to prepare several drugs, such as budesonide [45], danazol [43], 
beclomethasone dipropionate [46] and prednisolone [47].  
However, inhibiting the growth of freshly precipitated particles driven by Ostwald ripening 
is still a problem. The prolonged stabilization can only be achieved by immediate drying 
[48].  
1.2.1.2. Advanced 
One interesting approach is known as Evaporative Precipitation into Aqueous Solution 
(EPAS) [49]. In this process the active compound is dissolved in an organic solvent which 
is not water miscible. The drug solution is sprayed into heater water resulting in an 
immediate evaporation of the organic solvent, thus nanoparticles are instantaneously 
formed. Spray- freezing into liquid (SFL) and ultra-rapid freezing (URF) are alternative 
particle engineering process [50, 51] 
1.2.1.3. Supercritical fluids  
Two fundamentally different principles can be distinguished: either the supercritical fluid 
is used as solvent for the drug or the supercritical fluid is used as antisolvent. The Rapid 
expansion of Supercritical Solutions (RESS) belongs to the first type, which means it can 
be used in case the solute is well soluble in supercritical fluids, like supercritical carbon 
dioxide [52]. The expansion of this supercritical drug solution into an expansion chamber 
results in an extremely fast phase change from the supercritical to the gas-like state. By 
leaving the expansion nozzle, the active compound precipitates due to the loss of solvent 
power. The resulting particles have a very porous structure and are normally amorphous 
due to the fast precipitation. The Supercritical Antisolvent (SAS) process [53] comprises 
 In
tr
o
d
u
ct
io
n
: 
P
ar
ti
cl
e 
si
ze
 r
ed
u
ct
io
n
 
1
6 
 
an organic solvent in which the solute is dissolved. This solution is mixed with a 
supercritical fluid in a special nozzle. The solute, which is in not soluble in the 
supercritical fluids, precipitates and is collected as a fine particle. These technologies will 
be deeply discussed in Chapter 4. 
1.2.2. Chemical reactions 
Chemical reactions, i.e. polymerizations, are one way to produce nanoparticles, however 
they are normally not used for the production of drug nanoparticles consisting of pure 
drug. These techniques are commercially very important e.g. for the production of 
pharmaceutical coating materials in form of latex dispersions. Chemical reactions can also 
be used to manufacture polymeric nanoparticles consisting of a matrix forming polymer in 
which the active compound is embedded. The drug load of such particles is normally 
significantly lower than 100% therefore they have to be distinguished from drug 
nanoparticles produced via standard particle size reduction techniques [54]. 
1.2.3. Top-down approaches 
In this approach large drug particles are break to small nanoparticles. In Wet Ball Milling 
(WBM) [55] a milling chamber is charged with milling media (e.g. zirconium dioxide 
beads, silicium nitride beads, polystyrene beads), aqueous stabilizer/ surfactant solution 
and micronized drug. The moving milling media causes high shear forces and thus attrition 
of the drug particles.  
Jet milling is a process that uses high pressure air to micronize friable, heat-sensitive 
materials into ultra-fine powders. Powder sizes will vary depending on the material and 
application, but typically ranges from 75 to as fine as 1 μm. Often materials are jet milled 
when there are needed finer than 45 microns [56]. 
High-pressure homogenization (HPH) is another very important top-down technology. One 
can distinguish several process types. The first technology that was developed based on 
HPH with a piston-gap homogenizer is a process performed in aqueous media at room 
temperature [57]. During the homogenization step, a coarse suspension is forced through a 
very tiny homogenization gap. Cavitation forces, shear forces, and particle collision mainly 
cause the particle size reduction.  
A high shear process using jet stream homogenizers can also generate drug nanoparticles. 
In this case, the collision of two fluid streams under high pressures up to 1,700 bar leads to 
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particle collision, shear forces and cavitation forces. To preserve the particle size, 
stabilization with phospholipids or other surfactants and stabilizers is required. 
1.2.4. Combination technology 
The combinative approach describes a process where at least two different particle size 
reduction principles are combined. The most common combination is a bottom-up process 
which is combined with a top-down step. 
The first combinative approach shows the microprecipitation as bottom-up step with high 
pressure homogenization [58]. Hereby the active pharmaceutical ingredient (API) is at first 
dissolved in an organic solvent. This solution is then mixed with an aqueous phase, 
resulting in a precipitation of preferably friable crystals. The following high pressure 
homogenization step breaks these particles. The organic solvent has to be carefully 
removed from the nanosuspension otherwise it will act as a kind of cosolvent resulting in 
particle growth. A further development of the combination technologies is the separation 
of the bottom-up step and the following top down step. One approach is the combination of 
non-aqueous spray drying as bottom up step followed by high pressure homogenization. 
Due to the modification of the starting material, the following high pressure 
homogenization is much more effective than the conventional HPH process using 
micronized API as starting material. With only a few homogenization cycles, a 
nanosuspension with a very small mean particle size and a narrow particle size distribution 
can be obtained [59]. The most effective combination technology is the combination of a 
non-aqueous freeze-drying process (bottom-up) with high pressure homogenization (top-
down). Drug nanoparticles significantly smaller than 100 nm have been produced with this 
technology [60]. 
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2. Aim of the research 
The objectives of this study are to consider the development and feasibility of two 
innovative technologies such as microwave irradiations and supercritical fluids either for 
solid dispersion preparation or for drug micronisation.  
The topics covered in these three years of research were: 
 Applicability studies of microwave irradiation to develop drug- carrier solid 
dispersion either for immediate or sustained release.  
 Thermodynamic approach to study the solubility of pharmaceutical compounds in 
supercritical fluids  
 Affinity studies for polymer with organic solvents, pharmaceutical compounds or 
supercritical CO2.  
 Thermodynamic issues involved during the precipitation of active compounds during 
the supercritical antisolvent process (SAS) 
 Examination and controls of particle sizes in the near critical and supercritical 
regions.  
 Applicability of SAS technique to micronize drug particles  
 Application of SAS technique for the preparation of solid dispersions 
The objectives and results of the above points will be discussed in the next two chapters 
concerning the application of microwave and supercritical fluids, respectively. 
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3. Generality of Microwave 
irradiation  
 
Microwave irradiation is a form of electromagnetic energy, which falls at the lower end of 
the electromagnet spectrum and is defined in a measurement of frequency as 300 to 
300,000 MHz corresponding to wavelengths of 1 cm to 1 m [61].  
 
Figure 3.1: Range of frequency of electromagnetic radiation 
 
Wavelengths between 1 cm and 25 cm are extensively used for RADAR transmissions and 
remaining wavelength range is used for telecommunications. 
Usually, the heating has been permitted trough conduction with an external heat source 
where the temperature is elevated because of ∆T and heat is driven into the substance, 
passing first through the wall of the vessel in order to reach the solvent and reactants 
(Figure 3.2a). This is a slow method for transferring energy into the system, because it 
depends on the thermal conductivity of the various materials that must be penetrated. It 
results even in a higher external temperature than the final internal temperature, which is 
problematic as the required internal temperature can only be reached by sufficiently 
increasing the surface temperature of the material over the desired temperature [62]. 
The fundamental mechanism of microwave heating involves agitation of polar molecules 
or ions that fluctuate under the effect of an oscillating electric or magnetic field (Figure 
3.2b). 
The energy in microwave photons is very low relative to the energy required for molecular 
bonding. The typical oxygen, hydrogen-oxygen or carbon-carbon bond falls in the range of 
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80-120 kcal/mol: microwave energy is an order of less magnitude. Thus, microwaves will 
not affect molecular structure. In the excitation of molecules, the effect of microwave 
absorption is purely kinetic [63]. 
In the presence of electric and magnetic fields, particles try to orient themselves becoming 
in phase with their. Nevertheless, the motions of these molecules are limited by resisting 
forces such as inter-particle interaction and electric resistances. 
 
Figure 3.2: Working mechanism of Microwave heating: a)Schematic of sample heating by conduction: 
Temperature on outside surface is in excess of boiling point of liquid, b) Schematic of sample heating by 
microwaves, c) Dipole rotation: Microwave electric field interaction with Water molecule, d) Ionic 
conduction. Figure taken from [62]  
 
Only materials that absorb microwave radiation are relevant to microwave chemistry. 
Based on their response to microwaves, they can be mainly classified as:  
 Transparent 
 Reflectent 
 Absorbent  
These materials can be categorized according to the three main mechanisms of heating as: 
 Dipolar polarization  
 Conduction mechanism  
 Interfacial polarization.  
Dipolar polarization mechanism [64] 
It is a process in which the heat is generated in polar molecules. These molecules subjected 
to an appropriate frequency oscillating electromagnetic field try to follow the field and 
align themselves in phase. However, owing to inter-molecular forces, polar molecules 
experience inertia are unable to follow the field and the resulting random motion generate 
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heat. Dipolar polarization can generate heat by either one or both the following 
mechanisms: 
1. Interaction between polar solvent molecules (water, ethanol, methanol, etc.) 
2. Interaction between polar structure molecules (hydrophilic polymer or carriers, 
etc.) 
The requirement for the dipolar polarization is that the frequency range of oscillating field 
should be appropriate to enable adequate inter-particle interaction. If the frequency range is 
very high, the inter-molecular forces stop the motion of polar molecules before their tries 
to follow the field, resulting in an inadequate inter-particle interaction. On the other hand, 
if the frequency is low, the polar molecules have sufficient time to align themselves in 
phase with the field. Therefore, no random interactions take place between the contiguous 
particles. The frequency in the range of 0.3-30 GHz is able to oscillate polar molecules 
promoting the inter-particles interaction. Furthermore, the microwave photon energy is 
very low (0.037 kcal
.
mol
-1
) to break a molecular bond (80-120 kcal
.
mol
-1
) and this does not 
affect the structure of an organic molecule and the interaction is purely kinetic based. 
Conduction mechanism [64] 
Where the irradiated sample is an electrical conductor, the charge carriers (electrons, ions, 
etc) are moved through the material under the influence of the electric field, resulting in a 
polarization. These induced currents will cause heating in the sample due to any electrical 
resistance. For a very good conductor, complete polarization may be achieved in 
approximately 10
-18
 seconds, indicating that under the influence of a 2.45GHz microwave, 
the conducting electrons move precisely in phase with the field. 
If the sample is too conducting, such as a metal, most of the microwave energy does not 
penetrate the surface of the material, but is reflected. However, the colossal surface 
voltages which may still be induced are responsible for the arcing that is observed from 
metals under microwave radiation 
Thus, if one takes pure water and heats it in a microwave oven, where the polarization 
mechanism dominates, we find that the heating rate is significantly less than when one 
takes the same volume of water and add salt. In the latter case, both mechanisms occur, 
and contribute to the heating effect. 
Interfacial polarization [64] 
This mechanism can be considered as a combination of the conduction and dipolar 
polarization effects. It is important for heating systems that comprise a conducting material 
dispersed in a non-conducting material. For example, considering the dispersion of metal 
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particles in sulphur in which this last does not respond to microwaves, and metals reflect 
most of the microwave energy, the combination of these two makes them a good 
microwave-absorbing material. However, to make it possible, the metal must be in form of 
powder, this because the metal powder is a good absorber of microwave radiation. 
Absorbing radiations it heated by a mechanism similar to the dipolar polarization. The 
environment of the metal powder acts as a solvent for polar molecules and restricts the 
motion of ions by forces that are equivalent to inter particles interactions in polar solvents. 
These restricting forces, under the effect of an oscillating field, induce a phase lag in the 
motion of ions. 
3.1. Modes [64] 
When microwaves enter a cavity, the walls reflect them. The reflections of the waves 
generate a three dimensional stationary pattern of standing waves within the cavity, called 
modes. 
Microwave chemistry apparatus can be classified as Single-mode apparatus and Multi-
mode apparatus.  
3.1.1. Single-mode apparatus 
These apparatus are able to create a standing wave pattern that is generated by the 
interference of fields that have the same amplitude but different oscillating directions. This 
interference generates an array of nodes where microwave energy intensity is zero, and an 
array of antinodes where the magnitude of microwave energy is at its highest (Figure 3.3). 
 
Figure 3.3: Generation of a Standing Wave Pattern [65] 
The factor that governs the design of a single-mode apparatus is the distance of the sample 
from the magnetron (high-powered vacuum tube that generates microwaves using the 
interaction of a stream of electrons with a magnetic field). This distance should be 
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appropriate to ensure that the sample is placed at the antinodes of the standing 
electromagnetic wave pattern (Figure 3.4) 
 
Figure 3.4: Single-mode Heating Apparatus [66] 
3.1.2. Multi-mode apparatus 
These apparatus correspond to the typical domestic microwave oven in which the cavity is 
designed to have three-six different modes intended to provide a uniform heating pattern. 
The goal is to generate as much chaos as possible inside the apparatus. The greater the 
chaos, the higher is the dispersion of radiation, which increases the area that can cause 
effective heating inside the apparatus (Figure 3.5).  
 
Figure 3.5: Multi-mode Heating Apparatus [67] 
3.2. Microwave advantages 
Microwave include following advantages, over the conventional heating [68].  
 Uniform heating occurs throughout the material as opposed to surface and 
conventional heating process. 
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 High process speed  
 Decreasing of floor space requirements 
 Better and more rapid process control  
 Efficiency and decreasing of operating cost 
 High efficiency of heating 
 Reduction in unwanted side reaction (reaction Quenching) 
 Purity in final product  
 Improve reproducibility  
 Reduce wastage of heating reaction vessel  
 Selective heating i.e. heating selectively one reaction component.  
 Super heating: conventional heating is done from outside, therefore the core of 
solvent may be as much as 5 K cooler than the edge, while in microwave, the core 
is 5 K hotter than the outside, because of surface cooling, therefore in microwave, 
we can raise the boiling point of solvent by as much as 5 K, an effect is known as 
super heating. 
3.3. Microwave applications 
In the last decade microwave irradiation has become very attractive in chemical fields 
offering various applications.  
3.3.1. Microwave assists drug extraction 
The use of microwave oven for organic extraction enhances the level of preparation 
samples. Shrishailappa et al [69], developed microwave assisted extraction technique to 
optimize the extraction of mucilages and pectins from several commonly used plant 
sources such as Fenugreek, Drum Stick, Asparagus, Mustard, Guava, Orange-peel and 
mango. Mattina et al. [70], have applied Microwave assisted extraction to obtain taxanes 
from Taxus biomass. It is now possible to speed up extraction, reduce costs, boost 
effectiveness, consistency and simplicity of reactions. 
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Figure 3.6: Microwave extractor apparatus [71] 
3.3.2. Microwave digestion 
Microwave digestion is one of the standard preparation methods for elemental 
determination in analytical chemistry. In closed transparent pressurized vessel the samples 
are heated together with a suitable acid solution to temperatures between 473 K and 533 K 
so that the sample is completely degraded and dissolved. The advantage is the speed of 
heating of both sample and acid solution [72]. 
 
Figure 3.7: Microwave digester apparatus [73] 
3.3.3.  Microwave in chemistry synthesis 
The application of microwave irradiation has allowed running reactions faster than ever 
before, with higher yields and reliably from milligrams to much larger quantities, without 
the need of reaction re-optimization [74, 75].  
Kidwai et al. have shown microwaves to be effective in the synthesis of the novel 
antibacterial β- lactams, quinolines and cephalosporin [76- 78].  
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Baxendale & Ley [79] have discovered the convenient and efficient microwave synthesis 
of the well-known drug sildenafil (ViagraTM). Also microwave technology has been 
applied for the synthesis of inhibitors of malerial proteases plasmepsin I and II (PlmI and 
PlmII, respectively) [80, 81]. 
Ashraf et al. [82] have discovered that microwave irradiation can be used as a facile and 
general method for the synthesis of a variety of triazoloquinazolinones and 
benzimidazoquinazolinones. 
 
Figure 3.8: Microwave apparatus for organic synthesis 
Sometimes, chemical reactions need the use of solvents either to solubilize the solutes or to 
precipitate them. All the solvents can be used during the microwave irradiation but 
particular attention must be paid to their different interaction with the microwave that 
depends from their dielectric properties. When a solvent interacts with microwave 
radiation, the solvent can absorb microwave energy and converts it into heat. Moreover, 
the interaction is also dependent upon the viscosity of the solvent.  
3.3.4. Microwavein drying  
In the recent years, the use of microwave irradiation as a dryer technology has gained a 
good interest. When moist material is subjected to microwave that selectively excite the 
polar molecules and ions it chooses their alignment with rapidly alternating electric field. 
The frictional heat generated as a result of these rapid molecular rotations promotes 
evaporation of water [83] 
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Figure 3.9: Microwave dryer apparatus [84] 
3.3.5. Microwave in pharmaceutical dosage forms development 
The main advantage of not using organic solvents is the absence of any risk originating 
from residual solvents [85]. In addition, to the applications previously seen, the microwave 
energy has been employed to change the crystalline state of a drug, instead of conventional 
heating. Xianhong et al., [86] used microwave to obtain an inclusion complex of carvedilol 
and b-cyclodextrin with the aim to improve the dissolution properties of this poor soluble 
drug.  
Recently, Kerc et al. [87], Bergese et al. [88], and Moneghini et al. [89] have explored the 
usefulness of microwave as the alternative mode of preparation for solid dispersion. Kerc 
et al. [87] describe the method in which physical mixture of both Felodipine drug and 
porous amorphous silicon dioxide carrier is subjected to microwave treatment at 500 W for 
different times (between 5 and 15 min) showing the better drug release for the samples 
subjected to microwave irradiation for a longer time. The drug release propensity of 
microwave-treated mixture is greatly higher than those of pure drug and physical mixtures 
treated by vacuum at 373 K, or obtained using solvent deposition method. These 
observations are ascribed to the reduction of drug crystallinity following its treatment by 
microwave.  
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In order to improve solubility of class II drugs, Bergese et al [88], employed β- 
cyclodextrin and PVP CL M as carriers, attesting a reduction in residual crystallinity. β- 
cyclodextrin was used because instantaneously reaches a resonant state with the MW field, 
while in the case of PVP CLM electrothermal coupling probably occurs via the adsorbed 
water, that has a high mobility similar to that of bulk pure water.  
Similarly Moneghini et al. [89] prepared microwave activated solid dispersion systems in 
different ratios of Ibuprofen to PVP/VA 64 or HP-β-CD by irradiating these physical 
mixtures to microwave at 600 W for 6 and 15 min. 
 
In this thesis, the microwave technology saw its application either to increase the in vitro 
bioavailability of two poor soluble drug as Nimesulide and Itraconazole and to retard the 
release of Ibuprofen.  
Particular attention was withal gave to the carrier selection favoring the homogeneously 
dispersion and solubilization of the drug in it. For this purpose, the carriers were 
characterized by a low melting point and functional groups able to establish specific 
chemical interaction with the drug molecules.  
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3.4. Active pharmaceutical ingredients (API) for SDs 
microwave approach  
3.4.1. Poorly soluble drugs 
Nimesulide 
Nimesulide (NMS) is a poorly soluble nonsteroidal anti-inflammatory drug (0.01 mg
.
mL
-1
) 
chemically defined as 4-nitro-2-phenoxymethane-sulfonanilide. Nimesulide is a relatively 
COX-2 selective, causing relatively low occurrence of gastrointestinal injury [90]. The 
approved indications for this drug are the treatment of acute pain and the symptomatic 
treatment of osteoarthritis and primary dysmenorrhea in adults and in adolescents above 12 
years of age [91]. This drug has acidic properties, thus it can form salts with inorganic or 
organic bases, but due to the relatively high pKa of 6.5, a substantial solubility can be 
reach only at very high pH values.  
Nimesulide appears as a very fine odorless whitish crystalline powder, that melts at about 
423 K.  
Itraconazole 
Itraconazole (IT) is a weakly basic triazole antifungal agent indicated in the treatment of 
both local and systemic fungal infections. Successful treatment of infections is often 
complicated by its low aqueous solubility resulting in variable absorption and plasma 
concentration [92, 93]. IT is classified as a BCS class II compound [1], it has a strongly pH 
dependent solubility (pKa ∼ 3.7) with reported solubility in acidic and neutral media of 
approximately 4 μg.mL-1 and 1 ng.mL-1 respectively. While, limited by poor aqueous 
solubility, the highly lipophilic nature of the compound (C log P = 6.2) allows for high 
permeability of intestinal membranes [94]. 
IT pharmacokinetics has also been shown to be strongly affected by several factors 
including dose, diet and disease state, further complicating treatment. The dose dependent 
pharmacokinetics of IT have been well reported in the literature for both animal models 
[95] and human subjects [96], with higher doses providing non-dose proportional increases 
in bioavailability. moreover, administration of IT capsules in the fasted state [96] or with 
neutralizing agents such as antacids [97] has been shown to negatively affect 
bioavailability, while administration in conjunction with acidic beverages such as Coca-
Cola has resulted in improved blood levels due to the pH dependent solubility of IT [98]. 
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Itraconazole appears as white fine odorless crystalline powder, it is photosensitive. Its 
melting point is at about 443 K.  
3.4.2. Slightly soluble drug 
Ibuprofen  
Ibuprofen (IBU) is a non-steroidal anti-inflammatory drug, chemically noted as 2-(4-
isobutylphenyl)-propionic acid. At lower doses (0.6-1.2 g per day) ibuprofen is well suited 
for the treatment of fever, pain, migraine and dysmenorrhea. Effective treatment of chronic 
painful arthritic conditions requires daily doses between 1.6 and 2.4 g. Using conventional 
formulations Ibuprofen is rapidly and well absorbed (>98 %) and peak serum 
concentrations occurring within 1-2 h [99]. A part of drug is distributed in the tissues and 
in the synovial spaces where it reach high permanent concentrations. Food assumption can 
reduce the absorption velocity, but this does not alter its bioavailability. Ibuprofen has a 
short biological half-life of 1.4-2.6 h and successfully it goes towards biotransformation at 
hepatic level within metabolites formation conjugated with glucuronic acid that are 
eliminated by the renal route [100]. 
IBU is a white crystalline powder with a characteristic odor, which melts at about 349 K. 
Its pKa is 4.43. Ibuprofen is slightly soluble in water (<1 mg
.
mL
-1
) soluble in alcohols, 
acetone, ethyl ether and dichloromethane.  
3.4.3. Preparation method 
3.4.3.1. Physical mixtures preparations 
Different drug : polymer weighing ratios were gently mixing for 3 min in a beaker 
obtaining the so called physical mixtures (PMs). 
3.4.3.2. Solid dispersion preparations 
A fixed amount of each physical mixture (i.e., 1 g) was subjected to MW for 10 min at the 
chosen power of 600 W in a domestic microwave oven (model CE297DN – Samsung, 
Surrey, England). Only one beaker at a time was placed inside the microwave oven in a 
precise place, determined using a luminous antenna, which lit up when irradiated by MW. 
Times and powers of irradiation were selected on the basis of the following parameters: 
  Melting point of the single components 
 Final sample  
 Workability after cooling 
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At the end of the irradiation process, the liquid homogeneous samples were subsequently 
cooled at room temperature and pulverized using an analytical mill for few seconds (model 
A10 Janke & Kunkel IKA Labortechnik, Staufen, Germany) in order to obtain the SDs as 
easy-to-handle powders. Particle size fractions were selected by sieving for the 
successfully physicochemical analysis. 
3.4.4. Physicochemical characterizations  
The microwave influence on the drug solid state was evaluated comparing the binary SDs 
with the PMs. Furthermore, also the alone treated materials were compared with the raw 
ones.  
3.4.4.1. Differential scanning calorimetry (DSC) 
Temperature (Tfus) and enthalpy of fusion (ΔHfus) are determined with a DSC mod. TA 
4000 (Mettler, Greifensee, Switzerland), equipped by a measuring cell DSC 20. Samples, 
containing a fixed amount of drugs, are placed in pierced aluminum crucible and heated 
under air at a scanning rate of 10 K min
-1
 from 303.15 up to 30 K than the drugs melting 
temperature. 
3.4.4.2. Hot stage microscopy (HSM) 
Microscopic observations of morphological features and changes during heating in the 
samples were monitored performing hot stage microscopy studies. A hot plate (FP 52 
Mettler, Greifensee, Swiss), connected to a temperature controller (FP 5 Mettler, 
Greifensee, Swiss) was used. Each sample was placed on a glass slide and heated at 10 K 
min
-1
 in the temperature range 303.15 up to 30 K than the drug melting point. The 
behaviour of the samples was observed via an optical microscope (Reichert Biovar, Wien, 
Austria) at a (magnification of 100 x). 
3.4.4.3. Powder X-ray diffraction studies (PXRD) 
Powder x-ray diffraction studies data were obtained using a STOE  D500 (Siemens, 
Munich, Germany) diffractometer with Cu Ka radiation (λ= 1.5418 Å), monochromatized 
by a secondary flat graphite crystal. The scanning angle ranged from 3–40° of 2θ, the steps 
were 0.05° of 2θ, and the counting time was 5 s for each step. The current used was 20 mA 
and the voltage 40 kV.  
A profile fitting, based on Marquardt nonlinear least squares algorithm [101], was 
subsequently applied to selected data ranges, allowing the elimination of background 
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contributions and the separation of overlapping diffraction maxima. The values of 
diffracted intensity and full width at half maximum (FWHM) for each peak were taken 
from the fitted profiles to estimate the average crystallite size by means of Scherrer’s 
equation:  
  
  
     
          Eq. 3-1 
where D is the mean crystallite dimension, K is the shape factor with a typical value of 0.9, 
l is the x-ray wavelength, b is the line broadening value at the FWHM in radians and q is 
the Bragg angle. Drug crystallite size were calculated considering single peaks. 
3.4.4.4. Diffuse reflectance infrared Fourier transform spectroscopy (DRIFT) 
Diffuse reflectance infrared Fourier transform spectra were obtained using a Fourier 
transform (FT-IR) spectrometer (FT-IR 300 Jasco, Tokyo, Japan) and dispersed in KBr. 
Averages of 20 scans for each sample were collected at 4 cm
-1
 resolution in the range 
4000–400 cm-1. 
3.4.4.5. Solubility studies  
Drug solubility was measured in oversaturated conditions (C > 10 Cs), dispersing a 
weighted amount of drug or binary system (PMs and SDs) in 20 ml of opportune simulated 
gastrointestinal fluids (pH 1.2 or 7.4). The suspensions were stirred under constant speed at 
310 ± 0.5 K for 48 h (appropriate time for equilibration), filtered through a membrane 
(pore size 0.45 μm) and then assayed spectrophotometrically (Biochrom model Libra S12, 
UK). The composition of the simulated gastric fluid was 0.2 M NaCl/0.2 M HCl (pH 1.2) 
while the one at pH 7.4 was 0.2 M KH2PO4/0.2 M NaOH according to USP 32. The 
experimental values were the average of three replicates and standard deviation did not 
exceed 3% of the mean value.  
3.4.4.6. Determination of drug dissolution  
Drug release profiles were obtained according to the USP 32 paddle method: 100 rpm, 900 
ml of opportune simulated gastrointestinal fluid, T = 310±0.1 K, sink conditions (C < 0.2 
Cs). The aqueous solution was filtered (0.45 μm porosity) and continuously pumped to a 
flow cell in a spectrophotometer where absorbencies were recorded. Experimental points 
were the average of at least three replicates, and standard deviations did not exceed 5% of 
mean value. Dissolution profiles of SDs were compared with those of the raw drug and 
PMs, under the same experimental conditions. 
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3.5. Nimesulide MW solid dispersions 
3.5.1. Materials  
Nimesulide (NMS) was purchased by Galeno (Italy). The carriers used for the binary 
systems were Gelucire 50/13 and Lutrol F 68 provided by Gattefossé (France) and BASF 
(Germany), respectively. 
As known, Gelucire 50/13 is a semisolid excipient composed of fatty acid (C16 and C18) 
esters of glycerol, PEG esters and free PEG. It melts at approximately 50 °C and has a 
hydrophilic–lipophilic balance (HLB) value of 13 [11]. 
Lutrol F 68, also known as Poloxamer 188, is a nonionic polyoxyethylene–
polyoxypropylene block copolymer (HO(C2H4O)a (C3H6O)b(C2H4O)aH, where a=80 and 
b=27), is widely used as wetting and solubilizing agent, hydrophilic binder in the melt 
granulation. The polyoxyethylene segment of the Lutrol is relatively hydrophilic, while the 
polyoxypropylene segment is relatively hydrophobic. It melts at approximately 55 °C and 
has a hydrophilic– lipophilic balance (HLB) value of 29 [102, 103]. 
All the chemicals were of reagent grade. 
3.5.2. Binary systems preparations 
Nimesulide solid dispersions using Gelucire 50/13 and Lutrol F68 as carriers were 
prepared with the aim to improve its solubility and dissolution performance. 
SDs were prepared as mentioned in section 3.4.3.2, irradiating the binary mixtures 
containing Gelucire 50/13 and Lutrol F 68 for 15 and 9 min at 600 W, respectively. 
The considered drug : polymer ratios were of 1:1, 1:2 and 1:3 w/w. 
Afterward, the Nimesulide binary systems were characterized as reported in section 3.4.4. 
3.5.3. Results and discussions 
The influence of microwave irradiation was initially evaluated on the starting materials, 
where, from the low melting point of the single carriers, after only 3 min of treatment at 
600 W, a homogeneous melted mass was obtained. The drug after 30 min did not show a 
visual change.  
In all the SDs a homogeneous melted mass was obtained after 15 min and 9 min with 
Gelucire 50/13 and Lutrol F 68 respectivelly. The spectrophotometric evaluation of the 
drug content in these SD systems revealed a percentage of NMS of 98-101%. 
HSM is often combined with DSC to characterize the solid state of the drug in solid 
dispersions. The starting NMS at room temperature (r.t.) appeared as seed crystals that 
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completely melted at about 423 K. After MW treatment a particle reduction was observed 
at r.t. accompanied by a decrease in melting temperature. Gelucire 50/13 and Lutrol F 68 in 
their natural state completely change to liquid at about 318 and 338 K, respectively. At r.t., 
in all PMs the single starting materials were already recognizable while after heating and 
consequent melting of carriers, NMS gradually solubilized in these and, at about 423 K, a 
homogenous liquid mass was observed. Instead SDs at r.t. appeared as homogeneous 
particles where the single materials were difficult to distinguish. During program heating, 
at around 413 K they changed to liquid. This phenomenon could be ascribed to an 
interaction between components Figure 3.10. 
1 
 
2 
 
3 
 
4 
 
Figure 3.10: 1) HSM microphotographs of PM NMS:Gelucire 50/13 1:1 w/w at: 303 K a), 323 K b), 403 K 
c), 421 K d); 2) SD NMS:Gelucire 50/13 1:3 w/w at: 303 K a), 323 K b), 353 K c), 403 K d); 3) PM 
NMS:Lutrol F68 1:1 w/w at: 303 K a), 323 K b), 353 K c), 421 K d); 4) SD NMS:Lutrol F68 1:3 w/w  at: 
303 K a), 323 K b), 353 K c), 403 K d). 
DSC analysis was employed to evaluate the phase of transformation during the formation 
of solid dispersions. As reported in Figure 3.11 the starting Nimesulide shows a melting 
peak of 422 K with an enthalpy of fusion (ΔHfus) of 34.932 kJ
.
mol
-1
; after MW treatment at 
600 W for 30 min, only a slight shift in the melting point was observed, associated to a 
reduction in particle size in accordance with HSM analysis. DSC thermogram of starting 
Gelucire 50/13 showed an endothermic peak at 317 K with ΔHfus of 148.8 kJ
.
mol
-1
. After 
treatment the thermogram showed two endothermic peaks at 311.05 and 320.65 K 
b 
d c 
a 
c 
b a 
d 
a b 
c d 
a b 
c d 
 G
en
er
al
it
y
 o
f 
M
ic
ro
w
av
e 
ir
ra
d
ia
ti
o
n
: 
N
im
es
u
li
d
e 
M
W
 s
o
li
d
 d
is
p
er
si
o
n
s 
3
 5
 
associated with the formation of individual polymorph as reported from literature Figure 
3.11 [104]. Thermogram of Lutol F 68 before and after MW treatment showed only a slight 
decrease in melting from 327 to 326 K attesting a reduction in particle size Figure 3.11. 
 
Figure 3.11: DSC thermograms of treated and untreated starting materials 
In thermal profile of both PMs 1:1 w/w a little endothermic peak corresponding to the 
melting of NMS was recognized. In the other PMs the melting point of Nimesulide was 
hardly detectable. This phenomenon can be ascribed to the dissolution of the drug in the 
melted carriers during program heating.  
The same observations can be applied to DSC thermograms of all SDs, where the melting 
point of the drug wasn't detectable (Figure 3.12).  
Thus, the crystalline drug could not be detected with DSC in these systems and must be 
used in combination with PXRD analysis.  
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Figure 3.12: DSC thermograms of binary systems 
Figure 3.13 reports the powder X-ray diffractograms of starting materials untreated and 
treated by means of microwave irradiation. The diffractograms of the Lutrol F 68 before 
and after treatment attested that no modifications occurred after treatment while, the 
pattern of Gelucire 50/13, revealed that a polymorphism occurred after MW irradiation in 
accordance with previous DSC data. Starting NMS exhibits a strong and characteristics X-
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ray powder diffraction pattern, showing the crystalline nature of the powder. According to 
literature [105], NMS showed five typical peaks at 5.39,10.71,12.03,19.40 and 21.68° of 
2θ. After MW treatment were observed only little variations in the intensity of the signals 
ascribed to a reduction in crystallite size. 
 
Figure 3.13: Powder X-Ray patterns of starting materials 
The PXRD patterns of Nimesulide binary systems processed by microwave irradiations 
showed that the drug was in an amorphous state in the NMS:Gelucire 50/13 1:2, 1:3 w/w 
and NMS:Lutrol F 68 1:3 w/w. In the other SD systems the drug was present in 
nanocrystalline form (Figure 3.14).In all PM systems, the drug was still in a crystalline 
state and the PXRD signals corresponded to that of the starting drug.  
 G
en
er
al
it
y
 o
f 
M
ic
ro
w
av
e 
ir
ra
d
ia
ti
o
n
: 
N
im
es
u
li
d
e 
M
W
 s
o
li
d
 d
is
p
er
si
o
n
s 
3
8 
 
 
 
 
Figure 3.14: PXRD patterns of Nimesulide Binary systems  
The physical stability of microwave activated systems was confirmed after storage for 6 
months (Figure 3.15).  
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Figure 3.15: PXRD patterns of treated binary systems either with Lutrol or Glucire 50/13 in the ratio of 1:3 
w/w and 1:2 w/w, respectively. 
For successive analysis, the SD NMS:Gelucire 50/13 1:3 w/w was omitted because the 
drug was just in amorphous state in the ratio of 1:2 w/w. 
To evaluate the improving of in vitro dissolution rate of Nimesulide binary systems 
obtained by means of microwave irradiation, SDs profiles with both carriers were 
compared to those of pure drug and their corresponding physical mixtures (Figure 3.16).  
All the performed SD formulations showed a remarkable enhancement of the in vitro drug 
dissolution rate. In particular, SD NMS:Gelucire 50/13 1:2 w/w was able to reach 90% of 
the drug in solution within 13 min, while at the same time only 74% of the drug was 
released from its physical mixture. The corresponding percentage of the pure drug was 
only 18%. This behavior can be explained by a conversion of NMS into an amorphous 
state in the SDs (Figure 3.16 a). 
The greatest enhancement in NMS dissolution was achieved from SD NMS:Lutrol F 68 
1:3 w/w that produced 90% of the drug solution within 1.30 min, while at the same time 
only 6% of the drug was released from the corresponding PM (Figure 3.16 b). 
An increased dissolution rate was also observed from all the other SD systems, although 
these performances were considerably lower than those above mentioned. This result could 
be explained by the microcrystalline state of the drug. The dissolution profiles of 6 months 
storage SDs were very similar to freshly prepared ones. 
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Figure 3.16: Dissolution rate of Nimesulide considered systems at pH 7.4 and 100 rpm (CV < 3 %) 
 
From the dissolution behavior can be attested the importance in using surfactant carriers to 
achieve a highest degree of bioavailability for poorly soluble drug such as NMS and to 
stabilize the MW solid dispersions, avoiding drug recrystallization. 
  
a 
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3.6. Itraconazole MW solid dispersions 
3.6.1. Materials 
Itraconazole was purchased from Sigma-Aldrich (Germany). The carrier selected for the 
preparation of its binary systems was Vitamin E TPGS supplied by Eastman Chemical 
(USA).  
Vitamin E TPGS (TPGS) is a surfactant that can be used as an emulsifier, drug solubilizer, 
absorption enhancer, and as a vehicle for lipid-based drug-delivery formulations.  
TPGS is prepared by the esterification of the acid group of crystalline d-a-tocopheryl acid 
succinate by polyethylene glycol 1000. 
The chemical structure of vitamin E TPGS comprises both lipophilicity and hydrophilicity, 
resulting in amphiphilic properties. Moreover, its lipophilic alkyl tail (polyethylene glycol) 
and hydro-philic polar head portion (tocopherol succinate) are bulky and have large surface 
areas. Such characteris-tic makes it a good emulsifier, which can emulsify a wide range of 
water–oil immiscible systems. The hydrophile–lipophile balance (HLB) of TPGS is about 
13. It melts at 310–314 K and is heat stable under temperature 473 K [106]. 
TPGS has found wide utility in pharmaceutical 
formulations including the following applications: 
 Improving drug bioavailability 
 Surfactant properties enhance solubilization of 
poorly water soluble drugs 
 Stabilization of the amorphous drug form 
 Enhances drug permeability by P-glycoprotein 
efflux inhibition 
Figure 3.17: Micelle like TPGS 
 Emulsion vehicle 
 Functional ingredient in self-emulsifying formulations 
 Thermal binder in melt granulation/extrusion processing 
 Reducing drug sensitivity on skin or tissues 
 Carrier for wound care and treatment 
 Water-soluble source of vitamin E 
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3.6.2. Binary systems preparations 
Itraconazole solid dispersions using Vitamin E TPGS as carriers were prepared also in this 
case with the aim to improve the drug solubility and dissolution performance. 
SDs were prepared as mentioned in section 3.4.3.2, irradiating the binary mixtures for 10 
min at 600 W. 
The considered drug : polymer ratios were of 1:1, 1:2 and 1:3 w/w. 
Afterward, the Itraconazole binary systems were physicochemically characterized as 
reported in section 3.4.4. 
3.6.3. Results and Discussions 
Also in this case the influence of microwave irradiation was before checked on the single 
starting materials. The treatment of the carrier for only 2 minutes at 600 W led to the 
obtainment of a homogeneous melted mass. This is related to the low melting point of the 
carrier (~312 K). On the other hand, the drug processed even for 30 minutes at the same 
power did not show any visible change. Following the irradiation treatment, SD IT:TPGS 
1:1 w/w appeared as a fine suspension in a melted mass, while SDs IT:TPGS 1:2 and 1:3 
w/w appeared as clear liquid masses.  
The obtained samples were then cooled at room temperature and subjected to the 
physicochemical characterizations.  
From DSC analysis (Figure 3.18), the thermograms of untreated and treated drug showed a 
melting endotherm at 441.11 K with a heat of fusion (ΔH) of 54.9 kJ mol-1 . The DSC 
traces of starting and treated carrier showed a melting endotherm at 313.95 K (ΔH 180.95 
kJ mol
-1
) and at 311.95 K (ΔH 77.62 kJ mol-1) respectively, suggesting a decrease in TPGS 
crystallinity after MW process.  
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Figure 3.18: DSC thermograms of Raw and treated materials 
In all PMs the endothermic events corresponding to the melting of the carrier and the drug 
were present attesting the crystalline state of the components. Whereas the ΔH value of the 
melting point of the drug was smaller than the native drug. This phenomenon is 
attributable to the partially dissolution of the drug into the molten carrier during the DSC 
analysis. Moreover, the ΔH values reflected the carrier dilution effect (PM 1:1 w/w ΔH 
17.64 kJ mol
-1
; PM 1:2 w/w ΔH11.78 kJ mol-1 and PM 1:3 w/w ΔH4.52 kJ mol-1).  
Very similar trends were exhibited in the SD 1:1 and 1:2 w/w but here the drug 
endothermic peaks were lower than those of corresponding PMs attesting molecular 
interactions between components. The absence of IT peak in the 1:3 w/w solid dispersion 
might suggest the transformation of crystalline IT into an amorphous form. (Figure 3.19). 
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Figure 3.19: DSC thermograms of considered binary systems 
 
In order to further corroborate the hypothesis of the dissolution of the drug into the melted 
carrier during DSC scan, physical changes in the samples under heating were monitored by 
hot stage microscopy analysis. Representative micrographs are reported in Figure 3.20. 
The starting IT at room temperature (r.t.) appeared as seed crystals that completely melted 
at about 443 K. After MW treatment no changes were observed in their physical 
appearance. TPGS at r.t. appeared crystalline but it became liquid at about 318 K. Also 
MW-treated TPGS did not show any significant changes. During the program heating any 
birefringence were observed for untreated and treated TPGS.  
 G
en
er
al
it
y
 o
f 
M
ic
ro
w
av
e 
ir
ra
d
ia
ti
o
n
: 
It
ra
co
n
az
o
le
 M
W
 s
o
li
d
 d
is
p
er
si
o
n
s 
4
 5
 
 
Figure 3.20: HSM microphotographs of starting material before and after MW treatment: untreated IT at 303 
K (a), 441 K (b), 445 K (c); treated IT at 303 K (d), 441 K (e), 443 K (f); untreated TPGS at 303 K (g), 313 K 
(h), 318 K (i); treated TPGS at 303 K (j), 311 K (k), 315 K (l). 
 
At room temperature, all PMs show the presence of the discernible starting materials. 
However, after heating to 318 K, the carrier completely melted and IT began to dissolve 
into molten TPGS. A homogeneous liquid mass was observed at about 443 K in all PMs in 
accordance with DSC data. These results,further confirm the miscibility of IT in the 
selected molten carrier. For brevity in Figure 3.21 is reported only PM 1:1 w/w. 
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Figure 3.21: HSM microphotographs of PM IT:TPGS 1:1 w/w at 303 K (a), 313 K (b), 428 K (c), 440 K (d). 
The behaviour of the SDs is different. Already at r.t., the starting components were 
difficult to distinguish. During the heating program of SD 1:1 and 1:2 w/w the carrier 
started melting at about 313 K. At this temperature the drug became distinguishable as t iny 
particles dispersed throughout the molten TPGS. However, these particles were smaller, 
better dispersed and less birefringent as compared with respective PMs. At about 393 K in 
both 1:1 and 1:2 w/w solid dispersions, the drug dissolved into the molten carrier and a 
homogeneous melted mass was observed at about 433 K. In the SD 1:3 w/w a uniform 
liquid phase was observed at about 283 K (Figure 3.22). 
 
Figure 3.22: HSM microphotographs of SD IT:TPGS 1:1 w/w at 303 K (a), 313 K (b), 435 K (c), 437 K (d); 
SD IT:TPGS 1:2 w/w at 303 K (e), 313 K (f), 427 K (g), 435 K (h); SD IT:TPGS 1:3 w/w at 303 K (i), 311 K 
(j), 421 K (k), 427 K (l). 
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These results confirmed the previously assumption in DSC analysis. 
To understand the influence of the carrier and adopted technology on the drug solid state  
PXRD and DRIFT analysis were charred out. 
The powder diffraction patterns of pure IT (Figure 3.23) showed characteristic of high-
intensity diffraction peaks at 2Ө values of 14.49, 17.78 (doublet), 20.39 and 23.49°, which 
corresponded to the known powder diffraction patterns of pure IT [107]. 
TPGS showed two peaks at 19.19 and 23.25° of 2 Ө corresponding to the semicrystalline 
polyethylene glycol chains of TPGS. (Figure 3.23) 
No modifications occurred after MW treatment of the starting materials. 
 
Figure 3.23: PXRD patterns of starting materials 
The diffractograms of the SDs 1:1 and 1:2 w/w showed that the drug was still present in a 
crystalline state. Only a little reduction of the degree of crystallite was detected in 
comparison with the corresponding PMs. The PXRD patterns of SD 1:3 w/w confirm that 
the drug was in an amorphous state (Figure 3.24). 
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Figure 3.24: PXRD patterns of investigated binary systems 
To obtain an estimation of the crystallite size of the drug in the SDs and PMs particles, the 
Scherrer equation can be applied (Table 3.1). 
The Scherrer equation indicates that line broadening is inversely proportional to crystallite 
size, and can be used to estimate crystallite size between 10 and 100 nm [108]. 
The data suggest a trend in the dimension of the crystallite sizes in the investigated 
samples. In fact, the higher the amount of TPGS added, the lower the crystallite size of IT 
both in untreated and treated samples. More interestingly, a unique behavior is evidenced 
in the case of SD 1:3 w/w where the complete amorphisation of the drug is observed after 
the MW treatment. 
System Untreated (nm) Treated (nm) 
Itraconazole 29.33 ± 4 27 ± 5 
1:1 w/w 27 ± 6 27 ± 4 
1:2 w/w 26.67 ± 5 23 ± 1 
1:3 w/w 22 ± 4 amorphous 
Table 3.1: The average crystallite size of Itraconazole calculated by the Scherrer Equation based on peak 
broadering effect. Three reflectances were used for the calculation 20.48, 25.43 and 27.15 of 2θ angle. 
The main results of the DRIFT analysis on the starting materials and treated and untreated 
samples are reported in Figure 3.25.  
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Figure 3.25: DRIFT spectra of investigated systems 
The characteristic peaks of Itraconazole occurred at 3126, 3069, 2962, 2821, 1699, 1510 
and 1450 cm
-1
. The absorption bands between 2800 and 3200 cm
-1
 was attributed to the 
alkane, aromatic CH and amine groups. The wave numbers observed at 1609 and 1425 cm
-
1
 were assigned to the C=N and C-N bonds respectively, the sharp peaks at 1699 and 1228 
cm
-1
 were due to the stretching of C=O and C-O respectively. Vitamine E TPGS  instead, 
shows their characteristic peaks at 3500-3450, 2880, 1755 and 1250-1050 cm
-1
. The 
absorption band between 3500-3450 cm
-1
 was attributed to terminal OH. The broad band 
between 3100-2700 cm
-1
 was assigned to the aliphatic chain. The carbonyl band was 
observed at 1755 cm
-1
, and C-O were assigned between 1250-1050 cm
-1
.  
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The DRIFT spectrum of the PMs revealed no considerable interaction between IT and 
TPGS in the different ratios. In fact, they are simple summation of the those of pure 
compounds. 
In contrast, FTIR spectra of solid dispersions displays different absorption broad bands in 
the C=O and C-O regions of the drug which can be attributed to the formations of 
hydrogen bonds between these two groups of IT and the terminal OH of TPGS [109, 110]. 
This comportment is more visible in SD 1:3 w/w. The increase in the amount of drug 
hydrogen-bonded to TPGS is therefore accompanied by a corresponding decrease in the 
amount of crystalline IT in the SD systems. This is in accordance with the PXRD patterns 
[111]. 
Drug solubility Figure 3.26 was enhanced as the carrier content in the samples increases. 
This phenomenon can be ascribed in the PMs to a higher wettability of IT in presence of 
surfactant TPGS. In SDs, it was also due to the decrease in crystallinity of IT and, in 
particular, better result was evident in SD 1:3 w/w where IT was in amorphous form. 
These data were in agreement with those of PXRD and DRIFT assays.  
 
Figure 3.26: Solubility of IT in considered binary systems tested in pH 1.2 simulated gastric juice at 330 K. 
In order to assess the goal of improving IT dissolution rate by preparing MW activated 
systems in presence of TPGS, in vitro dissolution profiles of SDs were compared to those 
of pure drug and their corresponding physical mixtures. All the performed SDs 
formulations revealed a remarkable enhancement of the in vitro drug dissolution rate 
Figure 3.27.  
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Figure 3.27: Drug release of considered binary systems 
This phenomenon can be explained by reduction of IT crystallinity and the hydrophilic 
properties of the carrier able to reduce the interfacial tension between the drug and the 
dissolution medium. In particular, SD IT:TPGS 1:3 w/w was able to produce 90 % of the 
drug in solution within 2 min, while at the same time only 10 % of the drug was released 
from the corresponding physical mixture. This better performance can be explained in the 
light of the above-mentioned results of the physical characterization that showed an 
amorphous state of the drug and interactions between components. 
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3.7. Ibuprofen MW solid dispersions 
The applicability of microwave technology was also evaluated for the formulation of 
sustained release systems preparing solid dispersions using Ibuprofen as model drug and 
Inwitor 900 as carrier. 
3.7.1. Materials 
Ibuprofen was purchased from Comifar (Italy) while Imwitor 900 (GM) was provided from 
Sasol (Germany). 
Inwitor 900 is a fatty acid substance member of glyceryl monostearate, containing 40-50% 
monoglycerides with a melting range of 329-335 K. Glyceryl stearates are widely used in 
the pharmaceutical, cosmetic and food fields. Their surfactant properties allow them to act 
as emulsifiers, co-emulsifiers, solubilizers, dispersants, plasticizers, lubricants, consistency 
regulators, embedding agents, binders. In particular, Imwitor 900 has been widely used as 
a pharmaceutical excipient in the production of Solid Lipid Nanoparticles [112]. 
It acts as an effective stabilizer, that is, as a mutual solvent for polar and nonpolar 
compounds that may form water-in-oil or oil-in-water emulsions [113, 114]. These 
properties also make it useful as a dispersing agent for pigments in oils or solids in fats, or 
as a solvent for phospholipids, such as lecithin. Glyceryl monostearate has also been used 
in a novel fluidized hot-melt granulation technique for the production of granules and 
tablets [115]. 
Glyceryl monostearate is a lubricant for tablet manufacturing and may be used to form 
sustained-release matrices for solid dosage forms [116]. Sustained-release applications 
include the formulation of pellets for tablets [117] or suppositories [118], and the 
preparation of a veterinary bolus [119]. Glyceryl monostearate has also been used as a 
matrix ingredient for a biodegradable, implantable, controlledrelease dosage form [120]. 
Literature reports two mainly polymorphic forms that can occur during the formulations. 
The α-form is dispersible and foamy, useful as an emulsifying agent or preservative. The 
denser, more stable, β-form is suitable for wax matrices. This application has been used to 
mask the flavor of clarithromycin in a pediatric formulation [121]. 
3.7.2. Binary systems preparation  
Ibuprofen (IBU) solid dispersions using Imwitor 900 (GM) as carriers were prepared with 
the aim to prepare sustained release dispersed systems. SDs were prepared as reported in 
section 3.4.3.2, irradiating the binary mixtures for 9 min at 600 W. 
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The considered drug : polymer ratios were of 1:1, 1:2 w/w. 
The Ibuprofen binary systems were characterized as described in section 3.4.4. 
3.7.3. Results and discussions 
Microwave irradiation is able to transform each starting material in a molten liquid mass 
after 15 and 6 min for IBU e GM, respectively. 
From HSM, raw IBU appeared as non-aggregated long irregular acicular crystals 
undergoing melting at 350 K. After MW treatment a crystal reduction was observed at 
room temperature and a consequent decrease in melting temperature at about 348 K 
(Figure 3.28). 
 
Figure 3.28: HSM microphotographs of Raw IBU at 303 K (a), 348 K (b), 350 K, treated IBU at 303 K (d), 
345 K (e) and 348 K (f) (magnification 100 X). 
The starting GM at room temperature appeared as seed crystal that completely melted at 
335 K. After MW treatment, a different crystalline structure was observed at r.t. that 
melted at 333 K after heating (Figure 3.29). This phenomenon could be ascribed to a 
modification in crystal form as reported in literature [122, 123]. 
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Figure 3.29: HSM microphotographs of Raw GM at 303 K (a), 332 K (b), 335 K (c)  microwave treated GM  
at 303 K (d), 331 K (e) and 333 K (f). (magnification 100 X) 
At room temperature, in 1:1 and 1:2 w/w PM the single starting materials were already 
recognizable. After heating, GM melted at about 327 K and gradually IBU solubilized in 
this melted carrier. At 343 K both PM systems showed only one liquid mass Figure 3.30. 
Instead, solid dispersions at room temperature appeared as homogeneous, irregular and 
opaque particles, and which was difficult to distinguish the single component. In both 
samples at around 333 K they changed to liquid Figure 3.30. This phenomenon could be 
ascribed to an interaction between components.  
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Figure 3.30: HSM microphotographs of PM at 303 K (a), 329 K (b), 343 K (c) SD at 303 K (d), 323 K (e) 
and  329 K (f) 
DSC analysis was employed to evaluate the phase transformation during the formation of 
solid dispersion. As reported in Figure 3.31, the starting IBU was characterized by a 
melting peak of 349.65 K; after MW treatment at 600 W for 6 and 15 min only a slight 
shift in the melting point was observed. Usually, this may be caused by a variation in the 
different crystal habit or by a reduction in particle size in accordance with HSM analysis. 
As assumed by Rasenack et al. [124], ibuprofen could be present either in a needle-shaped 
or a plate- shape habit characterized respectively by a melting point of 349.55 and 348.95 
K and, according to Potthast et al. [125], ibuprofen does not exhibit genuine 
polymorphism.  
In addition, the enthalpy related to the endothermal event was 25.95 kJ mol
-1
 in the native 
IBU and slightly diminished in IBU treated for 6 and 15 min. This variation could be 
ascribed to an initial reduction in crystallinity, directly linked to the irradiation time. 
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Figure 3.31: DSC thermograms of Raw and treated IBU 
DSC thermogram of raw Imwitor 900 showed an endothermic peak at 335.55 K with ∆Hfus  
of 53.83 kJ mol
-1
, corresponding to β-form as reported in literature [122, 123]. After 
treatment at 600 W for 6 min the melting peak shift at 333.35 K with of ∆Hfus  25.75 kJ 
mol
-1
 attesting a formation of α-form [122, 123] (Figure 3.32). Also this data was in 
accordance with the HSM analysis.  
 
Figure 3.32: DSC thermograms of raw and treated Imwitor 900 
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Many fats and fatty acids possess the ability to form different polymorphs. Dependent on 
the unit cell structures mono-acid saturated triglycerides were classified into three main 
crystallographic forms. The less stable α-modification is characterized by loose packing of 
the hydrocarbon chains in a hexagonal unit cell structure. The intermediate β’-modification 
reveals an orthorhombic unit cell structure and the densest packing is reached with the 
stable β-form by triclinic packing [126, 127]. A polymorphic transformation occurs when 
the lipidic material undergoes thermal treatment. The less stable α-form nucleates first, 
followed by a transition to the intermediate β’-modification and finally, the optimal 
packing is completed by a rearrangement to the β -form [127]. Consequently, the presence 
of less stable α- or β’-forms after treatment results in a polymorphic transformation to the 
more stable polymorphs.  
DSC of the investigated binary systems revealed the disappearance of the sharp IBU peak 
in all SD and PM (Figure 3.33). In SD 1:1 w/w, the first endothermic peak that appeared at 
322.75 K was due to the melting of the eutectic, while the second one corresponded to the 
melting of the GM (between 324.55 and 331.65 K with melting enthalpy of 40.2 kJ mol
-1
). 
The third broad endothermal event was observed between 333 and 338 K with enthalpy of 
fusion of 7.57 kJ mol
-1
 corresponding to residual IBU crystalline form. Similarly in 1:2 
w/w SD the events corresponding to the eutectic form and carrier were observed but the 
endothermic event corresponding to the drug disappeared. In both PM systems, no eutectic 
events were observed (Figure 3.33). 
 
Figure 3.33: DSC thermograms of considered binary systems 
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IBU has been reported to form eutectics with many carriers at around 35% w/w 
concentration in the mixture [85, 128-130]. 
In accordance with this data, binary phase diagram of DS IBU:GM, showed the formation 
of eutectic at 36% w/w (Figure 3.34). 
 
 
Figure 3.34: IBU:GM phase diagram 
 
PXRD was considered to understand the influence of the carrier and the adopted 
technology on the drug solid state.  
The diffractograms of the GM before and after treatment attested that a polymorphism 
form occurred after MW treatment (Figure 3.35). In accordance with literature data, the 
commercial GM corresponded to the α-form, while the GM MW treated showed a crystal-
like β-form [122]. 
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Figure 3.35: PXRD patterns of raw and MW treated Imwitor 900 
The patterns of treated and untreated IBU were characterized by a substantial 
superimposition in the range 3-40 of 2θ angle and only slight variations in the intensity of 
the signals were noticed (Figure 3.36).  
 
Figure 3.36: PXRD patterns of raw and MW treated Ibuprofen 
To confirm that this behavior can be ascribed to a different crystalline habitus and a 
reduction in particle size as seen in DSC, a deepened analysis was performed employing 
new experimental conditions (scanning angle ranged from 2 to 30 of 2θ, steps were of 
0.05° of 2θ, and the counting time was of 4 s/step). Generally, when the patterns of two 
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crystal forms are identical in terms of peak positions, they have the same internal crystal 
structure, whereas if the patterns are different the crystals have different internal structures 
and are recognized as polymorphs [131]. The difference in the relative intensity of the 
peaks is due to either the variation of the crystal habit, because the relative abundance of 
the planes exposed to X-ray source is altered, or to differences in the size of the crystals 
[131]. As shown in Figure 3.37, the adopted different experimental conditions confirmed 
the previous assumption: no polymorphic modification but only crystal habit variation 
occurred together with a reduction in particle size. 
 
Figure 3.37: PXRD pattern of raw and MW treated Ibuprofen 
The PXRD patterns of all IBU-MW treated systems showed that the drug was present in 
microcrystalline form while in the PM systems the drug was still in a crystalline state and 
the PXRD signals corresponded to that of the starting drug.  
In SD systems, the obtained reduction of the crystal sizes could be caused by the formation 
of the eutectic. The differences between DS and PM were from 20 to 26 2θ showed the 
polymorphism of GM (Figure 3.38). 
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Figure 3.38: PXRD patterns of considered binary systems 
The considered formulations were also analyzed by in vitro dissolution test to evaluate 
both the influence of the adopted technology and carrier on the ibuprofen mechanism of 
release. From the dissolution profile of the solid dispersions, it was possible to notice how 
the adopted technology and carrier were responsible of significantly prolonged release of 
the drug. In fact, as reported in Figure 3.39, the pure drug and both PMs systems reached 
90% in 150 and 300 minutes respectively, while SDs 1:1 and 1:2 w/w reached 90% in 600 
and 900 min, respectively. 
 
Figure 3.39: in vitro dissolution rate 
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In order to understand the mechanism involved during the release of the investigated 
systems a mathematical approach was considered. 
Except for compounds undergoing phase or status (amorphous or crystalline) changes upon 
dissolution, release kinetics pertaining to an ensemble of solid particles depend on particle 
shape and size distribution, release environment volume, hydrodynamic conditions and 
drug solubility [132]. Assuming sink conditions and perfect spherically shaped particles, 
Hixon-Crowell dissolution kinetics [133] holds for each particle class into which the global 
particle size distribution can be ideally subdivided. Accordingly, the overall dissolution 
kinetics can be described as the weighted sum of each particles class contributes: 
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Ii = 1        t > R0i/(kd Cs)  Eq. 3-2
II
 
where 100(Mt/Minf) is the release %, ωi and R0i indicate, respectively, i
th
 particle class 
relative abundance (0 ≤ ωi ≤ 1) and initial radius, kdi is the i
th
 particle class drug dissolution 
constant, ρ is the drug density, N is the number of particle classes considered and t is the 
time. The different expression for Ii is due to the fact that for t > ρR0i/(kdi Cs) i
th
 particle 
class disappeared and, thus, its contribution to fractional release is just ωi. For t ≤ ρR0i/(kdi 
Cs), on the contrary, the Hixon-Crowell equation holds and the contribution is Ii ωi. If 
particle classes reduce to only one or two classes, Eq. 3-2 becomes, respectively: 
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The above explained Eq. 3-2 was fitted to experimental data referring to pure IBU and to 
the two physical mixtures considered (PM1 => (IBU:GM=1:1 w/w); PM2 => 
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(IBU:GM=1:2 w/w)). In order to reduce the number of model fitting parameters, an 
average value for the dissolution constant (kd) was considered for all particle classes. This 
value was determined by fitting Eq. 3-2 to experimental data assuming a mono-disperse 
particle size distribution (m = 1) characterized by the average initial diameter ϕ0 = 357.5 
μm. On the basis of this average value, Eq. 3-2 was improved assuming an increasing 
number of particle classes, each one characterized by its own mean diameter (ϕi) and 
abundance (ωi). Figure 3.40 shows that the best fitting model (represented by the solid 
lines) was very good for all three situations considered. Indeed the experimental F test 
value referred to IBU dissolution (FIBU(3,3,99) = 1755) was considerably larger than the 
theoretical one (F(3,3,99) = 29.46). The same considerations were possible as regards the 
release from the physical mixture IBU:GM=1:1 (FPM1(3,7,99) = 3647 > F(3,7,99) = 8.45) 
and IBU:GM=1:2 (FPM2(3,11,99) = 530 > F(3,11,99) = 6.22). 
 
Figure 3.40: Comparison between model best fitting (Equation 1, solid lines) and experimental data referring 
to IBU (open circles), physical mixture 1 (IBU:GM=1:1 w/w; grey circles) and physical mixture 2 
(IBU:GM=1:2 w/w; closed circles). 
In addition, Table 3.2 indicates that two particle classes were sufficient for the description 
of drug dissolution in all cases (the addition of further classes did not improve the fitting 
quality). Interestingly, it could be seen that the increase of GM content (zero, in the case of 
pure IBU) determined an increase in both class 1 and 2 diameters. 
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 IBU PM IBU:GM 1:1 w/w PM IBU:GM 1:2 w/w 
kd (cm min
-1
) 0.64 ± 0.06 0.49 ± 0.05 0.63 ± 0.06 
ϕ1 (mm) 96 ± 9 176 ± 12 190 ± 7 
ϕ2 (mm) 450 ± 65 675 ± 172 753 ± 193 
ω1 (-) 0.21 ± 0.03 0.49 ± 0.05 0.57 ± 0.02 
ω2 (-) 0.79 ± 0.03 0.50 ± 0.05 0.43 ± 0.02 
Table 3.2: Fitting parameters kd is the average dissolution constant, ω1 - ω2 and ϕ1 - ϕ2 indicate, respectively, 
class 1 and 2 relative abundance and initial diameter. 
At the same time, its increase provoked the reduction of class 2 (large particles) relative 
abundance (ω2) in favor of class 1 (small particle) one (ω1). Thus, GM should be 
responsible for a clustering action favoring the formation of small aggregates in the place 
of large ones. The fact that class 1 and class 2 diameters were, respectively, smaller and 
larger than the theoretical values (315 and 400 μm, respectively) was probably due to the 
incomplete fulfillment of the spherical particles hypothesis. 
In the light of the dissolution performances of the solid dispersions, it is reasonable to 
suppose that the drug release mainly occurs because of the surface erosion. In addition, it 
also seems reasonable that erosion kinetics is strictly dependent on release environment 
hydrodynamic conditions. Accordingly, assuming a mono-disperse particle distribution of 
non-interacting particles, the well-known Stokes-Einstein equation affirms that the friction 
force, F, acting on the surface of a spherical particle in relative constant motion within a 
liquid environment (small Reynolds number < 0.1) is proportional to particle radius R. 
Thus, we supposed that the velocity of particle radius reduction is proportional to F and, 
thus, to R: 
      tRKtRR
tt
tX
 0
d
d
d
d
       Eq. 3-3 
where X is radius reduction, R0 and R are, respectively, initial particle radius and particle 
radius at time t, while K is a proportionality constant. Eq. 3-3 solution reads: 
   tkeRtX i10      tkeRtR i0        Eq. 3-4 
Clearly, the real hydrodynamic conditions differ greatly from the ideal situation presented 
above. In order to account for this, we supposed that the generic particle undergoes the 
friction action of m forces acting from m different directions. Thus, assuming that the 
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superposition principle holds, radius reduction is the sum of m contributes of the Eq. 3-4 
type: 
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jj1   Eq. 3-5 
where Rj0 are integration constants that must fulfil the relation 0
1j
j0 RR
m


 in order to 
account for R(t) zeroing for sufficiently long times R(t). Finally, we have: 
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j
         Eq. 3-6 
This summation can be properly approximated by a stretched exponential function: 
 
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m
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 0
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j
        Eq. 3-7 
Once radius time dependence is known, the determination of the amount, M(t), of drug 
released up to time t simply descends from a mass balance made up on particles and 
release environment: 
  D
3
pD
3
0p
3
4
3
4
CRNCRNtM         Eq. 3-8 
where Np is particles number and CD is drug concentration in the particles. Thus, fractional 
release will be: 
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Figure 3.41 clearly shows that the developed model (Eq. 3-9, solid lines) was fully able to 
fit the experimental data satisfactorily for both solid dispersions considered. Indeed, the 
experimental F test value relative to solid dispersion 1 (FSD1(1,14,99) = 4096)) was 
considerably larger than the theoretical value (F(1,14,99) = 8.86). The same considerations 
are possible as regards solid dispersion 2 (FSD2(1,34,99) = 9960 > F(1,34,99) = 7.40). This 
was indirect proof of the reasonability of the hypotheses at the basis of our model. It was 
also interesting to note that the particle diameter undergoes a reduction of about 50% in 
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both cases (SD1, SD2; dashed lines). Model fitting parameters (SD1: k = 0.0103 ± 0.0008, 
a = 0.65 ± 0.02; SD2: k = 0.011 ± 0.0004, a = 0.61 ± 0.008) revealed that dissolution 
kinetics did not greatly vary in the two cases, even if SD2 implied a slower erosion. This 
suggested that the higher the GM content, the more resistant to erosion particles were. 
 
 
Figure 3.41: A: Comparison between model best fitting (Eq. 3-9, solid line) and experimental data referring 
to solid dispersion 1 (SD IBU:GM 1:1 w/w, open circles). Dotted line indicate particles radius reduction 
calculated according to Eq. 3-7. B: Comparison between model best fitting (Eq. 3-9, solid line) and 
experimental data referring to solid dispersion 2 (IBU:GM 1:2 w/w, open circles). The dotted line indicates 
particle radius reduction calculated according to Eq. 3-7. 
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These activated systems, prepared with Imwitor 900 used as a lipofilic carrier, were able to 
prolong the ibuprofen release.  
Mathematical modeling analysis suggested that in physical mixtures, IBU dissolution was 
slightly influenced by the GM presence even though GM would induce IBU clustering to 
form small aggregates. In addition, the model suggested that IBU release from both solid 
dispersions mainly occurred on a surface erosion basis. Erosion velocity was decreased by 
improving GM content in the solid dispersion. 
3.8. Conclusion of MW application research 
The above investigations revealed the advantageous use of the microwave technology to 
prepare solid dispersions systems either for immediate or sustained drug release. In 
particular, it was proved that this technique is a viable and alternative means of preparing 
solvent-free binary systems.  
The employed microwave technology offers an efficient heating of materials thus, reducing 
the time and increasing the yields of preparation systems either favoring the amorphization 
of the drug or creating more homogeneous mixtures than the physical mixtures.  
The use of surfactants carriers made possible to achieve a highest degree of bioavailability 
for poorly soluble drug such as NMS and Itraconazole and to stabilize the MW solid 
dispersions, avoiding drug recrystallization. Moreover, the complete amorphisation of the 
drug in SDs with major surfactant carrier ratio was attested. 
Instead, the use of lipophilic carrier such as Imwitor 900 was able to form a homogeneous 
matrix (suggested from the formation of the eutectic mixture) able to control the release of 
Ibuprofen. The Best result was noticed for 1:2 w/w solid dispersion. By means of ad hoc 
mathematical model the erosion mechanism for the release of the drug from the SDs were 
established. 
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4. Supercritical fluids applications  
4.1. Properties of supercritical fluids 
The properties of supercritical fluids have been known since the beginning of '900 and 
the first application can be traced back to the 40s, but it is only in the last two decades that 
found application for industrial applications.  
This phenomenon is attributable to the research of new extraction and formulation 
technologies able to replace the traditional ones that use organic solvents. Concerning this, 
in fact, the normative that governs the maximum permissible limits of solvent in the 
finished product tends to be more restrictive for toxicity reasons. The supercritical fluid, by 
their characteristics, can be advantageously employed either in methods that allow a better 
purification of the final product or in new methods of preparation, that involving few or 
nothing contamination from solvents and that do not require further treatment of the 
finished product. 
For a pure substance, the field of existence of a particular physical state (solid, liquid, gas) 
is bounded by a certain condition of temperature and pressure. 
In fact, looking at a generalized state diagram (Figure 4.1) we can distinguish three basic 
states of aggregation: solid, liquid and gas, each of them occupies a specific area of the 
diagram (P, T). The boundaries of each area are marked by equilibrium curves: for the 
values of temperature and pressure, corresponding to the points of these curves there is the 
coexistence of two states. Furthermore, in the same diagram of state it is possible to 
identify two characteristic points:  
 Triple point, where the three equilibrium curves intersect (at that temperature and 
pressure values) the three states coexist 
 Critical point that represents the maximum values of temperature and pressure for 
which can exist a gas and a liquid at the equilibrium, and over which the two phases 
are indistinguishable. 
The latest is of particular importance since above it, there is a continuous change from gas 
to fluid - liquid without  a clear distinction between the phases, while below it the change 
of state occurs with the appearance of interface gas - liquid and there is a clear difference 
in the density values of the two phases. 
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The fluid is in supercritical state when the substance is at temperature and pressure above 
its critical points. 
 
Figure 4.1: Phase diagram for a system at one component 
Therefore, a supercritical fluid is a system that is in a particular physical state, since it 
occurs as a single homogeneous phase with intermediate properties between those 
characteristics of the liquid and gaseous state (Table 4.1). Similarly to a liquid, it has high 
density and high solvent power with respect to compounds with low vapor pressure, while 
the low viscosity, high diffusion rate and, consequently, high permeability in porous 
materials are typical features of a gas [134] .  
 Liquid Supercritical fluids Gas 
Density (g
.
cm
-3
) 1.0 0.2 – 0.7 0.001 
Viscosity (cP) 0.5 – 1.0 0.05 – 0.10 0.01 
Diffusivity (cm
2.
s
-1
) 10
-5 
10
-4
 – 10-3  10-1 
Table 4.1: Comparison between physicochemical properties of liquid, supercritical fluids and gas 
The consequence of this is that supercritical fluids have solvent power equal to  liquids, but 
the best mass transfer characteristics, and therefore, a significantly  extraction capacity 
higher than that of a classical organic solvent. 
The supercritical region in the state diagram has a specific area that can be defined as: 
0.9 <Tr <1.2    with    
 
  
   Reduced temperature 
Pr> 1.0     with     
 
  
 Reduced pressure 
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In these conditions, the supercritical fluid appears to be highly compressible. Figure 4.2, 
shows the trend of density as a function of the reduced coordinates for one of the most 
used gases in the supercritical fluids fields that is the carbon dioxide. 
 
Figure 4.2: CO2 density-reduced pressure phase diagram 
Considering an isotherm at a temperature lower than the critical one, the fluid that is in 
gaseous state undergoes a sharp increase in density in the isobar passing phase, but when it 
reaches the liquid phase its density remains constant as it is not affected by the pressure. It 
is in these conditions that CO2 is normally used as a solvent: its high density allows a 
strong wrapping of solute molecules that are dissolved in solution. 
If the isothermal compression occurs at a temperature above the critical one, the strong 
variation of density is no longer isobaric because there is no state passage from gas to 
liquid. This implies a direct relationship between small increments of pressure and large 
increases in density. In this way, the complete control of solvent power through limited 
variations of operative condition (T,P) in the neighborhood critical point is the big 
advantage of supercritical fluids. 
As depicted in Figure 4.2 at even higher reduced temperatures (eg.: Tr = 1.2) the required 
increase in pressure to produce an equivalent increase in density appears to be much larger 
and that near the critical point can produce significant density changes with minor changes 
in temperature and pressure. 
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The solvent power is directly related to the density of the supercritical fluid: it can change 
continuously, simply by varying the operating parameters of the process.  
In particular, to dissolve a particular compound using supercritical fluids, it will be 
sufficient to determine an expansion of the fluid to drastically reduce its solvent power and 
afterwards, it can be removed in the form of gas, leaving substances dissolved in it without 
any trace of solvent [135, 136].  
There is a wide range of fluids, listed in Table 4.2, which can be used in supercritical 
conditions and chosen to suit the specific process. Generally the most used solvents are 
those with lower molecular weight presenting moderate critical parameters, allow their use 
also for thermolabile compounds, with low costs of plant and pumping. 
Solvent Tc (K) Pc (bar) 
Methane 191 46 
Ethylene 282 50.3 
Chlorotrifluoromethane 302 38.7 
Carbon Dioxide 304 73.8 
Ethan 305 48.8 
Propylene 365 46.2 
Propane 370 42.4 
i-butane 408 36.3 
n-butane 425 38 
n-pentane 470 33.7 
n-Hexane 507 29 
Ammoniac 406 113 
Diethyl ether 467 36.4 
Chloroform 536 53.7 
Acetone 508 47 
Methanol 513 80.9 
Ethanol 516 61.3 
Benzene 562 48.9 
Toluene 592 41.1 
Water 647 220 
Table 4.2: Critical parameters of different solvents used in supercritical conditions 
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As already mentioned, CO2 is the most widely used in supercritical fluids by its low critical 
temperature (304 K) and pressure (73.8 bar) values that permit to operate in easily and 
controllable conditions. In addition, carbon dioxide is non-toxic, nonflammable, non-
corrosive, non-polluting, with a good solvent power and cheap [137]. 
4.2. Applications of supercritical fluids 
Supercritical technology has been widely used in many fields and has found numerous 
applications in pharmaceutical area, food and cosmetics, in most cases using the 
supercritical carbon dioxide as a solvent for the reasons mentioned above. For example, the 
supercritical CO2 is used for the decaffeination of coffee, for the extraction of flavorings, 
cholesterol and fatty substances from food, for the extraction and elimination of 
temperature-sensitive products. 
The supercritical fluids are also used as eluents in chromatography, solvents in enzymatic 
reactions, for the micronisation and for the inclusion of a drug in a polymer. 
In the next few paragraphs will be described the most important applications of 
supercritical fluids. 
4.2.1. Supercritical Extraction 
Supercritical extraction (Figure 4.3) is a method of separation that uses solvents at 
temperature and pressure above the critical ones. 
This technique is proposed as an alternative to the traditional extraction techniques, such as 
distillation or extraction with liquid solvents. 
There are many fields of interest in which it finds application:  
 Petroleum sector, where it has allowed a simple separation of hydrocarbon mixtures  
 Food industry, where it is used, for example, in extracting oil from seeds and aromas 
from hops, in the decaffeination of coffee or to eliminate pesticides 
  Pharmaceuticals field, where it has proved particularly advantageous for the extraction 
of bioactive natural products (i.e. tannins, flavonoids, alkaloids, etc..) and the polymers 
fractionation.  
Despite the cost of supercritical fluids process is higher than the classical techniques, it is 
preferable for the higher purity of final products. 
The extraction with supercritical CO2 at low-density produces extracts similar to the 
essential oils replacing current vapor extraction, while that one at high-density produce 
viscous or semisolid extracts [138]. 
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Figure 4.3: Supercritical extraction scheme 
4.2.2. Supercritical Chromatography 
Supercritical Chromatography is an analytical and separation technique complementary 
to the supercritical extraction. Supercritical chromatography occupies an intermediate 
position between the gas chromatography and the high performance liquid chromatography 
(HPLC), overcoming the limitations of these two techniques: long execution times and 
difficulties of analysis thermolable products. 
In this technique, the mobile phase (usually composed of pure carbon dioxide or with some 
co-solvent) works at supercritical conditions and in a chromatographic packed or capillary 
column. The compound to be analyzed is injected into the column, after it is carried by the 
mobile phase and the various components are distributed between mobile and stationary 
phases according to their different affinities. At the output, a detector allows to measure the 
interaction entity between the substance and the stationary phase [139]. 
Recently, supercritical chromatography was also used in separation of racemic mixtures 
[140, 141, 142]. 
4.2.3. Impregnation 
The supercritical impregnation of polymeric materials is an innovative technological 
process, where the main strength is its solvent-free nature. 
The supercritical fluid, for their high solvent power, are able to spread within the matrix 
and porous polymer materials, causing a strong swelling that allows the penetration of 
substances within the lattice of the matrix. 
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The matrix is initially swollen with supercritical solution containing the substance to be 
impregnated and then a sudden decompression causes the deposition of the solute, while 
the solvent is released into the gas phase. 
The impregnation may take place by two different mechanisms. The first is a real 
interaction of drug molecule with the polymer: the drug leave the supercritical phase and 
reach the polymer matrix, while the drug concentration in the fluid is kept constant by the 
gradual dissolution of other drug, the process continues until equilibrium is reached. The 
second mechanism is based on a physical entrapment of drug within the polymer matrix 
while the solvent is removed. The first mechanism leads to an increased impregnation and 
often prevents a possible recrystallization of the drug [143]. 
This technique find application for the controlled-release of drugs. In literature are reported 
impregnation applications for drugs such as antibiotics, anti-inflammatories and analgesics 
[144, 145]. 
4.2.4. Powder technology 
In the pharmaceutical field, supercritical fluids has also been used to obtain fine and 
homogenous powder by reducing the size of the particles. 
There are different method able to produce powder using supercritical fluids:  
-RESS (rapid expansion of supercritical solutions) based on the nucleation of solid phase 
separates from the supercritical fluid due to rapid decompression of the solution through a 
nozzle of small dimensions. From the decompression parameters and the type of the solid, 
it is possible to obtain very fine powders, fibers or thin films. The main advantages of this 
technique are the absence of high temperature and obtaining a product with no solvent. The 
limits are related to poor solubility of polar molecules in CO2. 
-GASR (Gas Anti-Solvent Recrystallization) where the supercritical fluid acts as a an 
antisolvent and is added to a solution of the compound dissolved in an organic solvent. 
Following the progressive increase of pressure in the precipitator there is the expansion of 
the solvent and the subsequent elimination. 
Compared to the RESS technique here it is possible to work with multiple substances, 
since it is sufficient that the substances are soluble in organic solvent, but it need more 
time to remove completely the solvent (higher costs). In addition, the GASR technique can 
exceed pressure of 100 bar [136, 146]. 
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4.2.5. Fractional crystallization and solvents elimination 
Using the GASR technique in discontinuous mode is possible to separate the solutes 
contained in the same solution since they precipitate at different values of pressure.  
Chang (1999) apply GASR in this context to separate β - carotene from the other products 
of oxidation of carotene [147] ; Shiskikura et al. isolated the citric acid from the oxalic 
acid and from other impurities obtained during the fermentation. [148, 149]  
Moreover, to remove residual solvents from pharmaceutical products it is possible to 
operate at pressure in which the solvent has the highest solubility in supercritical fluid, 
while the solute at the same conditions shows the lowest solubility. To use this technique 
the CO2 must be chemically inert towards the active ingredient and the physicochemical 
characteristics of the drug should remain unchanged after the process. 
Kikic et al. saw how is possible to reduce the final dichloromethane quantitative from 
Megesterol acetate from 1500 to 20 ppm [150]. 
These techniques are routinely used as alternatives to air-drying or processing the product 
with a liquid that dissolves but without a strong affinity towards the solvent residue. 
4.2.6. Other applications 
Interesting is the application of supercritical fluids in the environment field: CO2 is 
used for the decontamination of land and water from solvents of low polarity, already on 
production scale.  
Furthermore, the CO2 is used as a solvent in the enzymatic reactions, polymerization and 
synthesis of a number of therapeutic products. 
The CO2 find also application for sterilization at high pressures: just a pressure of 150 bar 
for 15 minutes, compared to 3000 bar in the traditional method to eradicate the bacterium 
E. Coli. [151]  
SCO2 can also disable viruses like HIV - 1 and Sabin Polio, by treating plasma samples 
with high pressure [152] 
4.3. The techniques of precipitation 
In this part will be described, in greater detail, the precipitation techniques by means of 
supercritical fluids: 
• RESS (Rapid Expansion of Supercritical Solutions) 
• GASR (Gas Anti-Solvent Recrystallization Supercritical)  
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• PGSS (Particles from Gas-saturated Solutions / Suspensions) 
 
4.3.1. RESS (Rapid Expansion of Supercritical Solutions) 
The RESS technique from the chronological point of view is the first technique that 
was used and it is based on the saturation of CO2 with the substrate /s of interest. After, 
there is the depressurization, of the solution through a heated nozzle, inside a chamber 
maintained at low pressure to permit the rapid substrate nucleation, obtaining, in this may, 
very small particles, or fibers, or films (this happens when the jet is directed against a 
surface) [153]. 
As shown in Figure 4.4, the equipment consists of an extraction and precipitation of 
another. Pure CO2 is pumped into the extractor at a predetermined pressure, preheated 
through a heat exchanger and filtered. The supercritical solution is sprayed into the 
precipitation cell through a nozzle, heated to prevent clogging of the hole by the substrate 
that precipitates. 
 
Figure 4.4: RESS equipment 
The morphology of the product of precipitation will depend on both the structure of the 
starting material (crystalline or amorphous, etc...) and the variables of RESS process 
(temperature, pressure, distance of spray impact with the surface, the size of the vessel 's 
atomizing nozzle geometry) [136].  
The phase of dissolution depends only from the solvent power of the used fluid. 
Precipitation is rather induced by the fall of the solvent power following the expansion, so 
the fluid passes from the dense gas to ideal gas, characterized from a very low density. Due 
to the decreased solvent power obtained by sudden decompression, it is possible to obtain 
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high values of supersaturation in extremely short times. The result is the precipitation of 
small particles with a narrow particle size distribution curve. 
The major limitation of this application lies in the reduced solubility of many active 
substances in supercritical fluids (<10
-3
 molar ratio). 
The first RESS application in pharmaceutical field concerns the precipitation of lecithin, β-
estradiol, ferrocene, by Krukonis in 1984 [154].  
Hezave A.H. et al. in 2010 used Ibuprofen to compare the functionality of the nozzles 
[155]. 
The RESS technique is also used for the generation of liposomes: lipid mixture is atomized 
into an aqueous solution containing the drug, forming liposomes of 40-50 nm [156] 
4.3.2. GASR (Gas Anti-Solvent Recrystallization) 
The GASR technique exploits the phenomenon whereby a compound in dense gas state 
shows a high solubility in several organic solvents and in solutions of such solvents with 
the substance to recrystallize. 
In this process, the supercritical fluid is used as an antisolvent. The dissolution of the gas 
causes a significant volumetric expansion of the solvent, resulting in lowering of its solvent 
power which causes the precipitation of the solute. 
The compound solution and SCO2 are in contact among them as depict in Figure 4.5. 
 
Figure 4.5: Schematic GASR plant 
Since the gas dissolution in the liquid phase is fast, it is reasonable to assume that the 
supersaturation is reached uniformly throughout the mass.  
Following the solute can be recrystallized with one of these techniques: 
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4.3.2.1. GAS (Gas Anti-Solvent) or SAS (Supercritical Anti-Solvent) 
A certain amount of solution is greatly expanded by mixing with a dense gas in the 
precipitator. The expanded solvent has lower solvent power than the pure solvent. The 
mixture becomes supersaturated and then the solute precipitates in fine particles [153]. 
As shown in Figure 4.5, the precipitator is partially filled with the solution containing 
the component to be precipitated (eg, drug, polymer, or a mixture of both), the CO2 is then 
placed in the precipitator at the desired pressure (in each case over its critical point). 
At the end of the precipitation process, other CO2 is filled inside the vessel at the same 
pressure to remove completely the eventual solvent [157].  
The SAS process is a one-step process that facilitates control of particle formation 
characteristics and direct formation of dry and fine particles through an increased rate of 
mass transfer.  
4.3.2.2. ASES (Aerosol Extraction System) 
This second technique involves spraying solution through an atomized nozzle as fine 
droplets into compressed CO2 (Figure 4.6). The SCO2 dissolution into the liquid droplets is 
accomplished by a large volume expansion and, a reduction in the liquid solvent power 
occurred, causing a sharp rise in the supersaturation within the liquid mixture, and the 
consequent formation of small and uniform particles. The supercritical fluids, is pumped to 
the top of the high-pressure vessel by a high pressure pump. Once the system reaches 
steady state (T, P), the active substance solution is introduced into the high pressure vessel 
through a nozzle. To produce small liquid droplets in the nozzle, the liquid solution is 
pumped at pressure higher (20 bar) than that present inside the vessel. Particles are 
collected on a filter at the bottom of the vessel. The fluid mixture (SCO2 and solvent) exits 
the vessel and flows to a depressurization tank where the pressure and temperature 
conditions allow the gas-liquid separation. After that a sufficient amount of particles are 
collected, the liquid solution pumping is stopped and pure SCO2 continues to flow through 
the vessel to remove residual solvent from the particles [157]. 
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Figure 4.6: Schematic ASES plant 
4.3.2.3. SEDS (Solution Enhanced Dispersion by Supercritical Fluids) 
This third method consists to feed continuously both the solution and the SCO2 in the 
precipitator. In fact, in this case, the supercritical fluid is used either for its solvent 
properties or as a "spray promoter" thanks to the mechanical effects: a nozzle with two 
coaxial injectors allows the simultaneous introduction of the supercritical fluid and the 
solution containing the active ingredient within the precipitator where the pressure and 
temperature are controlled (Figure 4.7). The high supercritical fluid speed allows the 
dispersion of solution into finer droplets than previous methods and also the removal of the 
solvent takes place simultaneously with the precipitation [157]. 
 
Figure 4.7: Schematic SEDS plant 
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These three variants of the GASR technique allows to get particle sizes in the order of 10
-6
 
- 10
-9
 and are particularly suitable for the precipitation of less or totally insoluble 
compounds in supercritical fluids, or for those sensitive to shear forces, as peptides or 
proteins. 
They find advantageous use in the addition of a carrier (usually polymer) at the solution 
containing the active ingredient to obtain micro-/nano - spheres charged of the active 
substance, with the aim of creating special delivery systems. 
4.3.2.4. PGSS (Particles from Gas - Saturated Solutions / Suspension) 
This method, described by Graser in 1982, consists in the solubilization of supercritical 
CO2 in molten substances or suspended in a liquid, to obtain a solution or a suspension, 
saturated with gas that is then expanded through a nozzle to obtain solid particles or 
droplets (Figure 4.8). 
This process can precipitate a variety of substances, not necessarily soluble in CO2, 
especially with polymers that absorb large amounts of CO2 (10-40% by weight), and then 
undergo a large swell, in order to obtain microspheres containing the active ingredient 
suspended in a carrier [157]. 
 
 
Figure 4.8: Schematic PGSS plant 
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4.3.3. Process Variables 
There are several process variables that may influence the morphology and particle size 
obtained by precipitation with the techniques described above. 
It is possible to operate in:  
Discontinuous: the antisolvent is gradually introduced in the precipitation chamber that 
contains the solution. In this case, it is more difficult to obtain uniform conditions for the 
nucleation, since it is difficult that the antisolvent is evenly distributed in the liquid 
solution. 
Continuous: the supercritical fluid and the solution in which are dissolved one or more 
compounds are injected simultaneously within the precipitator and the solution is 
immediately subjected to a strong friction, that promotes the formation of crystalline 
particles or fibers [158-160].  
Semi-continuous: it is possible to reach more easily the steady state conditions and the 
supersaturation levels are higher for the combined effect of the antisolvent and the solvent 
evaporation. In this case, very small particles are obtained within a narrow range of 
distribution. The forms are rather different: spheres, fibers, needles, flakes or agglomerates 
similar to networks [161-163]. 
In a non-continuous system, a significant variable is the antisolvent injection speed: higher 
is the velocity, smaller will be the particles. In addition, a rapid injection favors the 
formation of particles of spherical shape, while a slow CO2 flow will form a pattern of 
lamellar crystals. [162]. Another variable to consider is the solvent, in fact, Thiering, R. et 
al, [164] saw as the choice of solvent can influence the morphology of the solute. In their 
experiment the p-hydroxybenzoic acid was dissolved respectively in methanol, acetone and 
ethyl acetate, and it was noted that with the last two solvents, they obtained a crystalline 
product, whereas with methanol were formed amorphous spheres of 1-2 μm of diameter. 
Methanol shows a higher affinity for the drug and a greater expansion capacity that 
generates a rapid nucleation preventing the formation of a crystalline structure [163]. 
The concentration of the solution can affect the appearance and particle size of the 
precipitate, i.e. a dilute solution can carry to amorphous particles, while a concentrated one 
can conduct to crystalline substances [147].  
Another variable is the configuration of the sprayer. The nozzle which disperses the 
solution into the chamber must form droplets of small diameter able to maximize the 
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exchange area, that will depend on the mass transfer rate of the gas . To obtain this, it is 
necessary to use sprinklers with high values of Weber number. 
Furthermore, It is possible to use spray with standard configuration in which is possible to 
vary the orifice size, or vibrating nozzle for a more stable spray [161]. Recently, co-axial 
nozzle that allows a continuous and simultaneous injection of the solution and the 
supercritical fluid has been tested. This nozzle carried to the formation of larger particles 
than the standard method due to the slow nucleation, but not agglomerated due to the faster 
elimination phase of the solvent occurred [165]. 
Increasing CO2 pressure at constant temperature, follows an increase of its viscosity and 
density, but decreases its diffusivity. In general, reduced diffusivity and increased viscosity 
hinder the mass transfer between the droplets and the surrounding CO2, consequently, the 
particle size increased at the increase of pressure. Nevertheless, increasing pressure led to 
fine droplets due to increasing aerodynamic force and breakup. Thus, various particle sizes 
were obtained with every pressure increment due to the contrary effect of mass transfer and 
atomization of particles [166]. 
In addition, temperature plays an important role. The particle size reduces with the increase 
in temperature. This trend may be explained as follows: the behavior is directly related to 
the solubility of the compound in the supercritical phase. At constant pressure, as the 
temperature was increased the density of SCO2 decreased, leading to a reduction in the 
solubility of solvent and solute in the phase. A lower solubility will allow a higher degree 
of supersaturation and particles with a smaller size. 
SCF process operating parameters can be adjusted to vary supersaturation and conditions 
for nucleation and crystal growth across a wide range. Accordingly, the different 
crystalline forms of a compound in which the molecules have different arrangements 
and/or conformations, can be controlled to exploit compound polymorphism using the SAS 
process [167]. Polymorphism is important in pharmaceuticals because different 
polymorphic forms usually exhibit different physicochemical properties, including melting 
point and solubility [168- 170]. 
 
In this thesis are considered the thermodynamic aspects involved in the precipitation or 
solubilization of pharmaceutical compounds by the supercritical technology (SAS/GAS or 
impregnation). A new semi empirical equation, with a modified Abraham’s solvation 
approach, able to predict the solubility of pharmaceutical compounds in supercritical 
fluids, was proposed. Moreover, it is demonstrated the advantage in using the well-known 
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Abraham’s solvation theory to predict the affinity of a polymer either for a pharmaceutical 
active compound or solvent (organic solvent and SCO2). This approach can provide useful 
information about the ability of SCO2 to interact with the solid compounds permitting the 
impregnation of a polymeric system with drug.  
In some cases, the low solubility of pharmaceutical compounds in SCO2 limits it use as 
solvent and to process the solute is helpful the addition of a third compound like an organic 
solvents having recourse in this case to the SAS technique. Of course, the final particle 
dimensions and particle size distribution depend also on fluid dynamics and nucleation 
growth kinetic, however, prior to investigate these aspects, it is indispensable to rationally 
understand the equilibrium and volumetric behavior of binary solute-SCO2 or ternary 
solute–solvent-SCO2 systems. For this reason, in this thesis, is also tested whether it is 
possible to predict the thermodynamic behavior of ternary systems used in the antisolvent 
precipitation process, using the information supplied by the corresponding binary systems. 
To test this approach, two systems constituted by Vitamin B6 and Piroxicam were selected, 
even proposing a mathematical approach for the prevision of the crystal nucleation and 
grow in the selected operative conditions. The SAS process was also applied to Quercetin 
at the Technique University of Graz where, through a visual cell, was verified the goodness 
of our thermodynamic approach for the precipitation prevision of drugs. The SAS process 
was at the end applied to prepare solid dispersions of Furosemide with Crospovidone even 
in this case with the aim to improve the dissolution rate of poor soluble drug. 
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4.4. Solubility in supercritical fluids 
The knowledge of the solubility of pharmaceuticals in SCO2 is essential for the design and 
the operations of the above-mentioned SCO2 methods. Experimental measurements on the 
solubility of these substances in SCO2 provided essential information for the 
pharmaceutical end engineering process. 
On the other hand, it is difficult to predict the solubility data from the solute structure 
because are involved two main factors: solute-solute interactions in the solid and solute-
solvent interactions in SCO2. While the solid interactions are commonly determined from 
endothermic or packing properties, the solute-solvent interactions are hardly determinable 
because different parameters affect their behavior i.e. pressure, density, temperature, 
polarity etc. 
Literature reports many correlations of solid solutes solubility in SCO2 using equations of 
state [171- 173], or semi empirical equations [174-182]. 
The equation of state needs large and complicated computational methods and the 
knowledge of critical parameters (i.e. macroscopic critical properties). 
However, semi-empirical models are utilized more frequently because of their relative ease 
of application compared to equations of state. To describe the solubility behavior of binary 
systems, in both approaches appear ad hoc values obtained by fitting these solubility data. 
As a consequence, neither of these approaches is a method of prediction. 
4.4.1. Method  
The semi empirical models like ours require the enthalpy and temperature of fusion for the 
solid and the activity coefficient of the solute in solution. Enthalpies of fusion data are 
abundant in the literature [143], or they can be quickly measured in a differential scanning 
calorimeter (DSC). Since the solubility of solids in liquids is usually insensitive to the 
quality of the solution model, an ideal solution model often performs adequately. For 
solids of low solubility solute–solvent interactions are significant, and an appropriate 
activity coefficient model must be chosen. In this context, supercritical carbon dioxide is 
treated as an expanded liquid. 
The proposed model was based on 39 pharmaceutical molecules and 329 data points were 
collected from literature (Table 4.3). Among these solids, we included antioxidants, anti-
inflammatories, steroidal substances, cardiogenic substances. The Newton’s method was 
used to determine the parameters of each equation [183] and it was employed to perform 
the nonlinear regression analysis between experimental and theoretical data. 
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Compound References 
9,10- Anthraquinone [184] 
Aspirin [185] 
Budesonide [186] 
Caffeine [187] 
Chlorthalonil [188] 
Cholesterol [189] 
Cholesteryl acetate [189] 
Cyproterone acetate [190] 
Codeine [191] 
p-Coumaric acid [192] 
Diazepam [191] 
Exemestane [193] 
Ferulic acid [194] 
Flurbiprofen [195] 
Ketoprofen [196] 
Lovastatin [177] 
Medrossiprogesterone acetate [190] 
Methyl gallate [197] 
Methylparaben [198] 
Methimazole [199] 
Naproxen [200] 
Nifedipine [201] 
Nimesulide [196] 
Nimodipine [202] 
Nitrendipine [201] 
Penicillin G [203] 
Progesterone [204] 
Propranolol [199] 
Protocatechualdehyde [197] 
Protocatechuic acid [197] 
Salicylic acid [205] 
Simvastatin [177] 
Stigmasterol [206] 
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Compound References 
Sulfamerazine [207] 
Tebuconazole [188] 
Theobromine [208] 
Theophylline [208] 
Uracil [186] 
Vanillic acid [209] 
Table 4.3: Data sources for solubility data 
This method is a modified version of the Abraham‘s linear free energy relationship (LFER) 
correlation proposed by Bush and Eckert [174] incorporating S, the 
dipolarity/polarizability of the CO2 at a given density.  
This allowed us to model data at temperature closed to 313 K and pressure ranging from 
100 to 500 bar, with R
2
 = 0.617 in the logarithm of calculated solubility versus 
experimental one. The model shows that solubility in supercritical CO2 is favored by the 
presence of S and hydrogen bond molecular acidity. Solute size and hydrogen-bond 
basicity are less important. 
It is important to realize that the experimental data (especially when the drug is poorly 
soluble in CO2) have a standard error of about 20%. Moreover, in literature are reported 
many data at the same operative condition that showed different solubility values. In 
Figure 4.9, for example, are depicted the literature solubility data of Cholesterol collected 
from five authors.  
 
Figure 4.9: Literature solubility data of Cholesterol at 313.15 K: ♦ [210], ■ [189]; ▲ [206]; X  [211]; * [212] 
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The Abraham's LFER approach needs five physicochemical properties or descriptors.  
In order to predict the properties of a series of solutes in a given solvent system (SP) the 
descriptors are combined to give the following LFER. 
                            Eq. 4-1 
                            Eq. 4-1’ 
where E is the excess molar refraction, i.e., the molar refraction of the solute minus the 
molar refraction of an alkane of equivalent volume; S is a combined 
dipolarity/polarizability descriptor showing how polar or polarizable the species is; A is the 
total solute hydrogen bond acidity for the molecule; B is the total solute hydrogen bond 
basicity for the molecule; V is the McGowan characteristic volume [213] and L is the 
solute gas- n-hexadecane partition coefficient at 298 K. 
The e coefficient indicates the ability of the phase to interact with solutes via π and n 
electron pairs. The s coefficient gives the tendency of the phase to interact with 
dipolar/polarizable solutes and indicates how well the electrons in the solute will be 
polarized. The a and b coefficients are the hydrogen-bond basicity and the acidity of the 
phase respectively. The v coefficient is a combination of positive exoergic dispersion 
forces and a negative endoergic cavity term [214]. The l coefficient is a combination of 
dispersion forces (that make a positive contribution) and cavity term (that make a negative 
contribution): in general the dispersion effect is predominant and as a consequence the 
term is often positive. In the case of gases and water it is negative and for that reason it can 
be regarded also as a measure of the hydrophobicity of the phase. 
The equation Eq. 4-1 described the transport processes involving two or more solution, 
liquid, or solid phases, while Eq. 4-1’ is used to describe the transport process involving 
transfer from the gas to a condensed phase. Clearly, in this frame, Eq. 4-1 was used for our 
approach . 
The numerical values of these coefficients are obtained by fitting experimental partition 
data and they can be regarded as constants for a given system. These data contain the 
complimentary effects of the phase on the interactions. 
In this work, we considered only the S, A, E and V values as molecular descriptors. For 
completeness, in Table 4.4, the drug parameters taken from ADME database [215] together 
with the heat and temperature of fusion are reported. 
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Compound T
f
 (K) ΔHf(kJ mol−1) E S A B V L 
9,10-Anthraquinone 559.15 31.59 1.84 2.05 0 0.79 1.5288 8.751 
Aspirin 407.36 23.01 0.84 1.42 0.57 0.77 1.2879 6.113 
Budesonide 499.65 28.22 2.33 3.23 0.48 2.16 3.268 15.528 
Caffeine 510.28 22.52 1.48 1.9 0 1.27 1.3632 7.793 
Chlorthalonil 523.4 29.56 1.43 1.99 0 0.28 1.5154 7.912 
Cholesterol 421.16 28.19 1.36 1.76 0.31 0.81 3.4942 14.089 
Cholesteryl acetate 387.94 25.97 1.22 1.89 0 0.87 3.7917 14.851 
Cyproterone acetate 473.65 28.94 2.08 3.09 0 0.254 3.089 15.562 
Codeine 429.4 24.25 2.16 1.92 0.23 1.58 2.2057 11.637 
p-Coumaric acid 486.48 27.48 1.13 1.39 1.07 0.79 1.2292 6.333 
Diazepam 401.9 22.7 2.11 1.72 0 1.04 2.0739 11.132 
Exemestane 428.3 25.73 1.81 2.6 0 0.254 2.3946 12.295 
Ferulic acid 445.15 25.14 1.11 1.46 0.85 0.87 1.4288 7.104 
Flurbiprofene 383.9 21.68 1.5 1.51 0.57 0.58 1.8389 8.679 
Ketoprofen 367.15 20.74 1.56 1.97 0.57 0.87 1.9779 9.757 
Lovastatin 445.5 43.14 1.38 2.34 0.31 1.76 3.2859 15.459 
Medrossiprogesterone acetate 480.6 29.37 1.6 2.84 0 1.41 3.1186 13.799 
Methimazole 418.82 27.15 1.24 1.09 0.13 0.94 0.841 4.086 
Methyl gallate 475.32 26.85 1.18 1.6 1.41 1.02 1.2487 6.791 
Methylparaben 402.27 23.2 0.87 1.24 0.66 0.72 1.1313 5.357 
Naproxen 427.24 31.5 1.54 1.49 0.57 0.75 1.7821 8.627 
Nifedipine 446 25.2 1.56 2.25 0.13 1.53 2.495 11.454 
Nimesulide 421.65 23.82 2.03 2.68 0.43 1.1 2.0787 11.455 
Nimodipine 398.15 26.65 1.6 2.41 0.13 1.79 3.1168 13.691 
Nitrendipine 430 41.1 1.56 2.25 0.13 1.862 2.635 12.499 
Penicillin G 483 41.59 2.27 2.71 0.84 2.05 2.3771 14.892 
Progesterone 400.15 26.89 1.56 2.49 0 1.04 2.6215 12.036 
Propranolol 369.15 28.57 1.76 1.44 0.29 1.36 2.148 10.12 
Protocatechualdehyde 426.48 24.09 1.19 1.57 1 0.82 0.9904 5.834 
 S
u
p
er
cr
it
ic
al
 f
lu
id
s 
ap
p
li
ca
ti
o
n
s:
 S
o
lu
b
il
it
y
 i
n
 s
u
p
er
cr
it
ic
al
 f
lu
id
s 
8
 9
 
Compound T
f
 (K) ΔHf(kJ mol−1) E S A B V L 
Protocatechuic acid 472.98 26.72 1.12 1.46 1.27 0.86 1.0491 6.096 
Salicylic acid 432.24 24.41 0.91 1.1 0.7 0.4 0.9904 5.26 
Simvastatin 412.6 32.17 1.35 2.29 0.31 1.45 3.4268 14.478 
Stigmasterol 435.15 29.14 1.52 1.85 0.31 0.254 3.733 16.075 
Sulfamerazine 509.75 31.6 2.1 2.52 0.59 1.41 1.8634 10.673 
Tebuconazole 377.85 21.34 1.67 1.76 0.31 0.93 2.4113 10.698 
Theobromine 620 41.11 1.46 1.89 0.24 1.22 1.2223 7.652 
Teophylline 547.5 29.71 1.46 1.99 0.35 1.29 1.2223 7.875 
Uracil 609.65 34.44 0.9 1.47 0.44 0.88 0.7516 5.158 
Vanillic acid 482.61 27.26 0.96 1.35 0.78 0.8 1.19 6.123 
Table 4.4: Physical properties and Abraham's descriptors for pharmaceutical compounds. 
In this formalism, the condition for equilibrium is that the fugacity of each component,    
must be equal in both phases. The subscript numbers 1 and 2 will be referred to CO2 and 
pharmaceutical compound, while the subscripts S and L stand for solid and liquid, 
respectively. The solubility y2 of the solute in CO2 in terms of standard state fugacities,   
 , 
is, 
   
 
  
 
  
       
  
       
         Eq. 4-2 
where  is the activity coefficient of the solute in solution. The ratio of the standard state 
fugacities is only dependent on the properties of the solute. Prausnitz et al. [216] have 
expressed this ratio in terms of measurable properties with: 
  
  (   )
  
        
 
 
   
∫ (   
  
      
  )   
 
  
∫    
  
  
  
  
  
 
  
      Eq. 4-3 
where the superscript tp refers to the triple point, but can be replaced by the solute melting 
point   
 
 with little error. Cp2 is the difference in heat capacity of the liquid and solid 
solute phases; ∆v is the pharmaceutical compound volume difference between the liquid 
and solid phase respectively and    
 
the solute enthalpy of fusion. The terms that include 
∆Cp2 and ∆v2 are much smaller than    
 
and at moderate pressures, tend to cancel each 
other out, leaving a much simpler expression: 
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)]       Eq. 4-4 
Combining Eq. 4-3 with Eq. 4-4: 
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)]        Eq. 4-5 
Since the solubility in CO2 is low, we assume that γ2 is independent of concentration and 
equal to   
   
From the above equation we can assume that: 
    
         [
   
 
 
(
 
  
  
 
 
)]       Eq. 4-6 
The activity coefficient can be expressed as a reduced LFER Abraham equation 
considering only the hydrogen bond acidity, the dipolarity/polarizability descriptors and 
the McGowan’s volume: 
    
                    Eq. 4-7 
The e, a, s and v coefficients obtained from fitting the values of Eq. 4-6, are reported in 
Table 4.5. 
The ln y2 should theoretically be linearly related to the density of CO2,   , and we use the 
relationship between activity coefficient and the partial molar volume  2 proposed by 
Eckert et al. [217].  
      
                 Eq. 4-8 
A is an adjustable parameter, Z is the CO2 isothermal compressibility, 
   
 
  
(
   
  
)
 
         Eq. 4-9 
Where V1 is the molar volume of CO2 
  
  is the solid molar volume of the drug.  
            ( 
  
 
 
)       Eq. 4-10 
Where c, α,   , and   are obtained from fitting the values of Eq. 4-8.  
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Fit parameters 
e 1.56808 c −2.368 
s 2.160 α −0.747 
a 4.462 s1 1.114 
v 2.561 v1 1.222 
Table 4.5: Fit parameters used in Eq. 4-10 for solubility data close to 313 K. 
The solubility can be calculated combining Eq. 4-7 with Eq. 4-10: 
     [
   
 
 
(
 
  
  
 
 
)]      
             Eq. 4-11 
Where      is the CO2 reduced density. 
4.4.2. Results and Discussion 
In literature, it has been common practice to empirically correlate the solubility of the 
solute in SCF as a function of the pure CO2 density. In Figure 1 are reported some 
comparisons, at temperature closed to 313 K, between experimental solubility data and 
those obtained through our approach (Eq. 4-11 with the fit parameters of Table 4.5) for 
Aspirin, Medrossiprogesterone acetate Cholesterol and Simvastatine.  
 
 
 
a 
 S
u
p
er
cr
it
ic
al
 f
lu
id
s 
ap
p
li
ca
ti
o
n
s:
 S
o
lu
b
il
it
y
 i
n
 s
u
p
er
cr
it
ic
al
 f
lu
id
s 
9
2 
 
 
 
Figure 4.10:(A) Calculated (model) and experimental (exp) solubility of Aspirin as a function of the reduced 
density (AADy2% = 2.35). (B) Calculated (model) and experimental (exp) solubility of Cholesterol as a 
function of the reduced density (AADy2% = 13.89). (C) Calculated (model) and experimental (exp) 
solubility of Medrossiprogesterone acetate as a function of the reduced density (AADy2% = 21.9). 
The comparison between experimental and estimated data were expressed in term of the 
average absolute deviation AADy2%, in y2 
        
   
 
∑ |
  
       
   
  
   |       Eq. 4-12 
In Figure 4.11 is reported the average absolute deviation between logarithmic experimental 
solubility data,     
   
, and those calculated,     
    , showing an AADlny2% of 8.209. 
b 
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∑ |
    
         
   
    
   |       Eq. 4-13 
 
Figure 4.11: Comparison between experimental (exp) and calculated (calc) drugs solubility reported in Table 
4.3 at temperatures close to 313 K  
As mentioned above, the lower is the solubility experimental data, the higher is the 
deviation with the estimated data, as showed for Diazepam in Figure 4.12. 
 
Figure 4.12: Calculated (Model) and experimental (exp) solubility of Diazepam as a function of the reduced 
density (AADy2%= 11.37)  
The foremost purpose of this study is also to test whether it is possible to predict the 
solubility of pharmaceutical compounds in supercritical CO2, using the literature molecular 
data. In Figure 4.13 is depicted the example of simulation made for Benzocaine [200] that 
is not in Table 4.3.  
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Figure 4.13: Calculated (Model) and experimental (exp) solubility of Benzocaine as a function of the 
reduced density (AADy2%= 19.92) 
Moreover, this approach finds application for the same drugs in a wide temperature spread 
(from 300 to 358 K) and at the same pressure range (80-500 bar) as well. For this 
estimation, 858 literature data were considered Table 4.3. Clearly, to adapt the showed 
method at these conditions, all the coefficients were recalculated Table 4.6. 
Fit parameters 
e 1.3611 c -1.0605 
s 5.1789 α 0.0617 
a 4.3037 s1 2.5316 
v 1.7589 v1 0.7527 
Table 4.6: Fit parameters used in Eq. 4-11 for solubility data in the temperature range of 300-358 K 
From these data emerges how the increased temperature range evidently affects the c and α 
values. Furthermore, also s, sa changes highlighted the increasing of both values, 
suggesting the bigger dipolarity/polarizability effect of the CO2 at a given density. As 
reported in literature [218] a decrease of v and va was observed.  
Figure 4.14 depicts the differences between logarithmic experimental data and those 
estimated by Eq. 4-11 and considering the coefficient reported in Table 4.6 (R
2 
of 0.75 for 
the ln y
exp
 versus ln y
cal 
that correspond to a total AADlny2% of 7.76). 
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Figure 4.14: Comparison between experimental (exp) and calculated (calc) drugs solubility reported in Table 
4.3 in the temperature range of 300-358 K 
To confirm the reliability of the experimental data, in Figure 4.15 are reported the 
solubility behaviors of Caffeine (Figure 4.15 a) and Vanillic acid (Figure 4.15 b).  
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Figure 4.15: (A) Calculated (model) and experimental (exp) solubility of Caffeine as a function of the 
reduced density (AADy2% = 14.07). (B) Calculated (model) and experimental (exp) solubility of Vanillic acid 
as a function of the reduced density (AADy2 = 12.0). 
 
With this formalism, we are able to describe the dependence of the solubility of 
pharmaceutical compounds in SCF on the density of the fluid phase. This approach 
provides useful information about the activity coefficient model, requiring only a 
dependence on CO2 concentration. Because of the common pure components properties, 
this method can be used to predict the solubility of active compounds of pharmaceutical 
interests. 
 
Furthermore, this approach provides an explanation for a common and useful literature 
observation in which the logarithm of the mole fraction of the solute in the fluid phase has 
an approximately linear dependence on the density of the SCF phase. 
The determination of activity and diffusion coefficient trough Abraham’s method can find 
application also for polymeric materials of pharmaceutical interest with the aim to 
investigate their possible interaction in different solvents, drugs or in SCO2.  
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4.5. Infinite–fugacity coefficient of volatile organic 
compounds and pharmaceutical compounds in Cyclic 
Olefin Copolymer and polyvinyl pyrrolidone. 
As showed in the previous chapters, the use of polymers in the pharmaceutical field is very 
common playing different roles. One of recent applications is the impregnation of a 
polymeric system with a drug by means of supercritical fluid. This process is based on 
dissolving the active principle in a supercritical fluid, the supercritical solvent swells and 
reduces the glass transition temperature (Tg) of the polymer and the solute splits between 
the solvent and the matrix itself. The process is feasible only if the impregnating agent is 
soluble in the supercritical fluid, or if the polymer has been swollen by the supercritical 
solvent and the partition coefficient is favorable to charge the matrix with enough active 
principle. 
Whatever process is used, the compatibility between the various components plays a key 
role. Inverse gas chromatography (IGC) can be employed for collecting information useful 
for the characterization of the polymers and for the investigation of the equilibria involved. 
In the IGC, the obtained experimental data are the specific retention volumes Vg° of a 
solute injected in the stationary phase (the polymer in this case) at different temperatures. 
The plot of the retention volume logarithm (lnVg°) vs the reciprocal of the temperature is 
called retention diagram. From this diagram it is possible to observe the plasticization and 
the phase transitions of the polymer investigated. The experimentally determined specific 
retention volumes Vg° can be used to characterize the investigated stationary phases in 
terms of dipolarity/polarizability, hydrogen-bond, basicity/acidity and lipophilicity by 
means of the equation of solvation proposed by Abraham. The use of linear free energy 
descriptors is proposed to extrapolate experimental information on polymer organic 
solvents interaction for the evaluation of the interactions with drugs.  
This approach has been applied to different Cyclic Olefin Copolimers (COCs), normally 
used as packaging materials, and polyvinyl pyrrolidone (PVP) grades, usually employed 
for the preparation of pharmaceutical solid oral dosage forms.  
4.5.1. Materials  
Cyclic olefin copolymers, with different properties (Table 4.7), designed as COC1, COC2, 
COC3 and COC4, were kindly donated by Hoechst (Frankfurt, Germany). They form a 
new and interesting group of materials suitable for high performance optical, medical, 
 S
u
p
er
cr
it
ic
al
 f
lu
id
s 
ap
p
li
ca
ti
o
n
s:
 I
n
fi
n
it
e–
fu
g
ac
it
y
 c
o
ef
fi
ci
en
t 
o
f 
v
o
la
ti
le
 o
rg
an
ic
 c
o
m
p
o
u
n
d
s 
an
d
 
p
h
ar
m
ac
eu
ti
ca
l 
co
m
p
o
u
n
d
s 
in
 C
y
cl
ic
 O
le
fi
n
 C
o
p
o
ly
m
er
 a
n
d
 p
o
ly
v
in
y
l 
p
y
rr
o
li
d
o
n
e.
 
9
8 
 
electrical, pharmaceutical and food packaging, syringes and other applications. The cyclic 
olefin copolymers are obtained by the copolymerization of an olefin with a cyclic olefin in 
the presence of a metallocene catalyst. 2-norbornene is the cyclic olefin used and it reacts 
with ethylene in the presence of a metallocene catalyst [219, 220]. Several types of COCs 
are obtained by the copolymerization of an olefin with a cyclic olefin in the presence of 
different other metallocene catalysts. All cyclic olefin copolymers (COCs) are completely 
amorphous. This morphology is due to the steric hindrance created by the incorporation of 
norbornene in their chains. In fact, norbornene is much bulkier than ethylene and has rigid 
bridged-ring structure that prevents crystallization [221]. Thus, the COCs are transparent 
and this has a direct consequence on their optical properties, which are excellent. They also 
present other properties [222] such as good stability, low density, good resistance to acids 
and bases, moderate permeability to gases, low resistance to nonpolar solvents (heptane, 
toluene) and to halogenous solvents (methylene chloride, for example), excellent 
transparency, strong water barrier (four times higher than in the case of PET), good 
resistance to polar solvents (ketones, methanol, ethanol, etc.).  The COCs can be used in 
this way in packaging films without interaction with the pharmaceutical compounds.  
The high purity and absence of ionic content in these materials provide high insulation 
resistance and very low dielectric loss. They are recognized as a resin with optical 
properties comparable to those of poly(methyl methacrylate) acrylic resin (PMMA). They 
have also superior heat resistance and dimensional stability relative to polycarbonate (PC) 
and PMMA. COCs have a very high moisture barrier, low water absorption, good 
resistance to hydrolysis and chemical media, and low density. In addition, they offer high 
transparency extending into the UV range, low birefringence, adjustable heat deflection 
temperature, and high rigidity.  
Property COC 1  COC 2  COC 3  COC 4  
MW [g/mol] 42000 45000 45000 50000 
Tg [K] ~408 ~408 ~448 ~356 
Norbornene % 50 50 60 37 
Table 4.7: COC property 
Polyvinyl pyrrolidone (BASF, Germany) are synthetic polymers consisting essentially of 
linear 1-vinyl-2-pyrrolidinone groups, the differing degree of polymerization results in 
polymers of various molecular weights. They are characterized by their viscosity in 
aqueous solution, relative to that of water, expressed as a K-value, in the range 10–120. 
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They are used in a variety of pharmaceutical formulations, primarily used in solid-dosage 
forms. In tableting, PVP solutions are used as binders in wet-granulation processes. PVP 
are also added to powder blends in the dry form and granulated in situ by the addition of 
water, alcohol, or hydroalcoholic solutions. PVP are used as a solubilizer in oral and 
parenteral formulations, and has been shown to enhance dissolution of poorly soluble 
drugs from solid-dosage forms. PVP solutions may also be used as coating agents or as 
binders when coating active pharmaceutical ingredients on a support such as sugar beads. 
They are additionally used as a suspending, stabilizing, or viscosity-increasing agent in a 
number of topical and oral suspensions and solutions. The solubility of a number of poorly 
soluble active drugs may be increased by mixing with PVP [223].  
In this work are considered PVP K25, PVP K30 and PVP K90 and in Table 4.8 are reported 
their main properties. 
Property PVP K25 PVP K30 PVP K90 
MW [g mol
-1
] 30000 50000 1000000 
Tg [K] ~428 ~448 ~453 
Table 4.8: PVP properties 
All the volatile organic compounds (Aldrich Chemical Co) were of reagent-grade and used 
without further purification. 
4.5.2. Method 
Inverse gas chromatograpy (IGC) 
A thermal-conductivity chromatograph (Fractovap Model B, Carlo Erba, Italy) was 
employed (Figure 4.16). 
 
Figure 4.16: Experimental apparatus adopted for IGC measurements 
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The thermostat stability of the oven was better than 0.05 K and measured by an electronic 
thermometer Systemteknik AB S1220. The carrier gas (helium) flow rate was measured by 
means of a soap film meter. The pressure drop in the column was measured to within ± 1 
mmHg by a mercury manometer. 
The measured experimental conditions were retention time of the solvents, dead time 
(retention time of air), carrier flow rate, column temperature, flow meter temperature, 
ambient pressure and pressure drop in the column. The carrier flow was set ranging from 
20 to 40 mL
.
min
-1
, and the pressure drop was about 40-150 mbar. 
For all the polymers, the influence of carrier gas flow rate was evaluated by extrapolating 
the retention volumes to zero flow rate: no influence of the flow rate was observed for all 
the stationary phases. 
Since the peaks did not show notable asymmetry, retention times were read using peak 
maxima. 
The uncertainties are estimated as follows: carrier flow, ± 0.005 mL
.
s
-1
; column 
temperature ± 0.05 K; soap-film meter temperature, ± 0.1 K; inlet and outlet pressures, ± 2 
mbar; solvent mass, ± 0.001 g. The effect of these variables in the activity coefficients is 
estimated to be about 2 %. 
Column preparation 
Known amount of polymers was solubilized in chloroform and mixed with a known 
quantity of silanized Chromosorb (WDMCS 100/120 mesh) which allows no adsorption on 
the support. The solvent was then removed by vacuum and nitrogen stripping, and the 
coated support was fed into 2 m long, 4 mm internal diameter. The solvent was further 
removed once the column was installed, by flowing helium at 353 K for about 24 h. The 
weight percent of polymer in the impregnated support was over 15 % for all the columns: 
in these conditions the effect of adsorption is negligible [224]. Solutes (0.1μL) were 
injected with a Hamilton syringe. 
Theory  
The specific retention volume (Vg
0
) is given by: 
  
  
 
  
      
   
  
       
 
   
               Eq. 4-14 
where    is the mass of polymer in the column,     and     are the retention time of the 
solvent and the dead time respectively, F is the carrier gas flow, Tfm and Pfm are the flow 
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meter absolute temperature and pressure,   
  is the vapor pressure of water at Tfm.   
  
represents the correction factor for gas compressibility inside the column and it is given by: 
  
  
 
 
(
  
  
)
 
  
(
  
  
)
 
  
          Eq. 4-15 
where    and    are the pressure at the input and exit of the column, respectively. 
Many theoretical approaches have been proposed in order to characterize the compounds 
(often polymers) used as stationary phases in gas-liquid chromatography. Some of them, 
on the basis of chromatography data for some reference substances, have been used to 
obtain characteristic parameters of stationary phases. With other approaches, the solute-
solvent interactions in both stationary and mobile phases have been investigated. 
These latter approaches involve the use of a number of parameters (descriptors) that 
describe the properties of the solute molecule and, for extension, the behavior of the solute 
molecule in solution. In particular, the present work employed the Abraham’s solvation 
equation (see section 4.4) [225, 226]:  
                             Eq. 4-1’ 
where the variable SP can be the partition coefficient of an organic solvent or, as is the 
case of the present work, the retention volume in gas-liquid chromatography. Each term in 
the equation refers to some particular solute-solvent interaction.  
The numerical values of these descriptors can be calculated on the basis of the molecular 
structures of the different organic solutes [215] and have been found to contain essentially 
the same chemical information as the theoretically calculated molecular descriptors of 
Klamt’s COSMO-RS [227].  
It must be clarified that in Eq. 4-1 it was considered the McGowan volume descriptor 
instead of the L descriptor. The different forms were designed to deal with transfer from 
one condensed phase to another, while the latter for the transfers from the gas phase to that 
condensed. 
The solute descriptors represent the solute effects on various solute-phase interactions; the 
regression coefficients c, e, s, a, b, and l correspond to the complementary effects of the 
phase on these interactions. These coefficients were obtained by fitting the experimental 
values of the quantity SP (in our case, the retention volume). 
In the literature [228-231], applications of solvation theory for the characterization of 
polymer-solvent interactions have been extensively reported. Gas-chromatographic 
retention volumes of the solvents are regressed, and the specific solvation parameters of 
the polymers, used as stationary phases, are able to reproduce the partition [230]. These 
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parameters can be used for the prediction of the partition and, consequently, of the 
interactions between other volatile organic compounds and the polymer, provided that the 
descriptors for these solutes are known. 
The experimental specific retention volume can also be used for the calculation of   
 , the 
infinite-dilution mass-fraction activity coefficient of a solvent in a polymer at temperature 
T, as   
   is related to the specific retention volume by the following equation: 
    
    (
        
    
   
   )  
(      
 )  
   
  
       Eq. 4-16 
where M1, B11,   
     and   
  are the molecular weight, the second virial coefficient, the 
vapor pressure, and the molar volume of the solvent at the column absolute temperature T, 
respectively. The saturation pressures were calculated with the Antoine’s equation, the 
second virial coefficient with the correlation of Hayden and O’Connell and the liquid 
molar volumes with the correlation of Yen and Woods
 
[232]. 
Moreover, using the experimental Vg
0
, fugacity coefficient at infinite dilution    ̂can be 
calculated by means of the following equation: 
   ̂  
   
  
     
          Eq. 4-17 
where M2 is the molar weight of the polymer and P the average pressure of the column. 
4.5.3. Results and discussion 
In the ICG technique, the retention mechanism of a solute in a polymer depends on the 
polymer state For a semicrystalline polymer [233], three characteristic temperatures can be 
identified: the glass transition temperature (Tg), the softening temperature (Ts), and the 
melting temperature (T
f
).  
In the temperature range below Tg, diffusion of the solute in the polymer bulk phase is 
precluded, so the retention mechanism involves only surface adsorption.  
At Tg, solute penetration begins, and the retention volume increases with temperature. 
Below T
f
, retention proceeds by bulk sorption, and the interactions between the polymer 
and the solute are restricted to the amorphous domains of the stationary phase.  
For temperatures above T
f
, the behavior is linear, corresponding to bulk absorption in the 
totally amorphous polymer. Retention diagrams were determined for all of the polymers 
studied in order to establish the correct range of temperatures to be investigated.  
A typical retention diagram is presented in Figure 4.17 for the polymer COC 4 with n-
hexane as solute.  
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Figure 4.17: Retention diagram for n-hexane in COC 4. 
 
The presence of the characteristic ζ behavior is evident, and the Tg and T
f
 values 
correspond approximately to the minimum and maximum, respectively. For each of the 
polymers, the temperatures chosen for the determination of the retention volume, which 
were suitable to give correct values of the activity coefficient, were always higher than the 
T
f
 value obtained from the retention diagram. In this way, the linearity of the plot of ln V°g 
versus 1/T was always satisfactory to better than ±0.024 in ln V°g, which gave an 
uncertainty of about 3 % in the activity coefficients.  
In Table 4.9 to Table 4.15, the natural logarithms of the retention volumes at different 
temperatures are reported. Values at 313 K were evaluated assuming the linearity of lnV°g 
at the temperature variations. 
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Solvent 
ln Vg° 
T= 313 K T= 438 K T= 443 K T= 449 K T= 457 K 
n-hexane 2.648 0.78 0.69 0.66 0.58 
n-heptane 3.949 1.43 1.31 1.27 1.16 
n-octane 4.890 2.01 1.88 1.83 1.70 
Hexene 2.545 0.78 0.70 0.67 0.59 
Heptene 3.909 1.39 1.27 1.23 1.12 
Octene 4.682 1.99 1.87 1.82 1.70 
Cyclohexane 9.991 1.69 1.60 1.57 1.48 
Methylcyclohexane 4.130 1.99 1.89 1.86 1.76 
Ethylcyclohexane 5.465 2.67 2.54 2.49 2.37 
Benzene 4.690 1.81 1.68 1.63 1.50 
Toluene 5.747 2.39 2.23 2.18 2.03 
Ethylbenzene 6.598 2.88 2.71 2.65 2.48 
Methylethylketone 5.336 0.86 0.65 0.57 0.38 
Diethyl ketone 4.668 1.41 1.26 1.20 1.06 
Methyl isobutyl ketone 4.005 1.50 1.39 1.34 1.23 
Propanol 3.648 0.39 0.24 0.18 0.04 
Butanol 4.586 1.14 0.98 0.92 0.77 
Ethtyl acetate 3.224 0.62 0.50 0.46 0.34 
Propyl acetate 3.759 1.24 1.12 1.08 0.97 
Butyl acetate 4.927 1.86 1.72 1.67 1.53 
Tetrahydrofuran 3.500 1.36 1.26 1.23 1.13 
Dibuthylether 5.747 2.39 2.23 2.18 2.03 
Chlorobutane 3.974 1.37 1.25 1.21 1.09 
Chloropentane 5.037 1.97 1.83 1.78 1.64 
Tetrachloromethane 3.213 1.72 1.65 1.62 1.56 
Chloroform 3.771 1.44 1.33 1.29 1.19 
Propionitrile 4.139 0.52 0.36 0.29 0.13 
Butyronitrile 4.350 1.18 1.03 0.98 0.84 
Table 4.9:Natural logarithm of experimental retention volumes (ln Vg°) of COC 1 in different organic 
solvents at different temperatures. 
 S
u
p
er
cr
it
ic
al
 f
lu
id
s 
ap
p
li
ca
ti
o
n
s:
 I
n
fi
n
it
e–
fu
g
ac
it
y
 c
o
ef
fi
ci
en
t 
o
f 
v
o
la
ti
le
 o
rg
an
ic
 c
o
m
p
o
u
n
d
s 
an
d
 
p
h
ar
m
ac
eu
ti
ca
l 
co
m
p
o
u
n
d
s 
in
 C
y
cl
ic
 O
le
fi
n
 C
o
p
o
ly
m
er
 a
n
d
 p
o
ly
v
in
y
l 
p
y
rr
o
li
d
o
n
e.
 
1
0
 5
 
Solvent 
ln Vg° 
T = 313 K T= 449 K T= 453 K T= 457 K T= 461 K 
n-hexane 2.961 0.81 0.76 0.72 0.68 
n-heptane 3.874 1.37 1.32 1.27 1.22 
n-octane 3.893 1.89 1.85 1.81 1.77 
Hexene 2.414 0.76 0.73 0.70 0.66 
Heptene 3.844 1.34 1.29 1.24 1.19 
Octene 3.873 1.87 1.83 1.79 1.75 
Cyclohexane 3.122 1.62 1.59 1.56 1.53 
Methylcyclohexane 3.792 1.94 1.90 1.86 1.83 
Ethylcyclohexane 4.553 2.55 2.51 2.47 2.43 
Benzene 4.042 1.69 1.64 1.59 1.55 
Toluene 4.391 2.24 2.19 2.15 2.11 
Ethylbenzene 4.894 2.69 2.65 2.60 2.56 
Methylethylketone 1.901 0.55 0.52 0.49 0.47 
Diethyl ketone 4.284 1.28 1.22 1.16 1.10 
Methyl isobutyl ketone 3.934 1.43 1.38 1.33 1.28 
Propanol 3.664 0.36 0.29 0.23 0.16 
Butanol 2.694 0.99 0.96 0.92 0.89 
Ethtyl acetate 4.017 0.61 0.55 0.47 0.41 
Propyl acetate 2.922 1.12 1.08 1.05 1.01 
Butyl acetate 4.062 1.71 1.66 1.61 1.57 
Tetrahydrofuran 3.263 1.26 1.22 1.18 1.14 
Dibuthylether 4.572 2.22 2.17 2.12 2.08 
Chlorobutane 2.410 1.26 1.23 1.21 1.19 
Chloropentane 3.332 1.83 1.80 1.77 1.74 
Tetrachloromethane 2.252 1.60 1.59 1.58 1.56 
Chloroform 4.123 1.32 1.26 1.21 1.15 
Propionitrile 3.824 0.47 0.40 0.33 0.27 
Butyronitrile 3.214 1.06 1.02 0.98 0.93 
Table 4.10: Natural logarithm of experimental retention volumes (ln Vg°) of COC 2 in different organic 
solvents at different temperatures. 
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Solvent 
 ln Vg° 
T= 313 K T= 478 K T= 488 K T= 498 K T= 508 K 
n-hexane 0.935 0.82 0.69 0.58 0.46 
n-heptane 1.464 1.28 1.09 0.90 0.72 
n-octane 1.994 1.75 1.50 1.25 1.01 
Hexene 0.933 0.82 0.70 0.59   
Heptene 1.280 1.18 1.05 0.94 0.85 
Octene 1.595 1.51 1.42 1.32 1.25 
Cyclohexane 1.779 1.58 1.39 1.18 0.99 
Methylcyclohexane 2.069 1.87 1.67 1.47 1.27 
Ethylcyclohexane 2.619 2.42 2.22 2.02 1.82 
Benzene 1.560 1.46 1.36 1.26 1.16 
Toluene 2.165 2.02 1.89 1.74 1.60 
Ethylbenzene 2.819 2.58 2.34 2.11 1.86 
Methylethylketone 0.065 0.03 -0.07 -0.10 -0.14 
Diethyl ketone 0.620 0.53 0.42 0.33 0.24 
Methyl isobutyl ketone 1.489 1.33 1.17 1.00 0.85 
Propanol 0.595 0.46 0.31 0.17 0.04 
Butanol 1.045 0.90 0.75 0.59 0.46 
Ethtyl acetate 0.605 0.52 0.41 0.33 0.24 
Propyl acetate 1.135 1.01 0.86 0.75 0.61 
Butyl acetate 1.739 1.54 1.33 1.12 0.93 
Tetrahydrofuran 1.259 1.06 0.86 0.67 0.46 
Dibuthylether 2.154 1.98 1.81 1.63 1.46 
Chlorobutane 1.339 1.14 0.94 0.73 0.54 
Chloropentane 1.884 1.69 1.49 1.30 1.10 
Tetrachloromethane 1.969 1.69 1.41 1.14 0.85 
Chloroform 1.310 1.17 1.05 0.91 0.77 
Propionitrile 0.080 0.02 -0.04 -0.11 -0.16 
Butyronitrile 0.615 0.56 0.50 0.43 0.39 
Table 4.11: Natural logarithm of experimental retention volumes (ln Vg°) of COC 3 in different organic 
solvents at different tempertures 
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Solvent 
 ln Vg° 
T= 313 K T= 383 K T= 393 K T= 403 K T= 413 K 
n-hexane 3.772 1.95 1.72 1.54 1.35 
n-heptane 5.343 2.83 2.49 2.24 2.00 
n-octane 6.319 3.57 3.22 2.93 2.67 
Hexene 4.232 2.01 1.75 1.50 1.29 
Heptene 5.246 2.77 2.47 2.18 1.97 
Octene 6.307 3.50 3.18 2.87 2.59 
Cyclohexane 5.188 3.00 2.75 2.51 2.29 
Methylcyclohexane 5.675 3.42 3.14 2.91 2.68 
Ethylcyclohexane 6.777 4.21 3.92 3.63 3.38 
Benzene 5.248 2.96 2.71 2.49 2.21 
Toluene 6.309 3.73 3.47 3.18 2.90 
Ethylbenzene 7.205 4.39 4.09 3.78 3.48 
Methylethylketone 4.242 1.57 1.22 0.95 0.69 
Diethyl ketone 5.241 2.64 2.31 2.03 1.79 
Methyl isobutyl ketone 5.824 3.08 2.74 2.46 2.18 
Propanol 4.730 1.64 1.25 0.92 0.63 
Butanol 5.547 2.47 2.10 1.76 1.47 
Ethtyl acetate 4.804 2.22 1.92 1.64 1.38 
Propyl acetate 5.627 2.71 2.35 2.03 1.76 
Butyl acetate 6.207 3.37 3.00 2.70< 2.44 
Tetrahydrofuran 4.533 2.41 2.24 2.01 1.73 
Dibuthylether 7.036 4.04 3.74 3.39 3.08 
Chlorobutane 5.071 2.58 2.26 2.01 1.76 
Chloropentane 5.963 3.37 3.01 2.76 2.51 
Tetrachloromethane 4.999 2.92 2.66 2.44 2.24 
Chloroform 4.828 2.59 2.31 2.10 1.85 
Propionitrile 5.019 1.64 1.25 0.89 0.54 
Butyronitrile 5.492 2.42 2.06 1.73 1.42 
Table 4.12: Natural logarithm of experimental retention volumes (ln Vg°) of COC 4 in different organic 
solvents at different temperatures 
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Solvent 
 ln Vg° 
T= 313 K T=493 K T=503 K T=513 K T=523 K 
n-decane 2.538 0.089 0.047 -0.029 -0.154 
n-dodecane 3.237 0.600 0.550 0.490 0.330 
n-tetradecane 2.915 0.961 0.919 0.868 0.763 
n-hexadecane 4.987 1.396 1.325 1.208 1.041 
Octene 1.320 0.030 -0.010 -0.050 -0.099 
Decene 2.216 0.380 0.330 0.242 0.207 
Dodecene 2.646 0.765 0.727 0.649 0.584 
Benzene 5.664 1.199 1.072 0.917 0.758 
Toluene 5.644 1.369 1.248 1.122 0.940 
Ethylbenzene 6.516 1.605 1.483 1.290 1.128 
Acetone 3.819 0.821 0.738 0.625 0.528 
Methylethylketone 5.091 1.043 0.902 0.754 0.646 
Diethyl ketone 5.269 1.154 1.025 0.872 0.751 
Methyl isobutyl ketone 4.433 1.169 1.054 0.940 0.846 
Methanol 5.154 1.328 1.199 1.069 0.949 
Ethanol 5.421 1.364 1.228 1.085 0.964 
Propanol 7.550 1.664 1.456 1.284 1.071 
Butanol 8.413 1.969 1.752 1.547 1.326 
Acetronitrile 6.320 1.596 1.452 1.304 1.125 
Ethyl acetate 3.940 0.706 0.606 0.477 0.393 
Propyl acetate 3.766 0.816 0.731 0.627 0.526 
Butyl acetate 5.443 1.101 0.985 0.836 0.672 
Chloroform 7.043 1.584 1.409 1.213 1.047 
Chlorobutane 5.092 1.347 1.229 1.116 0.971 
Chlorobutane 4.454 0.755 0.659 0.506 0.399 
Chloropentane 3.727 0.860 0.785 0.675 0.581 
Table 4.13: Natural logarithm of experimental retention volumes (ln Vg°) of PVP K25 in different organic 
solvents at different temperatures 
 
 
 S
u
p
er
cr
it
ic
al
 f
lu
id
s 
ap
p
li
ca
ti
o
n
s:
 I
n
fi
n
it
e–
fu
g
ac
it
y
 c
o
ef
fi
ci
en
t 
o
f 
v
o
la
ti
le
 o
rg
an
ic
 c
o
m
p
o
u
n
d
s 
an
d
 
p
h
ar
m
ac
eu
ti
ca
l 
co
m
p
o
u
n
d
s 
in
 C
y
cl
ic
 O
le
fi
n
 C
o
p
o
ly
m
er
 a
n
d
 p
o
ly
v
in
y
l 
p
y
rr
o
li
d
o
n
e.
 
1
0
 9
 
Solvent 
 ln Vg° 
T = 313 K T= 493K T= 503 K T= 513 K T= 493 K 
n-decane 
-1.633 0.069 0.152 0.184 0.069 
n-dodecane 
2.211 1.094 1.152 1.020 1.094 
n-tetradecane 
3.903 1.592 1.586 1.436 1.592 
n-hexadecane 
0.978 0.115 0.081 0.057 0.115 
Octene 
1.331 0.475 0.442 0.418 0.475 
Decene 
2.382 0.900 0.850 0.800 0.900 
Dodecene 
5.756 1.198 1.026 0.890 1.198 
Benzene 
7.093 1.444 1.242 1.062 1.444 
Toluene 
7.924 1.659 1.458 1.237 1.659 
Ethylbenzene 
3.220 0.660 0.579 0.487 0.660 
Acetone 
4.047 0.882 0.783 0.668 0.882 
Methylethylketone 
5.647 1.109 0.960 0.802 1.109 
Diethyl ketone 
6.380 1.282 1.121 0.938 1.282 
Methyl isobutyl ketone 
4.495 1.252 1.153 1.033 1.252 
Methanol 
4.698 1.279 1.173 1.049 1.279 
Ethanol 
7.277 1.595 1.397 1.212 1.595 
Propanol 
8.923 1.926 1.693 1.454 1.926 
Butanol 
16.407 1.512 1.369 1.242 1.512 
Acetronitrile 
4.815 0.609 0.465 0.326 0.609 
Ethyl acetate 
6.780 0.876 0.684 0.478 0.876 
Propyl acetate 
7.906 1.176 0.945 0.722 1.176 
Butyl acetate 
6.738 1.521 1.326 1.169 1.521 
Chloroform 
5.592 1.350 1.212 1.064 1.350 
Chlorobutane 
3.740 0.657 0.566 0.449 0.657 
Chlorobutane 
5.060 0.919 0.791 0.640 0.919 
Chloropentane 
-1.633 493.39 503.36 513.33 493.39 
Table 4.14: Natural logarithm of experimental retention volumes (ln Vg°) of PVP K30 in different organic 
solvents at different temperatures 
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Solvent 
 ln Vg° 
T= 313 K T= 503 K T= 513 K T= 523 K T= 503 K 
n-decane 
5.759 -0.067 -0.216 -0.434 -0.067 
n-dodecane 
6.305 0.400 0.366 0.029 0.400 
n-tetradecane 
9.689 1.017 0.765 0.470 1.017 
n-hexadecane 
11.837 1.584 1.237 0.937 1.584 
Octene 
4.919 -0.119 -0.252 -0.437 -0.119 
Decene 
6.661 0.347 0.118 -0.051 0.347 
Dodecene 
8.942 0.799 0.567 0.285 0.799 
Benzene 
5.626 0.801 0.632 0.496 0.801 
Toluene 
6.677 1.042 0.847 0.686 1.042 
Ethylbenzene 
9.036 1.259 0.977 0.768 1.259 
Acetone 
3.887 0.418 0.297 0.200 0.418 
Methylethylketone 
4.906 0.589 0.450 0.317 0.589 
Diethyl ketone 
5.727 0.750 0.563 0.436 0.750 
Methyl isobutyl ketone 
7.886 0.923 0.673 0.484 0.923 
Methanol 
5.424 1.022 0.865 0.744 1.022 
Ethanol 
5.382 1.036 0.881 0.762 1.036 
Propanol 
6.831 1.216 1.028 0.862 1.216 
Butanol 
6.804 1.474 1.283 1.138 1.474 
Acetronitrile 
5.100 1.227 1.082 0.982 1.227 
Ethyl acetate 
3.734 0.238 0.141 0.017 0.238 
Propyl acetate 
5.628 0.509 0.317 0.187 0.509 
Butyl acetate 
7.450 0.779 0.547 0.358 0.779 
Chloroform 
6.695 1.172 0.975 0.823 1.172 
Chlorobutane 
4.982 1.038 0.893 0.789 1.038 
Chlorobutane 
3.856 0.286 0.184 0.061 0.286 
Chloropentane 
6.101 0.574 0.409 0.225 0.574 
Table 4.15: Natural logarithm of experimental retention volumes (ln Vg°) of PVP K90 in different organic 
solvents at different temperatures 
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The retention volumes were correlated using the Abraham’s solvation equation, and the 
parameters obtained for the different COCs and PVP are reported in Table 4.16 and Table 
4.17 respectively, together with the corresponding average absolute deviations (AADs). 
T /K c e s a b l AAD % 
COC 1 
313 -0.281 2.318 -0.579 0.048 1.890 1.333 0.03 
438 -0.762 0.639 -0.037 -0.125 0.079 0.505 1.7 
446 -0.838 0.607 -0.012 -0.195 0.012 0.517 1.7 
449 -0.859 0.599 -0.006 -0.214 -0.005 0.521 1.8 
457 -0.927 0.574 0.010 -0.287 -0.062 0.532 2.8 
COC 2 
313 -1.819 1.222 -0.029 0.343 -0.199 1.039 0.5 
449 -0.779 0.523 0.063 -0.077 -0.095 0.508 1.8 
453 -0.842 0.514 0.080 -0.156 -0.110 0.524 2.1 
457 -0.903 0.506 0.097 -0.234 -0.124 0.539 2.7 
461 -0.964 0.497 0.113 -0.311 -0.138 0.555 3.4 
COC 3 
313 -1.817 0.867 0.299 0.314 -0.560 1.036 0.5 
478 -0.722 0.591 -0.086 -0.053 -0.06 0.41 3.8 
488 -0.721 0.603 -0.123 -0.107 0.001 0.386 3.0 
498 -0.721 0.616 -0.173 -0.192 0.096 0.362 3.1 
508 -0.679 0.614 -0.198 -0.244 0.134 0.326 3.0 
COC 4 
313 -0.391 0.417 0.592 2.319 0.600 1.788 0.5 
383 -0.522 0.498 0.051 -0.228 0.124 0.557 5.8 
393 -0.571 0.522 0.006 -0.332 0.132 0.539 5.6 
403 -0.624 0.544 0.005 -0.417 0.069 0.519 5.9 
413 -0.724 0.526 0.050 -0.430 0.004 0.510 6.2 
Table 4.16: Abraham parameters of COC polymers at different temperature 
T/ K c e s a b l AAD % 
PVP K25 
313.15 -1.495 3.567 5.175 9.826 0.380 0.804 0.50 
493.27 -1.247 1.251 1.767 2.965 0.102 0.332 0.86 
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503.25 -1.227 1.17 1.646 2.728 0.082 0.32 0.86 
513.22 -1.217 1.083 1.507 2.552 0.087 0.305 0.84 
523.17 -1.152 0.987 1.354 2.284 0.116 0.275 0.82 
PVP K30 
313.15 -3.832 4.035 9.767 4.977 0.625 1.002 0.96 
439.39 -1.425 1.366 1.687 2.892 0.204 0.385 0.84 
503.36 -1.343 1.133 1.526 2.82 0.072 0.372 0.84 
513.33 -1.166 0.953 1.337 2.648 -0.079 0.328 0.83 
PVP K90 
313.15 -1.623 1.474 3.387 7.482 0.079 1.705 0.36 
503.05 -1.66 1.125 1.605 3.019 0.077 0.399 0.82 
513.07 -1.533 0.969 1.507 2.873 -0.062 0.342 0.81 
523.05 -1.578 0.98 1.524 2.801 -0.078 0.304 0.81 
Table 4.17: Abraham parameters of PVP polymers at different temperature 
The e and l parameters provided the main contributions to the retention volumes and were 
constant for all of the investigated polymers at the closed temperature range, while at 313 
K there are some differences that are reported also for the other parameters. these 
differences can be ascribed to the different interaction between solute and polymer at lower 
temperature. In COCs, a very small value of the s parameter was obtained, indicating that 
the dipole-dipole interactions of the polymers (constituted by a paraffinic chain with 
olefinic rings) with the polarizable solutes are negligible. For PVP, instead, the high s 
values indicated an interaction between polar solute and polymer. The a and b COCs 
parameters also had scarce influence on the retention properties, while in PVP there is a 
considerable acidic components (a parameter). 
Mass-fraction activity coefficients were calculated from the retention volumes using Eq. 4-
17 and are reported in Table 4.18 to Table 4.24. For COCs, nitriles and alcohols showed 
the largest values of the mass fraction activity coefficients; globally, the smallest values 
were those of the nonpolar or slightly polar solutes. Instead, for PVP there are higher 
values for nonpolar solvents and smallest for those polar. These data suggest the affinity of 
organic solvents for the investigate polymers that is inversely proportional to Ω∞ (small 
value= high affinity, high value= small affinity).  
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Solvent 
     
  
T= 438 K T= 446 K T= 449 K T= 457 K 
n-hexane 15.37 14.96 14.79 14.40 
n-heptane 12.44 12.21 12.13 11.90 
n-octane 11.04 10.72 10.62 10.40 
Hexene 14.29 13.89 13.74 13.40 
Heptene 12.06 11.85 11.78 11.60 
Octene 10.35 10.04 9.93 9.70 
Cyclohexane 7.95 7.65 7.55 7.30 
Methylcyclohexane 8.75 8.39 8.28 8.00 
Ethylcyclohexane 6.82 6.60 6.53 6.40 
Benzene 7.01 7.03 7.04 7.10 
Toluene 6.52 6.54 6.56 6.60 
Ethylbenzene 6.20 6.21 6.22 6.30 
Methylethylketone 19.05 20.46 21.14 22.60 
Diethyl ketone 14.43 14.39 14.42 14.40 
Methyl isobutyl ketone 10.48 10.29 10.23 10.10 
Propanol 36.58 35.81 35.59 35.00 
Butanol 24.62 23.75 23.46 22.70 
Ethtyl acetate 18.94 18.79 18.74 18.70 
Propyl acetate 14.29 13.83 13.66 13.20 
Butyl acetate 11.99 11.64 11.50 11.20 
Tetrahydrofuran 8.78 8.53 8.47 8.30 
Dibuthylether 9.17 9.00 8.94 8.80 
Chlorobutane 9.25 9.16 9.14 9.10 
Chloropentane 8.27 8.23 8.23 8.20 
Tetrachloromethane 3.83 3.62 3.54 3.40 
Chloroform 4.57 4.51 4.48 4.40 
Propionitrile 53.27 54.47 55.16 56.60 
Butyronitrile 33.09 32.75 32.62 32.40 
Table 4.18: Weight-fraction activity coefficient at infinite dilution       
   of COC 1 at 438, 446, 449 and 
457 K in different organic solvents. 
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Solvent 
     
  
T= 449 K T= 453 K T= 457 K T= 461 K 
n-hexane 12.76 12.64 12.50 12.42 
n-heptane 11.03 10.85 10.73 10.59 
n-octane 9.97 9.62 9.30 8.99 
Hexene 12.47 12.22 12.01 11.84 
Heptene 10.56 10.42 10.30 10.17 
Octene 9.45 9.14 8.84 8.57 
Cyclohexane 7.18 6.95 6.74 6.53 
Methylcyclohexane 7.66 7.45 7.25 7.06 
Ethylcyclohexane 6.17 5.94 5.73 5.53 
Benzene 6.64 6.56 6.47 6.40 
Toluene 6.17 6.00 5.83 5.67 
Ethylbenzene 5.97 5.75 5.54 5.35 
Methylethylketone 21.64 20.91 20.14 19.43 
Diethyl ketone 13.39 13.22 13.00 12.85 
Methyl isobutyl ketone 9.43 9.29 9.15 9.04 
Propanol 29.90 29.41 28.89 28.57 
Butanol 22.08 20.77 19.60 18.56 
Ethtyl acetate 16.01 16.13 16.35 16.48 
Propyl acetate 13.14 12.68 12.28 11.89 
Butyl acetate 10.97 10.64 10.32 10.04 
Tetrahydrofuran 8.16 8.02 7.91 7.80 
Dibuthylether 8.59 8.30 8.02 7.77 
Chlorobutane 8.73 8.39 8.08 7.77 
Chloropentane 7.82 7.52 7.22 6.96 
Tetrachloromethane 3.63 3.46 3.30 3.15 
Chloroform 4.38 4.37 4.37 4.38 
Propionitrile 45.95 46.05 46.14 46.20 
Butyronitrile 30.17 29.16 28.18 27.33 
Table 4.19: Weight-fraction activity coefficient at infinite dilution       
   of COC 2 at 449, 453, 457 and 
461 K in different organic solvents 
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Solvent 
     
  
T= 478 K T= 488 K T= 498 K T= 508 K 
n-hexane 8.90 9.11 9.31 10.11 
n-heptane 7.91 8.32 8.89 9.48 
n-octane 7.03 7.76 8.57 9.49 
Hexene 8.41 8.55 8.81   
Heptene 8.25 8.19 8.12 7.96 
Octene 8.38 7.88 7.58 7.10 
Cyclohexane 5.01 5.40 5.90 6.42 
Methylcyclohexane 5.32 5.68 6.09 6.61 
Ethylcyclohexane 4.27 4.47 4.67 4.95 
Benzene 5.61 5.43 5.35 5.29 
Toluene 4.79 4.69 4.73 4.80 
Ethylbenzene 3.92 4.21 4.55 5.00 
Methylethylketone 24.12 23.24 21.40 19.91 
Diethyl ketone 18.99 18.25 17.46 16.91 
Methyl isobutyl ketone 6.90 7.13 7.51 7.82 
Propanol 15.97 15.74 15.68 15.59 
Butanol 13.32 12.91 12.68 12.31 
Ethtyl acetate 11.96 11.84 11.59 11.43 
Propyl acetate 9.21 9.21 9.03 9.09 
Butyl acetate 7.72 8.05 8.53 8.86 
Tetrahydrofuran 6.88 7.45 8.10 9.01 
Dibuthylether 6.43 6.43 6.56 6.72 
Chlorobutane 6.61 7.21 7.90 8.61 
Chloropentane 5.73 6.10 6.44 6.95 
Tetrachloromethane 2.24 2.62 3.07 3.67 
Chloroform 3.51 3.56 3.66 3.80 
Propionitrile 46.45 42.78 39.83 37.10 
Butyronitrile 30.28 27.43 25.22 22.89 
Table 4.20: Weight-fraction activity coefficient at infinite dilution       
   of COC 3 at 478, 488, 498 and 
508 K in different organic solvents 
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Solvent 
     
  
T= 383 K T= 393 K T= 403 K T= 413 K 
n-hexane 13.54 13.66 13.41 13.40 
n-heptane 10.39 11.42 11.49 11.77 
n-octane 9.34 9.93 10.13 10.17 
Hexene 11.51 12.05 12.67 13.14 
Heptene 10.00 10.49 11.19 11.06 
Octene 8.93 9.31 9.75 10.10 
Cyclohexane 6.55 6.66 6.82 6.97 
Methylcyclohexane 7.01 7.29 7.29 7.29 
Ethylcyclohexane 5.85 5.89 6.00 6.01 
Benzene 7.04 7.13 7.13 7.63 
Toluene 6.32 6.29 6.52 6.77 
Ethylbenzene 5.91 5.93 6.10 6.31 
Methylethylketone 30.09 33.56 35.00 36.68 
Diethyl ketone 16.03 17.14 17.58 17.71 
Methyl isobutyl ketone 7.21 7.91 8.26 8.78 
Propanol 49.18 52.46 54.10 54.53 
Butanol 36.17 36.45 36.87 36.13 
Ethtyl acetate 11.91 12.72 13.37 14.24 
Propyl acetate 12.45 13.55 14.36 14.82 
Butyl acetate 11.49 12.33 12.45 12.36 
Tetrahydrofuran 8.46 8.51 8.70 9.46 
Dibuthylether 7.99 7.87 8.30 8.58 
Chlorobutane 8.48 9.17 9.52 9.97 
Chloropentane 7.40 8.14 8.14 8.24 
Tetrachloromethane 3.49 3.59 3.61 3.62 
Chloroform 4.12 4.37 4.40 4.70 
Propionitrile 60.27 69.32 78.38 88.42 
Butyronitrile 38.55 41.48 44.05 47.12 
Table 4.21: Weight-fraction activity coefficient at infinite dilution       
   of COC 4 at 383, 393, 403 and 
413 K in different organic solvents 
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Solute 
     
  
T=493K T=503K T=513K T=523K 
n-decane 57.70 50.34 45.95 44.47 
n-dodecane 70.89 60.09 52.07 50.44 
n-tetradecane 29.01 26.33 24.14 22.49 
n-hexadecane 40.83 37.51 33.38 29.62 
Octene 5.94 6.01 6.31 6.70 
Decene 7,266 7.16 7.15 7.62 
Dodecene 8.01 7.76 8.15 8.37 
Benzene 7.46 7.47   
Toluene 7.13 7.33 7.66 7.79 
Ethylbenzene 8.10 8.09 8.37 8.44 
Acetone 6.62 6.63 6.69 6.67 
Methylethylketone 4.75 4.81   
Diethyl ketone 4.04 4.12 4.36  
Methyl isobutyl ketone 3.73 4.00 4.18 4.64 
Methanol 3.42 3.60 3.80 4.12 
Ethanol 7.93 8.17 8.53 9.26 
Propanol 7.51 7.60 7.80 8.31 
Butanol 6.83 6.79 7.03 7.35 
Acetronitrile 8.28 8.26 8.58 8.65 
Ethyl acetate 8.88 8.48 8.33 8.25 
Propyl acetate 9.23 8.92 8.99 9.28 
Butyl acetate 1.95 2.10 2.33 2.53 
Chloroform 261 2.62 2.65 2.79 
Chlorobutane 8.06 7.97 8.42 8.58 
Chlorobutane 10.52 9.99 9.90 9.73 
Table 4.22: Weight-fraction activity coefficient at infinite dilution       
   of PVP K25 at different 
temperature in different organic solvents 
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Solvent 
     
  
T=493K T=503K T=513K 
n-decane 
58.73 45.25 37.04 
n-dodecane 
26.59 23.99 21.65 
n-tetradecane 
37.03 27.28 27.95 
n-hexadecane 
5.93 6.29 6.47 
Octene 
6.73 6.34 7.58 
Decene 
7.57 7.95 8.59 
Dodecene 
8.76 8.76  
Benzene 
8.37 8.25 8.34 
Toluene 
8.46 8.63 8.95 
Ethylbenzene 
5.90 6.19 6.69 
Acetone 
5.12 5.03  
Methylethylketone 
4.39 4.34 4.52 
Diethyl ketone 
3.99 4.23 4.49 
Methyl isobutyl ketone 
3.56 3.82 4.17 
Methanol 
8.62 8.87 9.06 
Ethanol 
8.15 8.28 8.37 
Propanol 
7.05 7.38 7.66 
Butanol 
9.11 9.51 9.97 
Acetronitrile 
8.35 8.88 9.66 
Ethyl acetate 
8.55 9.27 9.99 
Propyl acetate 
2.07 2.28 2.43 
Butyl acetate 
2.60 2.67 2.79 
Chloroform 
8.89 8.75 8.91 
Chlorobutane 
9.91 9.92 10.24 
Table 4.23: Weight-fraction activity coefficient at infinite dilution       
   of PVP K30 at different 
temperature in different organic solvents 
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Solute 
     
  
T=503K T=513K T=523K 
n-decane 
56.63 55.57 58.93 
n-dodecane 
70.09 59.07 68.34 
n-tetradecane 
29.45 29.54 31.56 
n-hexadecane 
35.54 37.87 38.41 
Octene 
7.90 8.40 8.71 
Decene 
8.83 9.44 9.83 
Dodecene 
9.74 11.17 12.02 
Benzene 
10.30   
Toluene 
10.04 10.39 10.84 
Ethylbenzene 
10.68 11.41 11.57 
Acetone 
7.58 8.75 9.59 
Methylethylketone 
5.75 6.33  
Diethyl ketone 
5.00 5.35  
Methyl isobutyl ketone 
5.09 5.42 5.72 
Methanol 
4.78 4.96 4.99 
Ethanol 
10.26 10.66 10.69 
Propanol 
9.54 9.78 9.58 
Butanol 
8.90 9.23 9.21 
Acetronitrile 
11.97 12.02 12.60 
Ethyl acetate 
10.61 11.38 11.59 
Propyl acetate 
10.99 12.03 12.72 
Butyl acetate 
2.66 2.96 3.17 
Chloroform 
3.18 3.32 3.35 
Chlorobutane 
11.60 11.63 12.04 
n-decane 
12.37 12.94 13.91 
Table 4.24: Weight-fraction activity coefficient at infinite dilution       
   of PVP K90 at different 
temperature in different organic solvents 
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Weight-fraction activity coefficients at infinite dilution for common solvents in cyclic 
olefin copolymers and polyvinyl pyrrolidone characterized by different physicochemical 
properties have been measured at different temperatures. 
This work has highlighted the chemical properties of a series of COCs and PVP 
demonstrating the difference in the behaviors of polar and nonpolar solvents. 
The above-mentioned method was also used as semi-quantitative approach for the 
evaluation of affinity between polymer - drugs and supercritical carbon dioxide – polymers 
demonstrating its applicability as a valid tool for the impregnation process prevision. For 
these purposes were considered the Abraham’s pharmaceutical values reported in Table 4.4 
and the following CO2 parameters E= 0, S= 0.28, A= 0.5, B= 0.1, L 0.058. 
A semi quantitative evaluation of the compatibility between polymers and drugs can be 
derived from impregnation results. Unfortunately, the application of the impregnation 
technique from the literature [234, 235] report data regarding one drug and one polymer 
and there are not comparison on the obtained results using different compounds. 
The solvation theory can be used for the determination of the interactions in these systems. 
In particular, the fugacity coefficients of drugs in the polymers were calculated and the 
affinity was defined as the ratio between the fugacity coefficients of the different drugs. 
With this procedure it was possible to evaluate the affinity between drug and different 
COCs and PVP (Figure 4.18 and Figure 4.19).  
For brevity are reported only the affinity behaviors calculated by Eq. 4-17 at the following 
considered temperature.  
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Figure 4.18: affinity between drugs and COCs 
Due to the lipophilic nature of the COCs, also in this case they suggest more affinity for 
the nonpolar or slightly polar drugs. Nevertheless, the COCs can be used as medical 
packaging materials without interact with other pharmaceutical compounds. In fact, at 313 
K, temperature in which the drug and polymers are in solid state, COCs show a possible 
interaction only with Budesonide and Penicillin G. 
PVP polymers, instead show high affinity for all the hydrophilic drugs but also for the 
slightly polar compounds (Figure 4.19). For brevity are reported the behaviors at 503 K. 
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Figure 4.19: affinity between drug and PVP at 503 K 
It must be point out that in Figure 4.19 the affinity is normalized to the highest value that 
in this case corresponds to Methimazole. 
Furthermore, Literature shows interaction between Nimesulide and Naproxen [236, 237] as 
demonstrated in Figure 4.20. Any affinity was instead noticed for Penicillin G. 
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Figure 4.20: example of drug PVP affinity 
The affinity of the investigate polymer for CO2 was investigated at 313 K, assumed as 
typical temperature condition for the supercritical processes.  
 
Figure 4.21: CO2-polymers affinity 
The results depict in Figure 4.21 highlight the affinity of CO2 either for COCs or PVP and 
in particular for COC 4 and PVP K 25, confirming the literature data of CO2 absorption in 
PVP polymers [238].   
The applications of Abraham’s solvation theory for the evaluation of the interactions and 
compatibility between the different components, can be useful to understand and select 
potential candidates to be involved in the supercritical impregnation processes, obtaining 
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some quantitative information from the binary interactions (supercritical carbon dioxide – 
drugs and supercritical carbon dioxide – polymers). 
Moreover, the knowledge of these important solubility/affinity parameters can provide 
useful information about the most suitable equipment for the solute processing such as 
recrystallization, inclusion complex or solid dispersion with the aim to modify the 
bioavailability of the active compounds. While for soluble pharmaceutical compounds is 
possible to operate in pure CO2, for slightly soluble or insoluble compounds is useful the 
addiction of a third component like an organic solvent characterized by its solvating 
properties. The expansion degree of the organic solvent, modulated by the CO2 content in 
the mixture, offers different opportunities for the development of a suitable methodology 
for the processing of the materials, such as particle formation. The SAS technology, 
applies the supercritical fluid as an antisolvent. In a SAS experiment, a solution composed 
of a solute and a solvent is injected into the antisolvent. While the solvent and the 
antisolvent are miscible, the solute is quasi non-soluble in the mixture of solvent and 
antisolvent. Consequently, the mixture is supersaturated which is compensated by the 
formation of solute particles. As said before, the final particle dimensions and particle size 
distribution depend from the operative conditions and for this reason, it is important to 
know the solubility of the drug in different organic solvents and in presence of compressed 
CO2.   
Recently the thermodynamic behavior of these mixtures has been the subject of different 
studies. Shariati and Peters [239] highlighted the appearance of two different concentration 
regions in the CO2/1-propanol/Salycilic acid ternary system attributable to the presence of 
cosolvency and antisolvency areas. Furthermore, the authors successfully correlated the 
experimental data with Peng-Robinson equation of state (P-R EoS) as modified by Stryiek 
and Vera [240]. 
Wubbolts et al. [241] reported experimental data for CO2/ethanol/Acetaminophen and 
CO2/diethylether/Cholesterol systems. These data were correlated with P-R Eos. The Eos 
attraction parameters for the drugs were not predicted from pure component parameters, 
but they were evaluated fitting the ternary data. Alternatively, the authors proposed a 
simple equation that described the solubility of the solid compound as a function of the 
carbon dioxide concentration using two empirical constants. 
This equation reproduced the experimental data with the same accuracy obtained with the 
equation of state.  
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The same empirical model was also used by Muntó et al. [242] for the correlation of 
isothermal isobaric experimental data of ternary systems containing Ibuprofen and 
Naproxen. 
4.6. Solubility estimation of drugs in ternary systems 
for the antisolvent precipitation process 
The aim of this part was to test the possible pure prediction of the thermodynamic 
behaviors of ternary systems used in the antisolvent precipitation process, basing on the 
information supplied by the corresponding binary systems. 
For its simplicity, the P-R EoS is normally preferred to evaluate the supercritical carbon 
dioxide systems.  
Experimental data for the ternary systems are necessary to test the validity of the proposed 
prediction method. 
Unfortunately, in literature these data are not commonly reported because most of the 
papers on antisolvent process are more focused on the properties of the obtained products, 
and not on the carefully investigation of the thermodynamic behavior of the ternary 
systems [243]. 
In this work, for this reason, some ternary systems reported in the literature and containing 
Acetaminophen [241], Ibuprofen and Naproxen [242], Acyclovir [244], Atenolol [245] and 
Sotalol hydrochloride [246], will be considered to test our procedure. This approach will 
be also applied to predict the behaviors of Carbamazepine [247] and Nimesulide [248] 
employed in previous works on SAS precipitation  
4.6.1. Materials  
All the drugs were purchased from Galeno (Italy). All the solvents (acetone, dimethyl 
sulfoxide, dichloromethane and ethanol) were of analytical grade and were provided by 
J.T. Baker (Netherlands).  
4.6.2. Physicochemical characterizations 
4.6.2.1. Determination of drug solubility in organic solvents  
Drug solubility (Table 4.25) in the considered organic solvents was measured at 
atmospheric pressure and at temperature of 298 K. Weighted amount of the drug are added 
to 10 mL of solvent under stirring until turbidity is observed. After one hour, the drug 
solutions were than filtered and 1µL of each one was diluted in the selected solvent. The 
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concentration is than evaluated spectrophotometrically (Thermo Scientific Evolution 60 S, 
USA). Each experiment was carried out in triplicate (coefficient of variation (CV) <3%). 
Compound Temperature 
(K) 
Solvent Solubility molar fraction (x10
2
) 
Acetaminophen    
298 EtOH 0.83 
Acyclovir    
298 DMSO 0.46 
Atenolol    
 313 EtOH 1.56 
Carbamazepine    
 298 EtOH 0.39 
 298 Acetone 0.39 
Ibuprofen    
 298 EtOH 1.95 
 298 Acetone 2.28 
Naproxen    
 298 EtOH 0.63 
298 Acetone 5.02 
   
Nimesulide    
298 Acetone 3.75 
298 DCM 3.30 
298 EtOH 0.07 
   
Sotalol HCl    
298 EtOH 0.19 
   
Table 4.25: Solubility data of drug in considered organic solvents. 
4.6.2.2. Differential scanning calorimetry 
T
f
 and ΔHf are determined with a DSC mod. TA 4000 (Mettler, Greifensee, Switzerland), 
equipped by a measuring cell DSC 20. Samples, containing a fixed amount of drugs (1 
mg), are placed in pierced aluminum crucible and heated under air at a scanning rate of 5 K 
min
-1
 from 303.15 up to 30 K than the drugs melting temperature. The equipment was 
calibrated using indium as a standard. Each experiment was carried out in triplicate. 
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4.6.3. Phase equilibria calculation 
The knowledge of the solid component solubility is essential for the comprehension and 
tuning of the precipitation processes. In the case of the antisolvent crystallization, where 
the supersaturation is generated by the change of the solvent composition, it is essential to 
determine the solubility of the solid as a function of the solvent and antisolvent 
composition. 
At the equilibrium between the liquid phase (carbon dioxide dissolved in the organic 
solution) and pure solid:  
 Pxf
LS  222 ˆ          Eq. 4.19 
The fugacity of the pure solute is obtained as proposed by Prausnitz et al. [216] Eq. 4-4 
which is strictly valid at the triple point (PPT). To extend its applicability at different 
pressures, the fugacity has to be corrected with the Poynting factor: 
    dP
RT
v
PTfPTf
P
P
L
PT
LL
PT

2
22 exp,,
      Eq. 4-20 
    dP
RT
v
PTfPTf
P
P
S
PT
SS
PT

2
22 exp,,
      Eq. 4-21 
With this correction formula Eq. 4-4 becomes 
   
 























TR
vvP
T
T
TR
H
PTfPTf
SLfus
fus
fus
LS 222
2
2
22 1exp,,
   Eq. 4-22 
The fugacity of the liquid phase,  PTf L ,2 , is calculated by the expression of EOS 
fugacity for the liquid phase at temperature and pressure of the solid-liquid equilibrium 
data [249]. 
If a vapour phase is present phase equilibria for three components and three phases systems 
can be described by the following equilibrium equations: 
PyPx VL  1111 ˆˆ          Eq. 4-23 
PyPx VL  3333 ˆˆ          Eq. 4-24 
PyPx VL  2222 ˆˆ          Eq. 4-25 
Pxf LS  222 ˆ          Eq. 4-26 
ˆ i represent the fugacity coefficients of the different compounds in the mixtures. 
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The subscripts numbers 1, 2 and 3 indicate antisolvent, solute and organic solvent 
components, while the superscripts V, L and S stand for vapour, liquid and solid phases, 
respectively. 
For liquid (x) and vapour (y) phase compositions: 
 
i
ix 1 and   
i
iy 1        Eq. 4-27 
4.6.4. Model description 
In this work the well-known Peng-Robinson cubic equation of state [250] is used: 
 
  )( bvbbvv
Ta
bv
RT
P




       Eq. 4-28 
where P is the pressure, T the temperature, R the gas constant and a and b the Van der 
Waals energy and volume parameters, respectively. Application to mixtures is given 
through the simple Van der Waals mixing rules: 

N
i
N
j
ijji axxa
    

N
i
N
j
ijji bxxb
      Eq. 4-29 
)1( ijjiij kaaa      
)1(
2
ij
ji
ij l
bb
b 


     Eq. 4-30 
where x is the molar fraction and kij and lij are the binary interaction parameters.  
Parameters ai and bi are given by 
ci
ciirii
i
P
TRT
Ta
22),(
457235.0)(


       Eq. 4-31 
with  
22 )]1()26992.054226.137464.0(1[),( riiiirii TT    ,  Eq. 4-32 
ci
ci
i
P
RT
b  077796.0
         Eq. 4-33 
 is the acentric factor, Tc and Pc are the critical constants and Tr is the reduced 
temperature. 
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4.6.5. Parameter determination 
The P-R EoS pure component parameters are obtained from critical constants and acentric 
factor. For carbon dioxide and the organic solvents these properties are easily calculated 
and reported in many databases. On the other hands, the properties of the solid solutes, and 
in particular of drugs that present different functional groups in the molecule, are difficult 
to calculate. Their evaluation is often the main objection towards the use of cubic 
equations of state for the simulation of supercritical processes involving heavy compounds. 
For this reason, in the past [251], different estimation methods for the evaluation of critical 
temperatures, pressures and acentric factors such as Somayajulu [252], Costantinou Gani 
[253], Joback Reid [254] and Lydersen [255] methods were compared for different drugs. 
Large differences were particularly found for the values of the critical temperatures, 
whereas the values of critical pressures obtained with the different methods were similar. 
The Somayajulu, Gani Costantinou and Joback Reid methods are not used in this work 
since some of the groups present in the drugs structures are not characterized. 
As a consequence, the critical parameters are calculated using the Lydersen group 
contribution method. The required boiling temperatures are evaluated by means of the 
Simamora and Yalkowsky’s approach [256]. This method is based on group contributions 
given from a fragmentation of the molecule in relation of the molecular orbitals involved in 
the structures. For the sake of brevity, the obtained boiling point data are not reported.  
The calculated pure solid components properties together with those of solvent taken from 
literature are reported in Table A: 0.1 ΔHf and Tf values for the various solid substances 
are obtained from DSC analysis. Drugs solid and liquid volume (vS, vL) are calculated 
from crystal data and with Girolami’s method [257] respectively.  
For P-R EoS two binary interaction parameters are required in order to represent the 
behaviour of multicomponent systems.  
Temperature-independent parameters are calculated fitting experimental phase equilibrium 
data of the different binary systems.  
Table 4.26 reports the values of binary interaction parameters obtained and the references 
to the experimental data used for drug-CO2 and drug-organic solvent binary systems, while 
in Table A: 0.2 are reported the binary interaction parameters of CO2-organic solvents 
systems.  
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System  T /K kij(x10
2
) lij(x10
2
) Ref. 
Acetaminophen      
 CO2 315 17.84 -5.5 [258] 
 EtOH 298 0.05 0.0 [this work] 
Acyclovir      
 CO2 313 22.25 0.0 [244] 
 DMSO 298 -2.58 0.0 [this work] 
Atenolol      
 CO2 313 51.11 0.0 [245] 
 EtOH 313 -3.31 0.0 [this work] 
Carbamazepine      
 CO2 313 3.34 0.0 [191] 
 Acetone 298 0.63 0.0 [this work] 
 EtOH 298 1.03 0.0 [this work] 
Ibuprofen      
 CO2 313 8.51 0.0 [259] 
 Acetone 298 -6.25 0.0 [this work] 
 EtOH 298 -5.21 0.0 [this work] 
Naproxen      
 CO2 313 16.22 0.56 [200] 
 Acetone 298 -2.40 0.0 [this work] 
 EtOH 298 -0.84 0.0 [this work] 
Nimesulide      
 CO2 313 8.72 4.39 [196] 
 Acetone 298 -0.39 0.0 [this work] 
 DCM 298 -2.12 0.0 [this work] 
 EtOH 298 -4.0 0.0 [this work] 
Sotalol HCl      
 CO2 313 68.49 0.0 [246] 
 EtOH 298 -5.59 0.0 [this work] 
Table 4.26: Binary interaction parameters of solvent/antisolvent and solid/fluid systems 
The solvent-antisolvent binary interactions, are calculated regressing vapour-liquid 
equilibrium data.  
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The binary solid/carbon dioxide interaction parameters are calculated fitting the available 
solubility data of the drugs at 313 K and different pressures, except for Acetaminophen 
which are obtained at 315 K. For the systems with Carbamazepine and Ibuprofen only one 
binary interaction parameter is used. 
For Acyclovir, Atenolol and Sotalol hydrochloride no extensive solubility data are 
reported. These drugs were already checked in previous investigations [244- 246] and it 
was found that the solubility at 313 K and 150 bar were smaller than 10
-6
 molar fraction. 
For this reason, an arbitrary value of 10
-7
 molar fraction is chosen in order to have a rough 
estimate of the interaction parameter. Obviously, only kij parameter is calculated and lij is 
set equal to zero. In our opinion this option is closer to the reality in contrast to the choice 
of kij =0. 
The different drugs solubilities in organic solvents determined in this work at 298 K are 
used for the calculation of the kij parameters. 
4.6.6. Results: Ternary Systems 
Experimental data for the mixtures phase transitions, resulting from pressure variations, 
were found in literature and were measured using a variable-volume equilibrium cell with 
a sapphire window [244- 246]. 
These literature experimental data were used only for comparison with the results predicted 
using the binary interaction parameters of Table 4.26.  
The results obtained for the ternary system Acyclovir/DMSO/carbon dioxide at 313 K are 
reported in Figure 4.22.  
The ordinate value c is: 
  
    
              
         Eq. 4-34 
And the abscise XCO2 is: 
     
      
              
        Eq. 4-35 
Where      are the moles of drug,         are the moles of organic solvents and         
are the moles of CO2. 
The addition of CO2 to saturated drug solutions in the considered organic solvents 
following the lines depicted in Figure 4.22 (named as ideal dilution lines), denotes the CO2 
action (cosolvent or antisolvent). The curve over and under this line indicates the CO2-
cosolvent and -antisolvent behaviors respectively.  
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The calculations predict an antisolvent behavior for any carbon dioxide /DMSO ratio. The 
reported experimental points [244] are in good agreement with the simulation results. The 
curve obtained assuming equal to zero the interaction parameter of Acyclovir/CO2 system 
is also reported in the same figure. The second predicted behavior is quite different since a 
large cosolvent region appears and the antisolvent behavior is shown only after a carbon 
dioxide concentration of 0.75.  
 
Figure 4.22: Solubiliy of Acyclovir in the ternary system with DMSO/CO2 at 313 K. --- kij and lij equal to 
zero,… ideal dilution evolution, ___ kij and lij reported in table Table 4.26, ▪ experimental data [244] 
A similar procedure is used for the other two ternary systems Sotalol 
hydrochloride/ethanol/carbon dioxide and Atenolol/ethanol/carbon dioxide (Figure 4.23). 
The agreement with experimental data is satisfactory for the Sotalol hydrochloride ternary 
system [246] (Figure 4.23 a) whereas some discrepancies are shown in the case of ternary 
system containing Atenolol [245] (Figure 4.23 b). Nevertheless the discrepancies do not 
affect the prediction of antisolvency in all the composition range. In the same figure is also 
reported the predicted curve using the drug/carbon dioxide interaction parameters equal to 
zero. For these systems, cosolvent behavior is found for any solvent / carbon dioxide ratio 
in contrast with experimental evidences. These results support the choice done in this work 
for the calculation of the interactions between drugs and carbon dioxide when the 
solubility is lower than 10
-6
 molar fraction. 
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Figure 4.23: a) Solubility of Sotalol HCl in ternary systems with Ethanol/CO2 --- kij and lij equal to zero, 
…. 
ideal dilution evolution, ___ kij and lij reported in Table 4.26, ▪ experimental data [246]; b) Solubility of 
Atenolol in the ternary systems with ethanol/CO2 --- kij and lij equal to zero, 
…. ideal dilution evolution, ___ kij 
and lij reported in Table 4.26, ▪ experimental data [245] 
The above considered drugs present the common aspect of infinitesimal solubility in 
supercritical carbon dioxide.  
Systems containing drugs and for which isothermal isobaric ternary data are reported in 
literature will be also considered. The purpose of our investigation is limited to define the 
presence or the absence of cosolvent and antisolvent regions. 
Isothermal, isobaric data for the system Acetaminophen/ethanol/carbon dioxide were 
reported from Wubbolts et al. [241]. The experimental results reported in literature showed 
that at 315 K Acetaminophen can be precipitated for any carbon dioxide/ethanol ratio and 
that a cosolvent region did not exist. In this work, the solubility of Acetaminophen is 
calculated with the just described procedure, and in Figure 4.24 are reported the predicted 
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c 
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solubility feature. Even if there are some evident discrepancies between the experimental 
literature data and the predicted ones, the essential features of the system behavior are 
predicted. The qualitative prediction does not change using only one binary parameter for 
the drug-CO2 system.  
 
Figure 4.24: Solubility of Acetaminophen at 315 K in ternary systems with ethanol/CO2 
In the case of ternary systems containing Ibuprofen, the predicted results (reported in Figure 
4.25) confirm the cosolvent behavior of ethanol (Figure 4.25a) in all the concentration 
range. Apparently, a small window of concentration with antisolvent behavior can exist but 
very close to the pure carbon dioxide and it is too narrow to be practically used. The same 
conclusion is also reported in literature [242] and it is concluded that cosolvency is the 
normal behavior for the system in all the concentrations. In Figure 4.25a, for comparison, 
some experimental data from Muntó et al. [242] are also reported and in this case the 
agreement is better than that found for Acetaminophen system. A different behavior is 
found for the same drug using acetone as organic solvent (Figure 4.25b). A clear 
antisolvent region is present, starting from a carbon dioxide molar fraction (always 
expressed on solute free basis) of 0.9. Experimental data from literature, in the region of 
interest, are also reported and are in agreement with the predicted curve even if some 
differences. 
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Figure 4.25: Solubility of Ibuprofen at 298K in ternary systems with ethanol/CO2 (a) and acetone/CO2 (b). 
Ternary systems containing Naproxen and ethanol or acetone are showed in Figure 4.26. 
The effect of the two solvents is sometimes similar to that found for Ibuprofen but with 
well-defined antisolvent regions. For ethanol (Figure 4.26a) the antisolvent region starts at 
carbon dioxide concentration of 0.55 whereas in the system with acetone (Figure 4.26b) 
the antisolvent region is present in all the carbon dioxide concentration range. The 
literature experimental data [242] are very close to the predicted results for acetone 
whereas some discrepancies are present for ethanol system. In this case the predicted 
carbon dioxide concentration, that separates the cosolvency from the antisolvent behavior, 
is 0.55 against 0.72 of the experimental concentration. 
b 
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Figure 4.26: Solubility of Naproxen at 298K in ternary systems with ethanol/CO2 (a) and acetone/CO2 (b). 
 
In order to have a better evaluation of the proposed method, other systems containing 
Nimesulide, Carbamazepine, Piroxicam and Vitamin B6 were selected. 
In the case of Nimesulide, the ternary systems (Figure 4.27), with different organic 
solvents (ethanol, acetone and dichloromethane), are studied. The system with ethanol 
(Figure 4.27a) shows a cosolvent behaviour in all the concentration range, whereas both 
dicloromethane and acetone (Figure 4.27b and 3c respectively) behave as cosolvent and 
antisolvent depending on carbon dioxide concentration. These results support the use of 
acetone and dichloromethane in the antisolvent precipitation process of the drug [248].  
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Figure 4.27: Solubility of Nimesulide at 313K in ternary systems with ethanol/CO2 (a), 
dichloromethane/CO2 (b) and acetone/CO2 (c). 
Similar results are obtained in the case of ethanol and acetone systems with 
Carbamazepine (Figure 4.28). Ethanol (Figure 4.28a) acts as cosolvent for any carbon 
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dioxide concentration, whereas acetone (Figure 4.28b) justifies its previous choice as 
organic solvent in the SAS process [247]. 
 
 
Figure 4.28: Solubility of Carbamazepine at 313K in ternary systems with ethanol/CO2 (a) and acetone/CO2 
(b). 
 
The applicability of this equation was also verified for other pharmaceutical compounds 
like Vitamin B6, Piroxicam and Quercetin in which were also studied the final particles 
formation of the particles.  
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4.7. Recrystallization of Vitamin B6 by means of 
supercritical antisolvent technology 
Vitamin B6 is a water-soluble compound characterized by high polarity that limits the 
solubility in supercritical carbon dioxide. For this reason, the supercritical antisolvent 
technology could be an interesting way to process Vitamin B6.  
Preliminary simulation studies by means of Peng-Robinson Equation of State, were 
conducted to individuate the better operative condition for the Vitamin B6 precipitation. 
The data supplied by this approach were also used to predict the nucleation and crystal 
growth of Vitamin B6 having recourse to the screw dislocation growth theory. In this 
studies pressure of 55 and 72 bar and temperature of 298 and 313 K were selected. 
4.7.1. Materials  
The vitamin B6 (purity 0.98 molar fraction) was purchased from Sigma Aldrich (Italy). All 
of the organic solvents (tetrahydrofuran, THF; acetone; ethanol, EtOH; and methanol, 
MeOH) were of analytical grade and were provided by J.T. Baker (Netherlands). The CO2 
(purity 0.99 molar fraction) was supplied by SIAD (Italy). 
4.7.1. Vitamin Precipitation method  
The detailed apparatus used in the antisolvent precipitation experiments has been depicts in 
Figure 4.29. 
 
Figure 4.29: GSAS equipment [260] 
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A precipitation vessel with a capacity of 50 mL was loaded with a 7 mL solution of 
vitamin B6 in the organic solvent. The supercritical CO2 was added from the bottom of the 
chamber, and when the liquid phase expanded, the formed particles were retained in the 
vessel by a suitable filter. During the precipitation, the temperature was fixed at 298 K and 
313 K and the pressure was set at 55 bar and 72 bar, respectively. Precipitation 
experiments were carried out in triplicate. 
4.7.2. Physicochemical characterizations 
4.7.2.1. Determination of Vitamin B6 Solubility in Organic Solvents 
Vitamin B6 solubility Table 4.27 in the considered organic solvents was measured at 
atmospheric pressure and at temperature of 298 K, 308 K, 310 K, and 313 K as reported in 
section 4.6.2.1.  
Solvent T/K 10
2 
x 
Acetone 298 0.127 
 308 0.131 
 310 0.135 
 313 0.136 
Methanol 298 1.585 
 308 2.447 
 310 2.468 
 313 2.517 
Ethanol 298 0.363 
 308 0.380 
 310 0.384 
 313 0.396 
Tetrahydrofuran 298 0.240 
 308 0.249 
 310 0.253 
 313 0.271 
   
Table 4.27: Experimental Mole Fraction Solubility x of vitamin B6 in the considered organic solvents 
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4.7.2.2. Differential scanning calorimetry 
T
fus
 and ΔHfus were measured as reported in section 4.6.2.2 from 303 to 470 K  
4.7.2.3. Particle size measurement 
Macroscopic particle size distributions of precipitated samples were determined by means 
of digital imagines acquisition. Small amounts of each sample were uniformly dispersed on 
top of glass slide examining at least 500 particles. Acquired pictures were processed with 
the image analysis program ImageJ [261]. The particle dimension of each sample was 
determined as length and width (mm).  
4.7.3. Precipitation estimation method (PR-EoS)  
The precipitation estimation for Vitamin B6 in the considered ternary systems were 
investigated through the PR EoS reported in section 1284.6.4. The pure component 
characteristics are listened in Table A: 0.1. 
Only one binary interaction parameter kij was used for the correlation of the binary 
solubility of Vitamin B6 in the different organic solvents. Vitamin B6 is in the class of 
water soluble vitamins and as a consequence it is expected that the solubility in SCO2 is 
low and it was effectively impossible to measure with the normal experimental methods. 
From the failure of these measurements it is possible to argue that the solubility must be 
lower than 10
-7
 mole fraction. The only information on the thermodynamic properties for 
the binary system Vitamin B6 – carbon dioxide are the fugacity coefficients at infinite 
dilution of carbon dioxide in the vitamin determined at normal pressure
 
[262]. For this 
reason, the binary interaction parameter of the Peng Robinson equation of state for the 
system was calculated by regression of these data.  
For CO2-organic solvent binary systems, vapour liquid equilibrium data were used for the 
calculation of the two binary interaction parameters kij and lij.  
Table 4.28 and Table A: 0.2 reports respectively the numerical values of the binary 
interaction parameters for the different Vitamin B6 and CO2-organic solvent binary 
systems necessary to predict the Vitamin B6 behaviours in the ternary systems. 
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System  T (K)  10
2
kij 10
2 
lij 
Vitamin B6     
 CO2  -0.07 0.0 
 THF 298 -0.28 0.0 
  308 1.15 0.0 
  310 1.42 0.0 
  313 1.71 0.0 
 Acetone 298  -0.014 0.0 
  308 1.54 0.0 
  310 1.80 0.0 
  313 2.31 0.0 
 MeOH 298 0.32 0.0 
  308 0.28 0.0 
  310 0.45 0.0 
  313 1.71 0.0 
 EtOH 298 2.55 0.0 
  308 3.57 0.0 
  310 3.79 0.0 
  313 4.08 0.0 
     
Table 4.28: Binary interaction parameters calculated by PR-EoS. 
4.7.4. Particle size prediction 
According to S. Bristow et al. [263] the supersaturation is the driving force of the 
precipitation process and it is defined as the difference between the real concentration Cv 
and the equilibrium one C0 at a given pressure and temperature. The supersaturation is 
proportional to the correspondent fugacity coefficient: 
    
       
         
         Eq. 4-36 
For low concentration and non-volatile solute the fugacity effects can be neglected: 
    
  
  
          Eq. 4-37 
                         Eq. 4-38 
Where   and   are determined fitting the precipitation curve from the above solubility 
simulation and Csolv is the molar ratio of solvent. 
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The most important phenomena affecting the particle size is the primary nucleation 
mechanism that is promoted at high supersaturation conditions. Nucleation determines 
both the total number of particles and the final particle size. In the homogeneous one-phase 
solvent system, the well-known dependency of nucleation rate, J, on supersaturation, S is: 
  
 
    
               Eq. 3-39 
Where      is the pre-exponential nucleation constant and for spherical nuclei the 
parameter A is: 
   
         
 
   
   
         Eq. 4-40 
Where   is the nucleus specific free surface energy and    is the Boltzman constant. 
The crystal growth rate (in the two axes), dRi/dt is described as the screw dislocation 
equation [264]: 
   
   
  
   (
  
  
)     (
  
 
)        Eq. 4-41 
where Ri is the change in crystal size Di is a growth constant that is different for each of the 
axis of the Vitamin B6 crystal (i = 1, 2, that indicate the major and minor axes respectively) 
and that was determined fitting the experimental particle size data. Si is the supersaturation 
value for which the growth rate dependency switches from first to second order. The 
theory predicts the particle grow (i.e.         ) when S<< Si (low supersaturation 
condition), and when occurs a linear dependence (i.e. 
  
  
  ) in a S῀Si situation [264]. 
4.7.5. Results and discussion 
Tri-phase phase equilibria have been calculated for different liquid phase concentration at 
value of temperature and pressure closed to the critical CO2 conditions. In fact, the 
experiments to determine the equilibrium solubility of vitamin B6 organic solvent solution 
in CO2 were conducted at pressure of 55 bar and 72 bar and temperature of 298 K and 313 
K, respectively. The selected organic solvents were characterized by different polarity like 
tetrahydrofuran (THF), acetone, ethanol (EtOH) and methanol (MeOH). Figure 4.30 shows 
the simulated precipitation behaviors for Vitamin B6 in the considered ternary systems. 
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Figure 4.30:Vitamin B6 solubility behaviors in ternary systems with THF-CO2 (a), Acetone-CO2 (b), EtOH-
CO2 (c), MeOH-CO2 (d).  
An increase of XCO2 determines a continuous decrease of Vitamin B6 solubility from the 
saturation value in pure organic solvent, to the saturation value in pure CO2.  
In all the considered ternary systems, the increased temperature and pressure carry to an 
enhancement of the CO2 cosolvent power. These considerations are less evident with 
ethanol. 
In Table 4.29 are reported the predicted yields and corresponding pondering quantities of 
Vitamin B6 precipitated from the ternary systems.  
Vitamin B6 ternary system with: T (K) P (bar) Yield % Precipitation (mg) 
THF-CO2 298 55 54.8 2.72 
 313 72 35.7 2.09 
Acetone-CO2 298 55 34.1 1.03 
 313 72 19.4 0.62 
EtOH-CO2 298 55 20.8 2.26 
 313 72 22.1 2.66 
MeOH-CO2 298 55 38.1 28.3 
 313 72 34.8 27.6 
Table 4.29: simulated yield of Vitamin B6 precipitation from ternary systems 
At the light of these simulations and from the THF toxicity, precipitations of Vitamin B6 
were performed only with ethanol and methanol solutions. For brevity, in Figure 4.31 is 
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reported only the recrystallized Vitamin B6 in ethanol –CO2 solution at 313 K and 72 bar 
in comparison to the starting Vitamin B6. 
 
Figure 4.31: Vitamin B6 before (a) and after (b) precipitation in ethanol solution at temperature T= 313 K 
and pressure P= 72 bar 
Simulations of particle size dimension were conducted starting from the equilibrium 
solubility (C0) of Vitamin B6 ternary system with EtOH and MeOH and CO2 at 72 bar and 
313 K. Supersaturation S has been calculated fitting the solubility curve obtained from PR-
EoS. 
Vitamin B6 crystal growth highlights, in both systems, an anisotropic phenomenon, in 
which the substance raises, in the time, along two axes suggesting the formation of needle 
crystals (Figure 4.32). 
At the end of the precipitation (that coincides with the plateau in Figure 4.32), these results 
agree with the experimental measure reported in Table 4.30, even if there is a certain 
difference between the calculated and experimental width. The variation in crystal habit 
results from the modification of the relative growth rates of crystal faces, which are 
governed by the degree of supersaturation of the solution, density and CO2 flow rate. In 
general, it is known that as supersaturation increased, the crystal form tends to change from 
granular to needle-like [265]. During the experiment, there is a continuous increase of 
Vitamin B6 concentration inside the vessel. Crystals can nucleate and grow only if the 
solution is supersaturated. Nucleation does not occur until the solute concentration exceeds 
its C0 value. Moreover, in a solution where more solute molecules are present, collisions 
are more frequent and nuclei of critical radius can be formed faster. After the nucleation 
starts, the accumulating particles become more significant, and the supersaturation inside 
the vessel increase rapidly. 
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Figure 4.32:Particle size increment along the two axes (gi) versus Time of Vitamin B6 with (a) Ethanol- CO2 
and (b) Methanol- CO2 at 313 K and 72 bar. Dot lines depict the major axe. Dash lines depict the minor axe. 
Vitamin B6-(1) Vitamin B6-(2) 
Exp
b
 calc
c
 Exp
b
 calc
c
 
L/mm W/mm L/mm W/mm L/mm W/mm L/mm W/mm 
3.95±0.71 0.14±0.07 4.31 0.54 5.43± 0.65 0.39± 0.09 5.95 0.81 
Table 4.30: Vitamin B6 particle size analysis obtained at temperature T = 313 K and pressure P = 72 bar a 
with CO2-EtOH (1) and CO2-MeOH (2)
a
 Standard uncurtains are u(T) = 0.1 K, u(P) = 0.07. 
b
 experimental 
value (mean ± SD, n= 500). c calculated value by means of Eq. 4-36. L = length, W = width 
As more particles are formed, the concentration reaches a value close to the C0 value of 
0.779 and 0.652 for EtOH and MeOH systems respectively at 313 K and 72 bar (XCO2) and 
the growth and nucleation rates of the precipitated particles inside the vessel ended. 
Therefore, monitoring the Vitamin B6 concentration time response provides a useful 
indicator of the particle formation mechanism inside the collector vessel.  
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At the light of these behaviors, it was tested the applicability of these approach to the 
precipitation of Piroxicam from different organic solvents. Physicochemical properties of 
the samples were analyzed before and after the treatment to highlight possible changes in 
the form of the crystals. In order to identify which process was responsible for the above 
results, Piroxicam was further precipitated from the same solvents by traditional 
evaporation method (RV-samples). 
4.8. Piroxicam solid state studies after processing with 
SAS technique 
Piroxicam is a non-steroidal anti-inflammatory drug (NSAID), licensed for acute and long-
term use in the relief of signs and symptoms of osteoarthritis and rheumatoid arthritis but 
not analgesia due to its delayed onset of pain relief. According to the Biopharmaceutical 
Classification System (BCS), it is a class II drug, characterized by low solubility and high 
permeability which mainly displays dissolution-dependent oral bioavailability [1, 266]. 
Indeed, the reported delay in the onset of pain relief is mainly due to the poor water soluble 
nature of the drug rather than to a particular pharmacological effect. 
4.8.1. Materials  
Piroxicam and CO2 (purity 99.9%) were purchased from Galeno (Italy) and Siad (Italy) 
respectively. All the solvents (acetone, ethyl acetate, dichloromethane, methanol and 
ethanol) were of analytical grade and were provided by J.T. Baker (Netherlands). 
4.8.2. Traditional evaporation method 
Piroxicam (PXC) was added to the appropriate solvent in a round bottom flask under 
stirring. The solvent was then removed under reduced pressure in a rotary evaporator 
(Buchi R-114, Flawill, Switzerland) at 313±1 K for 30 min. Before the characterization, 
samples were kept for 3 days in a desiccators under vacuum at room temperature. 
4.8.3. SAS Method 
A schematic diagram of SAS equipment used in this study is reported in Figure 4.33. 
The precipitator (AISI-316 steel, internal diameter and volume of 50 mm and 400 cm
3
 
respectively) was jacketed ensuring temperature to be kept within 313 ± 0.5 K. the sample 
solutions, kept at the precipitator temperature by an electric heat plane, were pumped 
(ConstaMetric
®
 3200 P/F) to the top of the precipitator and then sprayed through a nozzle 
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with a diameter of 100 µm (Lechler ® model n° 212.004.17). Liquid CO2 was fed from the 
top of the precipitator by a high pressure pump (Lewa EK-M-210V1). The outlet flow was 
then filtered (0.22 µm) to prevent precipitate losses and regulated by a heated metering 
valve (Whitey SS-21RS4). 
Temperature and pressure values in the precipitator were measured by a Delta OHM 
thermometer (HD 9214, ± 0.1 K) and a DRUCK pressure transducer (DPI 260, ± 0.1 bar). 
The precipitator was filled with CO2 to the experimental pressure; then the solution and 
CO2 were pumped to the reactor at constant flow. The experiments were performed using a 
solution flow rate of 2 mL min
-1 
and 40 mL were
 
pumped in the precipitation chamber. A 
CO2/ solution flow rate ratio of 10 was used. After spraying the precipitate was washed 
with approximately 5 l of CO2 before its collection. The pressure and temperature selected 
for the precipitation of Piroxicam were 100 and 120 bar at 313 K. Saturated solutions were 
used for SAS precipitations. 
 
Figure 4.33: SAS apparatus 
 
4.8.4. Physicochemical characterization  
4.8.4.1. Determination of drug solubility in organic solvents 
Furosemide solubility in organic solvents (Table 4.31) was measured as reported in section 
4.6.2.1 at room temperature with acetone, ethyl acetate, dichloromethane, methanol and 
ethanol. 
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Solvent y
.
10
3
 (± SD n=3) 
Methanol 0.27±0.06 
Ethanol 0.60±0.05 
Ethylacetate  5.02±0.36 
Acetone 2.45±0.25 
Dichloromethane 9.63±0.49 
Table 4.31: Piroxicam solubility in the considered organic solvents 
4.8.4.2. Scanning electron microscopy (SEM) 
The shape and surface characteristics of the samples were observed by SEM. Samples were 
sputter-coated with Au/Pd using a vacuum evaporator (Edwards, Milan, Italy) and 
examined using a scanning electron microscope (model 500, Philips, Eindhoven, The 
Netherlands) at 10 KV accelerating voltage using the secondary electron technique 
4.8.4.3. Differential scanning calorimetry (DSC) 
Calorimetric analysis were performed as reported in section 4.6.2.2 from 303 to 500 K 
under air atmosphere. 
4.8.4.4. Hot stage microscopy (HSM)  
HSM observations of morphological features and changes during heating in the samples 
were monitored using a hot plate (FP 52 Mettler, Greifensee, Swiss), connected to a 
temperature controller (FP 5 Mettler). An adequate amount of each sample was placed on a 
glass slide and heated at 10 K
.
min
−1
 in the temperature range 303–500 K. The behavior of 
the samples was observed via an optical microscope (Reichert Biovar, Wien, Austria) 
(magnification 100×). 
4.8.4.5. Particle size and shape analysis 
Particle size and elongation factor characterizations of samples were determined using an 
optical microscope (Reichert Biovar, Wien, Austria) (magnification 400 x). Small amounts 
of each sample were uniformly dispersed on top of a microscopy glass slide. For each 
powder batch, three microscopy glass slides were prepared, examining at least 5,000 
particles per sample. Pictures were examined with the image analysis program Sigma Scan 
Pro 5 [26]. The size of each sample was determined as Feret diameter [26] while the shape 
factor was expressed as elongation (EL) as reported from Mikli et al.[27]. 
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4.8.4.6. Powder X-ray diffraction studies (PXRD) 
PXRD studies were done using a STOE D500 (Siemens, Monaco, Germany) 
diffractometer with Cu Kα radiation (λ = 1.5418 Å), monochromatised by a secondary flat 
graphite crystal. The scanning angle ranged from 3° to 40° of 2 θ, steps were of 0.05° of 2 
θ, and the counting time was of 5 s/step. The current used was 20 mA and the voltage 40 
kV. Structural assignments were made with reference to the JCPDS powder diffraction file, 
and also using MAUD (Material Analysis Using Diffraction), a Java program developed 
by Lutterotti and co-workers [28].  
4.8.4.7. Diffuse reflectance infrared Fourier transform (DRIFT) spectroscopy 
The DRIFT spectra were obtained after appropriate background subtraction using an FT-IR 
spectrometer (FT-IR 300 Jasco, Tokyo, Japan). Samples were dispersed in KBr. An 
average of 20 scans for each sample were collected at 4 cm
-1
 resolution in the range 4000-
400 cm
-1
. 
4.8.4.8. Determination of drug solubility in simulated gastrointestinal fluids 
Solubility of commercial PXC and the treated ones was measured in oversaturated 
conditions (C>10 Cs), dispersing a weighted amount of drug in 10 mL of simulated 
gastrointestinal fluids at pH 1.2 and 7.4. the suspensions were stirred under constant speed 
at 310 ± 0.5 K for 24 h (appropriate time for equilibrium), filtered through a membrane 
(pore size 0.45 µm) and then assayed spectrophotometrically at 334 and 354 for pH 1.2 and 
7.4 respectively. The composition of the dissolution media was 0.2 M NaCl/0.2 M HCl 
(pH 1.2) or 0.2 M KH2PO/0.2 M NaOH (pH 7.4) according to USP. 
4.8.4.9. Determination of drug dissolution 
Profiles of Piroxicam release were obtained according to the USP 33 paddle method: 100 
rpm, 900 mL of simulated gastrointestinal fluids at pH 1.2 and pH 7.4, T= 37 ± 0.1 °C, 
sink conditions (C<0.2 Cs). The aqueous solution was filtered (0.45 μm porosity) and 
continuously pumped to a flow cell in a spectrophotometer and absorbance were recorded 
at 334 and 354 nm for pH 1.2 and 7.4 respectively. Experimental points were the average 
of at least three replicates, and standard deviations did not exceed ± 5% of mean value. 
Dissolution profiles were compared to that of the pure and RV crystallized drug. 
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4.8.5. Results and discussions 
Solubility of PXC in supercritical CO2 at 313 K ranges between 5·10
-6
 and 5·10
-5
 mole 
fraction at 100 and 200 bar respectively [196].  
Solid liquid and Vapor liquid equilibrium data were correlated with the Peng Robinson 
EOS in order to obtain the values of PXC-CO2  and PXC-organic solvent temperature 
indipendent kij and lij binary interaction parameter (Table 4.32) and those of CO2- organic 
solvents binary systems (Table A: 0.2). The pure components properties are shown in 
Table A: 0.1. 
.System   T/K kij lij 
PXC      
 CO2 298 0.0894 -0.0118 
 Acetone  298 0.0171 0. 
 Ethyl acetate 298 0.0156 0. 
 Dichloromethane 298 -0.0069 0. 
 Ethanol 298 0.0399 0. 
 Methanol 298 0.0075 0. 
Table 4.32: Iinteraction parameters kij and lij for the different binary systems 
With these parameters the behaviour of the different binary and ternary systems can be 
predicted at 313 K. Tri-phase phase equilibria were calculated for different liquid phase 
concentrations at 313 K and at the equilibrium pressure [249]. Figure 4.34 and Figure 4.35 
show the results obtained with the different organic solvents. In the case of “CO2 – 
methanol” and “CO2-ethanol” solvent mixture (Figure 4.34a and b) the addition of carbon 
dioxide to the saturated solution does not yield the Piroxicam precipitation at any CO2 
composition mixtures (co-solvent behaviours).  
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Figure 4.34: Estimation solubility curves (-) of Piroxicam at 40°C in the system PXC-CO2-methanol (a), 
PXC- CO2-ethanol (b). Pointed lines depict ideal dilution evolution 
In the case of Piroxicam in CO2 – expanded dichloromethane, the CO2 behaves as 
cosolvent in the range of XCO2 between 0 and 0.58 (P= 53 bar) as indicated in Figure 4.35a. 
When XCO2 is higher than the threshold value the CO2 starts to produce the precipitation of 
the Piroxicam acting as antisolvent.  
Similar diagrams can be constructed for the other considered solvents. The behaviours of 
ethyl acetate (Figure 4.35b) and acetone (Figure 4.35c) are similar to that of 
dichloromethane. The main difference is the value of the so-called threshold carbon 
dioxide concentration that is 0.77 (P= 60.5 bar) and 0.635 (P= 47.5 bar) respectively.  
c 
a 
b 
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Figure 4.35: Estimation solubility curves (-) of Piroxicam at 313 K in the system PXC-CO2-
dichloromethane (a), PXC-CO2-ethyl acetate (b), PXC-CO2-acetone (c). Pointed lines depict ideal dilution 
evolution. 
a 
b 
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These crossing points identifies both the minimum CO2 concentration and the pressure 
necessary to obtain a solid phase from the different organic solution saturated with CO2.  
In order to have a monophasic system in the SAS experiment, it is necessary to operate at 
pressures higher than these values.  
For this reason, and on the basis of binary CO2 organic solvent, V-L data at 100 and 120 
bar were selected as operative pressures for DCM, acetone and Ethyl acetate. 
The CO2-precipitation of PXC from the selected solvents gave a fluffy, voluminous 
powder. In the selected experimental conditions the binary systems were monophasic. 
Representative SEM images, reported in Figure 4.36, highlight a different morphology of 
the starting drug when processed with SAS or traditional method.  
To go into details, raw PXC is characterized by a mixture of rods and prisms that changed 
to needle shapes when processed with the three considered solvents in CO2, as typical 
comportment of CO2-precipitated samples [137, 267-270].  
Comparing these microphotographs with the samples recrystallised by traditional method 
revealed a great difference in shape: piroxicam RV-treated with acetone or DCM were 
characterized by the presence of prisms while the recrystallization in AcEt showed a 
mixture of rods and prisms, like raw PXC.  
For brevity are reported only the microphotographs of raw PXC, PXC RV-treated with 
AcEt, PXC RV-treated with acetone and PXC CO2-treated with acetone at 120 bar. Other 
results are synthesized in Table 4.33.  
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Figure 4.36: SEM images of raw PXC (A), PXC RV-treated with EtAc (B), PXC RV-treated with acetone 
(C), PXC CO2–treated with acetone at 120 bar (D). 
Sample Crystal aspect 
Raw PXC Rod+prism 
PXC RV-treated with acetone Prism 
PXC CO2–treated with acetone at 100 bar Needle 
PXC CO2–treated with acetone at 120 bar Needle 
PXC RV-treated with EtAc Rod+prism 
PXC CO2–treated with EtAc at 100 bar Needle 
PXC CO2–treated with EtAc at 120 bar Needle 
PXC RV-treated with DCM Prism 
PXC CO2–treated with DCM at 100 bar Needle 
PXC CO2–treated with DCM at 120 bar Needle 
Table 4.33: Crystal aspect of samples at SEM analysis 
As reported in Figure 4.37 the thermogram of starting PXC shows two endothermic peaks 
at about 471 and 475 K attesting the presence of two crystal forms, reported in literature as 
α (needle) and β (prism) respectively [271- 273].  
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After the rotavapor recrystallization in DCM or Acetone, PXC changes to pure β form, 
while the drug in EtAc is characterized by the presence of both α and β forms as reported 
in literature [273]. 
All the SAS precipitation samples show an α form of the drug. 
 
Figure 4.37: DSC thermograms of different Piroxicam systems 
These data were confirmed by HSM and Figure 4.38 shows the different morphology of 
the drug. For brevity are reported only the β-form and α-form of PXC obtained with the 
RV and SAS (at 100 bar) processed with Acetone. 
 
Figure 4.38: HSM microphotographs of PXC RV- treated with acetone at 303 K a), 468 K b), 474 K; PXC 
CO2- treated with acetone at 100 bar at 303 K d), 468 K e), 471 K f). 
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The results of particle size analysis, expressed as values of diameter and elongation factor 
for each sample, are reported in Table 4.34. 
The elongation factor is computed as follow:  
 
        (
    
    
)         Eq. 4-42 
Where dmax and dmin are the diameter of the particles. 
These results highlight that the processing of Piroxicam with SAS technique changed 
dramatically the shape of drug crystals. The values of elongation factor were quite constant 
for all CO2-treated samples. The different pressure or solvent did not affect an appreciable 
changing in the dimension and shape of the drug. On the other hand, starting raw PXC and 
RV-treated with EtAc showed an higher standard deviation than the other systems and it is 
due to the presence of both α- and β-forms. Crystals of PXC RV-treated with acetone 
showed the highest dimension and the lowest value of elongation factor, suggesting its 
presence in β-form. The same consideration can be done for the crystals of PXC RV-
treated with DCM, but here the elongation factor is quite higher than PXC RV-treated in 
acetone.  
Sample Particle size 
Feret diameter (µm) 
EL 
Raw PXC 22.34 ± 10.75 1.21 ± 1.09 
PXC RV-treated with acetone 50.78 ± 4.23 0.43 ± 0.2 
PXC CO2–treated with acetone at 100 bar 7.23 ± 4.45 5.35 ± 0.1 
PXC CO2–treated with acetone at 120 bar 5.12± 4.12
 
5.89 ± 0.12 
PXC RV-treated with EtAc 21.45± 8.53 2.1 ± 1.1 
PXC CO2–treated with EtAc at 100 bar 5.23± 1.56 5.62 ± 0.78 
PXC CO2–treated with EtAc at 120 bar 5.89± 3.78 4.7 ± 0.65 
PXC RV-treated with DCM 37.17± 3.23 0.8 ± 0.23 
PXC CO2–treated with DCM at 100 bar 7.67± 4.32 5.46 ± 0.34 
PXC CO2–treated with DCM at 120 bar 7.45± 3.87 5.84 ± 0.4 
Table 4.34: Particle size of samples (mean ± SD, n = 5,000) 
Applying the previous approach showed for Vitamin B6 particle formations in Figure 4.39, 
for brevity, is reported the simulation behavior for PXC treated with SAS method in 
presence of acetone at 120 bar. Also in this case the prevision is in agreement with the 
experimental behaviors even if some discrepancies in term of width (Table 4.35). 
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Figure 4.39: Particle size increment along the two axes (gi) versus Time of Piroxicam with Acetone- CO2 at 
120 bar. Dot lines depict the major axe. Dash lines depict the minor axe. 
Piroxicam -Acetone- CO2 
Exp
b
 Calc
c
 
L/μm W/μm L/μm W/μm 
30.95±1.71 1.2±0.3 29 2.6 
Table 4.35: Piroxicam particle size analysis obtained at temperature T = 313 K and pressure P = 120 bar a 
with CO2-Acetone
a Standard uncurtains are u(T) = 0.1 K, u(P) = 0.07. b experimental value (mean ± SD, n= 
5000). c calculated value by means of Eq. 4-36. L = length, W = width 
The XRD patterns of raw drug, RV and CO2-treated samples are reported in Figure 4.40. 
JCPDS powder diffraction file reports the main typical reflects of both α and β-forms at 
9.05, 10.19, 15.23, 15.84, 18.12, 23 and 8.56, 11.63, 12.49,14.52, 17.69, 21.74, 22.48, 
23.37 of 2 Ѳ respectively. Commercial and RV-treated PXC prepared with EtAc 
diffractograms confirmed the presence of both α and β forms even if the concentration of 
needle form is higher than cubic one (79.5% α and 20.5 β % for PXC RV- treated in EtAc, 
82.3 % α and 17.7 % β for raw PXC calculated by MAUD [274]). The PXRD patterns of 
RV-treated with Acetone and DCM samples showed the typical β form reflects while all 
PXRD patterns of the CO2-treated samples indicate the complete organization into α form. 
All the data are in accordance with DSC analysis although the thermograms of commercial 
and RV-treated PXC prepared with EtAc show a bigger endothermic peak in 
correspondence of β-form and this is in contrast with PXRD patterns. These behaviors 
were explained by the thermal instability in mixture of the melt α-form giving rise to β-
form after crystallization. No solid polymorphic transition of α to β in the time was 
observed at r.t. [272]. 
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Figure 4.40: PXRD patterns of different Piroxicam systems 
The main results of the DRIFT analysis on the starting PXC and treated samples showed 
two different spectra (Figure 4.41). The starting PXC, PXC CO2-treated and RV-treated 
with ethyl acetate presented the typical band of the α-form even if they were a mixture of 
both crystal forms (hardly to see for the small quantities of β-form contained), while the 
drug RV-treated with Acetone and DCM attested the presence of β-form. The peaks at 
3333 and 3389 cm
-1
 correspond to the N-H stretch in α and β forms, respectively as 
expected for hydrogen-bonded trans secondary amides. Appearance of N-H stretch for α-
form at a higher frequencies than that for β-form is explained by Sheth et al. [275].  
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Figure 4.41: DRIFT spectra of Piroxicam systems 
Even though previous physicochemical characterizations attested the almost complete 
transformation into two pure different crystal forms after SAS and RV-processing with the 
Starting PXC 
RV-PXC Acetone 
CO2-PXC Acetone 100 bar 
CO2-PXC Acetone 120 bar 
RV-PXC EtAc  
CO2-PXC EtAc 100 bar 
CO2-PXC EtAc 120 bar 
RV-PXC DCM 
CO2-PXC DCM 100 bar 
CO2-PXC DCM 120 bar 
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tested solvents, the aim is to test the solubility and dissolution performance of the CO2-
treated samples compared to the RV-samples. 
The solubility of Piroxicam (Figure 4.42) is higher in pH 7.4 than pH 1.2. Therefore, 
according to the USP solubility definition, Piroxicam can be considered as a practically 
insoluble drug at pH 1.2 and very slightly soluble at pH 7.4. No appreciable variation in 
the solubility behaviors were observed between α and β-forms.  
 
Figure 4.42: Solubility assay of PXC α and β form in pH 1.2 and 7.4 
The dissolution profiles are reported in Figure 4.43. A remarkable increase of the PXC 
dissolution rate was achieved by its processing with supercritical CO2 as compared to the 
RV-samples.  
These great differences between the dissolution rates were attributable to changes in 
particle size and morphology as reported from the particle size analysis (Table 4.34).  
It is plausible that the better crystal shape of all the CO2-treated PXC (needles) favored the 
dissolution process. Furthermore, the RV-samples seemed to have larger dimensions and a 
smallest shape form (in particular PXC RV-treated with acetone that reach the 90% of 
release in about 115 min) if compared to those treated with supercritical CO2. The 
improvement of dissolution kinetics in the system treated with SAS is played also by the 
consequential increase of the surface area of the samples in contact with the dissolution 
medium. 
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Figure 4.43: PXC in vitro dissolution profile at pH1.2 a) and 7.4 b) 
It must be also pointed out that no significant differences were found between the 
dissolution performances of the samples obtained with different solvents and pressure in 
the SAS process.  
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In collaboration with the Graz University of Technology were implement the 
thermodynamic aspects involved in the precipitation of pharmaceutical compounds using 
supercritical antisolvent equipment characterized by a different geometry and bigger 
volumes than those present at the University of Trieste.  
4.9. Quercetin precipitation by SAS technology (in 
collaboration with TU Graz) 
The candidate active compound for this study was the well-known antioxidant Quercetin. 
Quercetin (QUER) is a bioactive polyphenolic flavonoids characterized by a phenyl 
benzo(y)pyrone-derived structure consisting of 2 benzene rings linked by a heterocyclic 
pyran or pyrone ring. It is widely used as health supplement and it is widely expressed in 
fruits and vegetables. Particularly onions and apples, were identified as the primary sources 
of naturally-occurring dietary Quercetin. Black tea also was identified as a rich dietary 
source of Quercetin [276, 277]. Its oral bioavailability is quiet low due to the poor 
solubility of the molecule [278].  
Quercetin has attracted much attention for its potential to prevent cardiovascular [279], 
neoplastic [280], and neurodegenerative [281] diseases. Because oxidative stress has been 
implicated in the pathogenesis of these diseases, the antioxidant activity of Quercetin (and 
other flavonoids) may be at least partly responsible for its mode of action [282].  
As reported in literature, Quercetin is insoluble in SCO2, showing a molar fraction 
solubility of 10
-6 
at pressure and temperature of 400 bar and 373 K [88]. This low value is 
due to the polar nature of the polyphenols molecules. For this reason, the SAS technology 
was used to process the Quercetin with the aim to prepare microparticles characterized by a 
better dissolution performance.  
4.9.1. Materials  
Quercetin dihydrate (purity 0.98 molar fraction) was purchased by Galeno-Italy. Dimethyl 
Sulfoxide, Ethanol, and Acetone were provided from J.T. Baker-USA. CO2 (purity 0.98 
molar fraction) was purchased by Linde Gas (Graz, Austria). 
4.9.2. Supercritical precipitation method 
First of all the Quercetin precipitation was observed using the supercritical visual cell 
depict in figure 31. 5 mL of Quercetin-organic solvent saturated solution were put inside 
the view cell (140 cm
3
) with a stirrer. After that, the cell was thermostated in a water bath 
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at temperature of 313 and 323 K and CO2 was introduced inside using the high pressure 
pump (Lewa EKM210V1) at pressures of 100, 150 and 200 bar for 1 hour (steady state). 
Then, the SCO2 was continuously flowed until the complete extraction of organic solvent 
was observed maintaining constant temperature and pressure (dynamic way). The gas 
released through the regulating valve was passed through a filter (0.22 μm) water saturator 
and a wet test meter for volume determination (SETRA, model 204, (0 to 1.7 (19 – 10-4) 
MPa).  
 
Figure 4.44: Visual cell equipment 
4.9.3. Physicochemical characterizations  
4.9.3.1. Quercetin solubility in organic solvents 
Also in this case, the solubility of Quercetin was measured as reported in section 4.6.2.1 
with acetone, ethanol and DMSO and at temperatures of 299, 303, 308 and 313 K (Table 
4.36).  
solvent T (K) 10
2 
x 
acetone 299 0.005 
 303 0.007 
 308 0.015 
 313 0.021 
ethanol 299 0.030 
 303 0.032 
 308 0.045 
 313 0.049 
DMSO 299 0.658 
 303 0.631 
 308 0.644 
 313 0.658 
Table 4.36: Experimental molar fraction solubility x of Quercetin in the considered organic solvents  
stirrer 
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4.9.3.2. Particle size and shape analysis 
Particle size and elongation factor of samples were determined using an optical microscope 
(Reichert Biovar, Wien, Austria) (magnification 1000x). Small amounts of each sample 
were uniformly dispersed on top of a microscopy glass slide. For each powder batch, 10 
microscopy glass slides were prepared, examining at least 1,800 particles per sample. 
Pictures were examined with the image analysis program ImageJ and the size of each 
sample was determined as Feret’s diameter while the shape factor was expressed as 
roundness [261]. 
           
      
             
        Eq. 4-43 
4.9.3.3. Powder x ray analysis 
The powder X-ray patterns were obtained as reported in section 4.8.4.6. Structural 
assignments were performed using Jana2006 software [283] and comparing the literature 
data [284].  
A profile fitting based on Marquardt non-linear least squares algorithm [101] was 
subsequently applied to selected ranges of the data, allowing the elimination of background 
contributions and the separation of overlapping diffraction maxima. The values of 
diffracted intensity and of full width at half maximum (FWHM) for each peak, were taken 
from the fitted profiles to estimate the average crystallite size by means of Scherrer’s 
equation [285]: 
   
  
     
          Eq. 4-44 
Where D is the mean crystallite dimension, K is the shape factor with a typical value of 
0.9, λ (CuKα 1.5418 Å) is the X-ray wavelength,   is the line broadening value at the 
FWHM in radians and  is the Bragg angle. Quercetin crystallite size was calculated from 
the single reflections.  
4.9.3.4. FTIR–ATR absorption measurements 
A FTIR mid-infrared spectrometer instrument (Buker VERTEX 80/80 v, Ettlingen, 
Germany) was used to obtain spectra which comprised a KBr Beamsplitter, a diffuse 
reflectance absorbance scanning accessory equipped with a mercury-cadmium telluride 
(MCT) detector and a sampling compartment fitted with a horizontal attenuated total 
reflectance (HATR) sampling. An average of 30 scans for each sample were collected at 4 
cm
-1
 resolution in the range 4500-600 cm
-1
. 
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4.9.3.5. Determination of drug solubility in gastrointestinal fluids 
The drug solubility was measured at 310 K in simulated gastrointestinal fluids at pH 1.2 
and 7.4 and assayed by spectrophotometer at 253 nm and 265 nm respectively as reported 
in section 4.8.4.8.  
4.9.3.6. Determination of drug dissolution 
The drug dissolution performance was carried out in the simulated gastrointestinal fluids as 
reported in section 4.8.4.9. 
4.9.4. Results and discussion 
In this study were investigated the precipitation conditions using the visual cell depicted in 
Figure 4.44. With this equipment is possible to see what happen inside the chamber, 
controlling, at a certain temperature, the required pressure to precipitate the Quercetin 
solutions. The cell was fall with 5 mL of Quercetin saturated solution. During the 
precipitation experiments at 313 K was seen the first particle formation at pressure close to 
95 bar for ethanol, and acetone solutions while at 100 bar for that in DMSO. At 323 K the 
precipitation was observed at pressure close to 115 bar for ethanol and acetone solutions 
while no difference was observed for DMSO. For brevity in Figure 4.45 are reported the 
precipitation of Quercetin in ethanol and DMSO solutions at 313 K.  
 
Figure 4.45: visual cell pictures at temperature T close to 313 K of Quercetin in ethanol at: a) 1 bar, b) 94.3 
bar, c) 97 bar; and Quercetin in DMSO at: d) 1 bar, e) 102.1 bar, f) 173.5. the white line correspond to 5 mL.  
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With the Peng-Robinson Equation of State it was possible to predict the precipitation 
behaviors as reported for Vitamin B6 and Piroxicam.  
Table A: 0.1 showed the pure component properties of solvents and drug. In Table A: 0.2 
are listened the references of equilibrium data of binary systems CO2-organic solvents used 
in the determination of the reported binary interaction parameters. 
 System  T (K) 10
2
kij 10
2 
lij 
Quercetin     
 CO2 373 27.44  
 DMSO 299 -0.004  
  303 0.21  
  308 0.24  
  313 0.3  
 Acetone 299 12.35  
  303 11.97  
  308 11.17  
  313 10.67  
 EtOH 299 6.94  
  303 7.27  
  308 7.22  
  313 7.46  
Table 4.37: binary interaction parameters calculated by PR Eos 
In Figure 4.46 are depicted the precipitation simulation of considered Quercetin ternary 
system that are in accordance with the experimental data. For brevity in Figure 4.46 is 
reported the behaviour of the simulated precipitation of Quercetin in the ternary system 
with Ethanol at 313 K and at the equilibrium pressure. The precipitation occurred at about 
80 bar showing a strictly correlation to the experimental data.  
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Figure 4.46: precipitation prevision of Quercetin in the ternary system with Ethanol at 313 K and at the 
equilibrium pressure. 
At the light of the above data, the following precipitation were conducted at 100 bar and 
313 K in dynamic way, to allow the elimination of the organic solvent and the recovery of 
dry particles.  
Due to the high density of DMSO, and to the long lead times needed to precipitate the 
drug, subsequent precipitations were carried out in ethanol. Moreover, Quercetin is more 
soluble in Ethanol than in Acetone, and higher yelds were obtained in the experimental 
precipitation. For this reason, the precipitation obtained with Ethanol at 100 bar and 313 K 
QUER EtOH 100 bar 313 K was selected as a lead. 
The CO2-precipitation of QUER from ethanol gave a very fluffy and voluminous powder.  
Figure 4.47, shows the precipitated Quercetin particles highlighting a reduction of their 
size in comparison with the Raw one.  
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Figure 4.47: up microphotographs of: a) Raw Quercetin and b) Quercetin precipitated at 100 bar and 313 K 
with EtOH (magnification 1000x); down particle size distribution. 
Among the particle aspects were investigated the powder diffraction patterns of QUER 
EtOH 100 bar at 313 K in comparison with the Raw one (Figure 4.48) in order to 
understand the effect of SAS technique on the QUER solid state. 
b 
a b 
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Figure 4.48: Powder diffraction patterns of Raw Quercetin in comparison with the Treated one at 100 bar 
and 313 K precipitated with EtOH 
The X-ray analysis highlighted a different pattern for the treated QUER, that should be 
ascribed to the monohydrate form, as reported from the Rietveld analysis in Figure 4.49. 
This analysis was carried out having recourse to the single crystal literature data [284] 
reporting a GOF of 1.22 with a Rp= 14.49 and Rwp= 18.96. However, this issue will be 
the object for further studies. 
 
Figure 4.49: Rietveld analysis of QUER treated at 100 bar and 313 K with ethanol. 
The main results of the DRIFT analysis on the Raw QUER and the treated one report two 
slightly different spectra (Figure 4.40). FTIR of Raw Quercetin shows the typical spectra 
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of dihydrate form with a broad phenolic OH band centered around 3400 cm
-1
, 
characteristic –CO stretching at 1654 cm-1, aromatic bending and stretching around 1100 
and 1600 cm
-1
, –OH phenolic bending around 1200 and 1400 cm-1. QUER EtOH 100 bar 
at 313 K, instead, shows a shift of the phenolic OH band at about 3280 cm
-1
 and a slight 
moving to higher values for –CO stretching and aromatic bending peaks. Changes in –OH 
phenolic bending were also noticed. These shifts could be ascribed to the loss in water 
from the structure as reported in literature [286]. Nevertheless, also these aspects will be 
better investigated. 
 
Figure 4.50: DRIFT spectra of considered samples 
X-ray analysis was adopted also to estimate the crystallite size of the considered systems. 
By means of Sherrer’s equation it is possible to infer the strong reduction in crystallite size 
for QUER EtOH 100 bar at 313 K respect to the Raw QUER as reported in Table 4.38.  
Sample Crystallite size (nm) 
Raw QUER 40.9 ± 7.0 
QUER 100 bar 313 K 22.5 ± 1.5 
Table 4.38: Crystallite size of considered samples 
The influence of SAS technique on Quercetin solid state was also evaluated trough the 
dissolution behaviors in the simulated gastrointestinal fluids . It must point out that the 
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Quercetin solubility is pH dependence showing values of 6.9 ± 0.6 μg.mL-1 and 28 ± 1.15 
μg.mL-1 respectively at pH 1.2 and 7.4 at 310 K confirming the literature values [287].  
 
 
 
Figure 4.51: Dissolution performance of considered systems at a) pH 1.2 and b) pH 7.4 
The dissolution behaviors of QUER EtOH 100 bar at 313 K show a best dissolution profile 
in both pH medium respects to the Raw Quercetin. This issue highlights, even in this case, 
how the particle and the crystallite size reduction play an important role, favoring the 
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increase in surface area of the drug and carrying to an improvement of the dissolution 
kinetics. 
 
Supercritical fluids were also investigated for the formation of solid dispersions, with the 
aim to improve the dissolution rate of poor soluble drugs. For this purpose, was selected 
Furosemide as poor soluble drugs while Crospovidone was used as hydrophilic swellable 
carriers.  
4.10. Furosemide micronisation and solid dispersions 
with SAS technology 
In the present study we report upon the in vitro bioavailability improvement of Furosemide 
through particle size reduction as well as formation of solid dispersions (SDs) using the 
hydrophilic polymer Crospovidone. Supercritical carbon dioxide was used as the 
processing medium for these experiments. In order to successfully design a CO2 
antisolvent process, preliminary studies of Furosemide microparticles generation were 
conducted using Peng Robinson’s Equation of State. 
This approach can be useful also in the preparation of solid dispersions. The influence of 
SAS technology on the systems solid-state was compared with those obtained by 
traditional method (rotavapor = RV). 
In addition, the dissolution tests of the FUR in all the prepared systems were also 
discussed. Relying on these in vitro dissolution tests, the in vivo effect of FUR dissolution 
improvement was estimated according to an ad hoc developed mathematical model. All the 
systems obtained by SAS technology were compared with those obtained by traditional 
method. 
Furosemide (FUR) (pKa 3.6) is a diuretic, that explicates the action on the ascending loop 
of Henle in the kidney to allow the removal of unneeded water and salt from the body into 
the urine. It is an anthranilic acid derivative (5-(aminosulfonyl)-4-chloro-2-[(2- 
furanylmethyl)amino]benzoic acid), used in the treatment of congestive heart failure and 
edema. It is also used to treat high blood pressure (hypertension). FUR works by blocking 
the absorption of salt and fluid in the kidney tubules, causing a profound increase in urine 
output (diuresis). The diuretic effect of FUR can cause body water and electrolyte 
depletion. Therefore, careful medical supervision is necessary during treatment [288].  
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This drug is practically insoluble in water (solubility 0.006 mg mL
-1
) and it is known to 
exist in five forms of modifications (three polymorphs and two solvates) [289]. 
Crospovidone is a water-insoluble disintegrant and dissolution agent manufactured by a 
polymerization process that produces a mainly physically crosslinked popcorn polymer. It 
rapidly exhibits high capillary activity and pronounced hydration capacity, with little 
tendency to form gels. It can also be used as a solubility enhancer [289].  
4.10.1. Materials  
Furosemide and micronized Crospovidone (PVP CLM) were purchased from Farmalabor 
(Italy) and BASF (Germany), respectively. CO2 (purity 99.9%) and organic solvents 
(methanol, acetone and ethanol) were acquired from SIAD (Italy) and Baker (Germany), 
respectively. All other chemicals were reagent grade and used as received. 
4.10.2. Determination of drug CO2 solubility method 
The solubility of Furosemide was measured using an analytic high-pressure apparatus, 
schematically presented in Figure 4.52.  
 
Figure 4.52: solubility apparatus  
The solubility of Furosemide was measured using an analytic high-pressure apparatus, 
schematically presented in Fig. 1. The determination of Furosemide solubility was 
performed in a stainless steel column, with an internal volume of approximately 20 cm
3
, 
equipped with filters (0.22 µm) to avoid the loss of particles and puts into an oven, heated 
by means of a controller that maintained temperature within 313 ± 0.1 K. The column was 
initially filled with the drug. CO2 was introduced into the column using a pneumatic 
compressor until the desired pressure is attained. The pressure inside the column was 
measured with a pressure transducer (SETRA, model 204, (0 to 34.40 (0.04) MPa), 
calibrated between 0 and 20.6 MPa. The mixture of CO2 + Furosemide was left at 
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equilibrium for 1 h. After, at constant pressure and temperature, CO2 was continuously 
flowed through the column at 10 l
.
h
-1 
measured at ambient conditions (ELSTER AMCO, 
Germany). These samples were collected after the depressurization and expansion into a 
small glass trap. After the expansion the pressure was measured with a pressure transducer 
(SETRA, model 204, (0 to 0.17 (1.9 - 10-4) MPa).  
To ensure that all solute was recovered in the trap, methanol was injected through the 
sample loops and expansion lines. Finally, the lines were cleaned with fresh CO2 smoothly 
pressurized.  
The collected samples were diluted in methanol to a convenient volume. To determine the 
amount of drug, the resulting solutions were analysed by spectrophotometry. Temperature 
of 313 K and pressure of 100 and 200 bar were investigated to determine the Furosemide 
solubility in supercritical CO2. 
4.10.3. Supercritical precipitation method 
A schematic diagram of the dynamical equipment used in this study is reported in Figure 
4.53. 
 
Figure 4.53: supercritical antisolvent apparatus 
The precipitator (NWA, Lörrach, Germany, internal diameter and volume of 30 mm and 
100 cm
3
 respectively) was jacketed ensuring temperature to be kept within 313 ± 0.5 K. 
The sample solution, kept at the precipitator temperature was introduced into the 
precipitator. Liquid CO2 was fed from the top of the precipitator by a high pressure pump 
(NWA, PM-101, Germany). The outlet flow was then filtered (0.22 µm) to prevent 
precipitate losses and regulated by a heated metering valve (Whitey SS-21RS4). 
Temperature and pressure values in the precipitator were measured by a Delta OHM 
thermometer (HD 9214, ± 0.1 K) and a DRUCK pressure transducer (DPI 260, ± 0.1 bar). 
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The precipitator was filled with 10 mL of saturated Furosemide solution; then the CO2 
were pumped to the reactor at constant flow of 1 l
.
min
-1 
(standard conditions) and under 
stirring of 250 rpm (NWA, DC, Germany). The CO2 volume passed through the reactor 
was 200 l (standard conditions). The same procedure was adopted to prepare the drug 
polymer solid dispersions, where Crospovidone was added to Furosemide solution under 
stirring in 1:1 or 1:2 in drug / polymer weight ratio obtaining a suspension that was 
introduced in the precipitator. The pressure and temperature selected for the precipitation 
of Furosemide and Furosemide : Crospovidone 1:1 and 1:2 w/w were 100 and 200 bar at 
313 K (called FUR 100 bar, FUR 200 bar, FUR:PVP CLM 1:1 w/w 100 bar and FUR:PVP 
CLM 1:1 w/w 200 bar, respectively).  
4.10.4. Traditional evaporation method 
Organic solvent of Furosemide solution or Furosemide : Crospovidone suspensions in 1:1 
or 1:2 w/w drug : polymer ratios, was removed under reduced pressure in a rotary 
evaporator (Buchi R-114, Flawill, Switzerland) at 313 ± 1 K for 30 min. Before the 
characterization, samples were kept for 3 days in desiccators under vacuum at room 
temperature. The samples had been called FUR RV, FUR:PVP CLM 1:1 w/w RV and 
FUR:PVP CLM 1:2 w/w RV, respectively. 
4.10.5. Physicochemical characterizations 
4.10.5.1. Particle size and shape analysis 
Particle size and elongation factor characterizations of samples were determined using an 
optical microscope (Reichert Biovar, Wien, Austria) (magnification 1000 x) as reported in 
section4.9.3.2. 
4.10.5.2. Transmission Electron Microscopy (TEM) 
TEM images were taken on Philips EM 208 (Philips, Eindhoven, the Netherlands) using an 
accelerating voltage of 100 kV.  
The samples fixed in epoxy resin were firstly treated in osmium tetraoxide for staining 
proposes to prevent the interaction of both drug and polymer with resin. Ultra-thin sections 
of those samples were cut (ultramicotome Leica Ultracut UCT equipped with diamond 
blade Drukker, Italy) for the analysis.  
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4.10.5.3. Powder X-ray diffraction studies (PXRD) 
The powder X-ray patterns were obtained as reported in section 4.8.4.6. Structural 
assignments were performed using Jana2006 software [283] and comparing the literature 
data [289]. Crystallite size were estimated as reported in section 4.9.3.3.  
.  
4.10.5.4. Raman spectroscopy analysis 
The Raman measurements were performed in a Renishaw microscope using an excitation 
wavelength of 532 nm, the power was set to 2.5 mW (0.05%). The line mapping was set to 
perform 1 measure each 100 nm. The mapping analysis was performed using Wire 3.3 
Renishaw software, applying the signal to baseline mode. The limits for the analysis were 
obtained from the Raman spectra of Furosemide and PVP CLM, from 1540 to 1610 cm
-1
 
and from 1400 to 1480 cm
-1
 respectively. 
4.10.5.5. Determination of drug solubility in simulated gastric fluids 
Solubility of commercial FUR and the treated ones with and without Crospovidone was 
measured in 10 mL of simulated gastric fluids at pH 1.2 as reported in section 4.8.4.8. and 
assayed by spectrophotometer at 274 nm. 
4.10.5.6. Determination of drug dissolution 
Profiles of Furosemide and Furosemide binary systems release were obtained according to 
the USP 33 paddle method in simulated gastric fluids at pH 1.2, as reported in section 
4.8.4.9 and assayed by spectrophotometer at 274 nm. 
4.10.6. Mathematical modeling 
In order to predict the in vivo behavior of our systems, furosemide pharmacokinetics 
constants were estimated making recourse to GastroPlus 
TM
 version 6.0.0010 (Simulation 
Plus Inc., Lancaster, CA). Briefly, GastroPlus
TM 
was asked to simulate the time course of 
Furosemide blood concentration (Cb) following the oral administration of a Furosemide 
solution (dose M0 = 100 mg) to a 82 Kg weighing volunteer. These data were fitted 
according to the following one compartment model: 
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                     Eq. 4-45 
     
   √     
 
         Eq. 4-46 
    (
  
  
  )            Eq. 4-47 
    
  
  
            Eq. 4-48 
where ka and ke are, respectively, the absorption and the elimination constants, Vb and Vr 
are, respectively, the distribution and gastro-intestinal (GI) fluids volume, t is time while 
Cr0 is the ratio between M0 and Vr. Assuming Vr = 300 cm
3
 [290] Eq. 4-45 best fitting to 
GastroPlus 
TM
 simulation proved to be statistically satisfactory (F(2,99, 0.95) < 3407) and 
led to ka = (4.7 ± 0.1)*10
-3
 h
-1
, ke = (4.0 ± 0.4)*10
-1
 h
-1
 and Vb = (40742 ± 3400) cm
3
. 
Interestingly, a two compartments model resulted to be statistically unnecessary. 
Based on the Furosemide pharmacokinetics constants knowledge, it was possible 
simulating the Cb time course in the case of our systems. Indeed, assuming that drug 
release kinetics in the GI fluids can be replaced by the in vitro release kinetics (R(t)) and 
that R(t) can be described by the following powerful equation: 
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
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  
       
 Eq. 4-49’ 
where Mt is the drug amount released (both in vitro and in vivo) up to time t while M∞ is 
the drug amount released (both in vitro and in vivo) after an infinite time (in our 
experimental conditions it coincides with M0), Cb time dependence is given by the 
analytical solution of the following system of differential equations: 
   br
r
b
ar0
r
d
d
CC
V
V
kCtR
t
C
        Eq. 4-50 
  belbra
b
d
d
CkCCk
t
C
         Eq. 4-51 
Eq. 4-50 accounts for the drug release process in the GI tract (first right hand term) and for 
the absorption through GI membrane (second right hand term) while Eq. 4-51 accounts for 
the drug transfer (first right hand term) and metabolism/elimination (second right hand 
term) in the distribution volume. Assuming that, initially, Cr = Cb = 0, Cb analytical 
solution reads: 
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   Eq. 4-52 
It is easy to see that when         , Eq. 4-52 coincides with Eq. 4-45 (instantaneous 
drug release: administration of a drug solution). 
4.10.7. Results and discussions 
Preliminary studies in order to predict the better operative conditions to precipitate 
Furosemide were conducted by means of Peng Robinson’s Equation of State (PR-EoS) as 
reported for Vitamin B6.  
Table A: 0.1 showed the pure component property of Furosemide and investigated 
solvents.  
The mole fraction solubility of Furosemide in supercritical CO2 at 313K and at the pressure 
of 100 and 200 bar was 1
.
10
-6
.  
Vapor liquid equilibrium data taken from literature for carbon dioxide – organic solvents 
were correlated. Solubility of Furosemide in the different organic solvents (data obtained 
through the method described in section 4.6.2.1) was reported in Table 4.39.  
Solvent Solubility 10
3 
x 
Acetone 9.31 
Methanol 2.48 
Ethanol 2.39 
Table 4.39: experimental mole fraction solubility of Furosemide x in the considered organic solvent  
These data were fitted by the Peng Robinson EOS in order to obtain the kij and lij values 
listen in Table 4.40 (Furosemide binary systems) and Table A: 0.2 (CO2 binary sysatems).  
System T (K) kij (x 10
2
) lij (x 10
2
) 
Furosemide     
 CO2 313  -5.34 0 
 Acetone 298 -12.72 0 
 Methanol 298 -5.31 0 
 Ethanol 298 -5.12 0 
Table 4.40: pressure independent binary interaction parameters 
Also in this case the binary interaction parameters were used to predict the behaviour of 
the different binary and ternary systems at 313 K. Solubility of the drug in the organic 
solvents-CO2 mixtures were calculated for different liquid phase concentrations at 313 K 
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and at the pressure of 100 and 200 bar [260]. Figure 4.54 and Figure 4.55 show the results 
obtained with the investigated organic solvents.  
In the case of “CO2 – methanol” and “CO2-ethanol” solvent mixture (Figure 4.54a and b) 
seem to be evident the mix action of CO2 that entails both cosolvent and antisolvent 
behaviours showing only the 30% of precipitate. 
 
Figure 4.54: Estimation of Furosemide solubility in different systems: a) methanol-CO2 and b) ethanol CO2. 
Solid lines depict ideal dilution evolution. 
For Furosemide in CO2 –acetone, the CO2 behaves as antisolvent in all the
2CO
X  range as 
depicted in Figure 4.55. 
a 
b 
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Figure 4.55: Estimation of Furosemide solubility in the acetone-CO2 system. Solid lines depict ideal dilution 
evolution. 
At the light of these simulations, acetone was selected as optimal organic solvent because 
it carried a precipitation in the entire CO2 ratio suggesting the highest yield of the assay. 
The above simulations were confirmed weighting the precipitates. In consequence of this 
simulation, the above operative conditions were used also for the solid dispersion 
formulations. Moreover, acetone is able to swell Crospovidone of 70 % (Crospovidone 
stirred in acetone at 298 K for 15 min) as reported in Figure 4.56 confirming also the 
literature data [291]. 
 
Figure 4.56: Particle size distribution of Crospovidone swelling in acetone  
Powder X-ray analysis of treated and untreated Furosemide reveal the presence of two 
different crystalline forms of drug (Figure 4.57). By means of Retvield analysis, our 
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samples were compared with the crystal structures reported in literature [289]. Raw 
Furosemide, Furosemide precipitated at 100 bar and in rotavapor in presence of acetone 
show the same diffractogram pattern attesting their triclinic crystal system (GOF 0.99, Rp 
11.01 %, Rwp 16.89 %) Instead, pattern of the drug precipitated at 200 bar revealed the 
monoclinic crystal system (GOF 1.14 Rp 10.88 % Rwp 15.35 %) even if the reflection at 
about 5 of 2 θ attests the concomitant presence of small percentage of triclinic form (about 
20% estimated by Powder Cell 2.4 [292]). 
 
Figure 4.57: Powder X- ray diffractogram of treated Furosemide in comparison with the Raw Furosemide 
Furthermore, the above results were confirmed by DRIFT and Raman analysis (Figure 
4.58a and b) that are in agreement with the literature spectra [289]. In fact, raw 
Furosemide, Furosemide precipitated with CO2 at 100 bar and in RV show the typical 
DRIFT peaks of Furosemide triclinic system with the asymmetric sulfonamide NH stretch, 
secondary amine NH and symmetric sulfonamide NH at 3400, 3351 and 3285 cm
-1
, 
respectively; while Furosemide treated at 200 bar reports the typical spectra of monoclinic 
system showing two diagnostic peaks at 3347 and 3253 cm
-1
 associated to the secondary 
ammine NH and symmetric sulfonamide NH, respectively. Raman analysis of raw 
Furosemide, Furosemide precipitated with CO2 at 100 bar and in RV show the aromatic 
vibrations of CH at 3159, 3125 and C=C at1602, 1586 and 1510 cm
-1
 while in Furosemide 
precipitated at 200 bar the aromatic vibrations of CH appears at 3161, 3129, 3076 and 
aromatic vibrations of C=C are at 1638, 1602, 1586 and 1504. 
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Figure 4.58: a) DRIFT spectra and b) Raman spectra of treated Furosemide in comparison with the Raw 
Furosemide 
The effects of pressure and solvent on the Furosemide’s solid state were investigated also 
for the drug polymer binary systems in both ratios of 1:1 and 1:2 w/w obtained by SAS and 
compared with those precipitated with traditional method. From Powder X-ray diffraction 
(Figure 4.59) a slightly decrease of crystallinity was observed for 
Furosemide:Crospovidone 1:1 w/w precipitated by SAS at 100 bar in comparison with the 
one obtained by traditional method, that instead refers the same crystallite size of raw 
Furosemide. A reduction of drug crystallites dimensions appeared also for SAS samples at 
200 bar and in 1:2 w/w ratio precipitated with traditional method. Amorphisation of 
a 
b 
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Furosemide was observed only for Furosemide:Crospovidone 1:2 w/w treated by SAS at 
100 bar. For this reason, a precipitation at 200 bar was not needed.  
 
Figure 4.59: Powder X- Ray diffractogram of investigated binary systems 
With the Sherrer equation, the crystallites sizes of all the above discussed samples were 
reported in Figure 4.60. 
 
Figure 4.60: Crystallite size behaviors of investigated systems  
The presence of amorphous drug in Furosemide : Crospovidone 1:2 w/w precipitated by 
SAS at 100 bar (Figure 4.61a) was also investigated with TEM analysis and compared with 
Furosemide : Crospovidone 1:2 w/w obtained by traditional method (Figure 4.61b). The 
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samples were embedded in an epoxy resin and cut in ultra-thin slices. From Figure 4.61a it 
seems possible to appreciate the absence of drug crystals inside the polymer network, 
while in Figure 4.61b the crystalline drug is still present on the polymer surface. 
 
Figure 4.61: TEM images of: a) FUR:PVP CLM 1:2 w/w precipitated by SAS method at 100 bar, b) 
FUR:PVP CLM 1:2 w/w obtained by traditional method highlighting a drug crystal. 
To investigate the possibility of drug polymer interaction, DRIFT analysis (Figure 4.62a) 
were performed for all the binary systems. No interaction were observed for 1:1 w/w drug 
polymer preparations, while for 1:2 w/w ratios the Crospovidone masked the significant 
Furosemide peaks and for this reason Raman analysis was performed (Figure 4.62b). For 
brevity only the Raman spectra of Furosemide:Crospovidone 1:2 w/w precipitated both by 
SAS at 100 bar and by traditional method are reported. 
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Figure 4.62:a) DRIFT spectra of investigated binary systems, b) Raman spectra of FUR:PVP CLM 1:2 w/w 
binary systems 
In order to know the disposition for the drug in the polymer, Raman mapping were 
achieved for the above two systems. Looking for characteristic peaks of Furosemide or 
Crospovidone, that are shown in Figure 4.62 the peaks located from 1550 to 1650 cm
-1
 and 
from 1400 to 1500 cm
-1
 are selected for drug and polymer respectively.  
The slices analyzed by TEM were undergone to Raman spectroscopy (Figure 4.63). A 
broad shoulder can be observed from 1000 to 1750 cm
-1
, this shoulder is due to the 
embedding resin, also the peaks from the samples are strongly attenuated because the low 
laser power (1.5 mW) preventing damages to the sample. The mapping profiles confirm 
the TEM data, i.e. in the sample FUR:PVP CLM 1:2 w/w RV (Figure 4.63d) the drug is 
present mainly in the surface of the particle. In the same context, the Raman profile of the 
sample FUR:PVP CLM 1:2 w/w 100 bar (Figure 4.63b) shows that the drug is present 
inside the particle.  
b 
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Figure 4.63: Raman mapping of FUR:PVP CLM 1:2 w/w binary systems 
The particles size expressed like Feret’s diameter and shape factor of raw Furosemide and 
those precipitated at 100, 200 bar and with RV method were measured (Figure 4.64). 
Considerable difference were observed for Furosemide precipitated at 200 bar that showed 
an average diameter of about 3 µm while the others did not refer substantial changes and 
showed a middling diameter of about 6 µm. 
 
Figure 4.64:Particle size distribution of treated Furosemide in comparison with the raw one 
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A decrease in particle size was also detected in all the solid dispersions prepared by SAS 
technology if compared to the ones obtained through the traditional method. Furthermore, 
Furosemide:Crospovidone 1:2 w/w precipitated by SAS at 100 bar shows the narrower 
particles distribution (Figure 4.65). 
 
Figure 4.65: Particle size distribution of investigated binary systems 
Even though previous physicochemical characterizations confirmed the almost complete 
transformation into two different crystal forms and a reduction of crystallite and particle 
sized were attested, the aim of this study is also to test the solubility and dissolution 
performances of the CO2-treated samples compared to the RV-samples. 
The solubility of Furosemide at pH 1.2, according to the USP solubility definition, is 
vanishing. No appreciable variation in the solubility behaviours were observed between the 
two polymorphic forms (Figure 4.66).  
An increase in solubility was either observed for all the binary mixtures and in particular 
for Furosemide:Crospovidone 1:2 w/w precipitated by SAS 100 bar that showed the best 
solubility enhancement for the amorphisation of drug. 
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Figure 4.66: Solubility behaviors of investigated systems in comparison with Raw Furosemide 
The dissolution profiles are reported in Figure 4.67.  
 
Figure 4.67: in vitro Dissolution performance of investigated systems in comparison with Raw Furosemide 
at pH 1.2 
A remarkable increase of Furosemide dissolution rate was observed when it was processed 
with supercritical CO2 at the pressure of 200 bar in comparison to the raw and precipitated 
ones by SAS at 100 bar and with the traditional method, which those instead, do not show 
considerable differences. It is plausible that the crystallite and particle size reduction and 
the observed polymorphic form observed after Furosemide micronisation process at 200 
bar might induce an increase of the surface area and therefore a dissolution rate 
enhancement.  
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The same phenomenon occurs for all the binary systems processed by SAS and RV except 
for the FUR:PVP CLM 1:1 w/w RV that along the disintegrant PVP CLM effect, they 
show a diminution in crystallite and particle size as compared to raw Furosemide. These 
issues play an important role for the increase of the surface area of the samples in contact 
with the dissolution medium. Clearly, the amorphous drug dispersion achieved in 
FUR:PVP CLM 1:2 w/w at 100 bar refers the best dissolution performance. It must be 
point out that the amount of monoclinic form presents also in FUR:PVP CLM 1:1 w/w at 
200 bar together with the particle size reduction show a similar dissolution profile of 
FUR:PVP CLM 1:2 w/w RV attesting even in this case the benefit of the SAS process in 
addition to the crystal form. No differences, on the contrary, were observed between 
commercial Furosemide and RV system in 1:1 w/w ratio that, besides the highest particle 
size of all the systems, share the same crystallite size shown by raw Furosemide.  
After 6 months the binary system in 1:2 w/w ratio precipitated by SAS at 100 bar shows 
the stable amorphous form of Furosemide as shows in the powder x-ray analysis in Figure 
4.68. 
 
Figure 4.68: Powder X- Ray diffraction of FUR:PVP CLM 1:2 w/w precipitated by SAS method at 100 bar 
after 6 months in comparison with the fresh one 
Moreover, the monoclinic form of Furosemide treated at 200 bar in presence of acetone 
shows the same DRIFT spectra after 6 months as well (Figure 4.69).  
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Figure 4.69: DRIFT spectra of Furosemide processed at 200 bar in presence of acetone after 6 months in 
comparison with the fresh one. 
In order to simulate the in vivo performance of our systems, Eq. 4-49’ was fitted to the 
dissolution profiles referring to the raw Furosemide, FUR 200 bar, FUR:PVP CM 1:2 w/w 
RV and FUR:PVP CM 1:2 w/w 100 bar (Figure 4.70).  
 
Figure 4.70: Eq. 4-49’ best fitting (solid lines) to dissolution profiles (symbols) referring to the studied 
systems (Raw FUR, FUR 200 bar, FUR:PVP CLM 1:2 w/w RV, FUR: PVP CLM 1:2 w/w 100 bar) 
 S
u
p
er
cr
it
ic
al
 
fl
u
id
s 
ap
p
li
ca
ti
o
n
s:
 
F
u
ro
se
m
id
e 
m
ic
ro
n
is
at
io
n
 
an
d
 
so
li
d
 
d
is
p
er
si
o
n
s 
w
it
h
 
S
A
S
 
te
ch
n
o
lo
g
y
 
1
9
 3
 
Data fitting, always very well (see solid lines in Figure 4.70), led to the fitting parameters 
(Ai, ki) reported in Table 4.41. 
 Raw FUR FUR 200 bar FUR:PVP 
CLM 1:2 w/w 
RV 
FUR:PVP 
CLM 1:2 
w/w 100 bar 
AUC (g h/cm3) 5.80 6.16 6.16 6.16 
Cbmax (g/cm
3
) 0.99 1.10 1.09 1.11 
tmax(h) 2.73 2.29 2.21 2.06 
 
A1(-) 0.943 1.0 0.700 0.740 
A2(-) 0.057 0.0 0.300 0.260 
k1(h
-1
) 1.59 3.46 19.90 27.83 
k2(h
-1
) 10
-6
 0.0 1.81 3.88 
Table 4.41:Area under the curve (AUC), maximum drug concentration Cbmax, Cbmax appearance time tmax and 
Eq. 4-45 fitting parameters (Ai, ki) for the systems Raw FUR, FUR 200 bar, FUR:PVP CLM 1:2 w/w RV, 
FUR:PVP CLM 1:2 w/w 100 bar 
On the bases of the release and the pharmacokinetics constants previously determined, Eq. 
4-52 made possible depicting the theoretical in vivo behaviour of the studied release 
systems. Figure 4.71, reporting the Cb trend versus time t, shows the in vivo effect of the 
dissolution improvement competing to FUR 200 bar, FUR:PVP CM 1:2 w/w RV and 
FUR:PVP CM 1:2 w/w 100 bar systems over the reference system (raw Furosemide).  
 
Figure 4.71: Theoretical blood concentration (Cb) trend versus time (t) referring to different delivery systems 
(Raw FUR, FUR 200 bar, FUR:PVP CLM 1:2 w/w RV and FUR: PVP CLM 1:2 w/w 100 bar). Dose 100 
mg, weigh 82 Kg. 
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It is evident that while no big differences exist among the improved dissolution systems 
(FUR 200 bar, FUR:PVP CM 1:2 w/w RV and FUR:PVP CM 1:2 w/w 100 bar), the 
performance of the reference system (raw Furosemide) is the worst. Indeed, not only 
improved dissolution systems show a bigger AUC, but, also, their onset of action is 
improved (smaller tmax) and more incisive (increased Cbmax) (see Table 4.41). The most 
important difference existing among improved dissolution systems consists in the tmax 
value that decreases passing from FUR 200 bar to PVP CM 1:2 w/w RV to get the 
minimum for FUR:PVP CM 1:2 w/w 100 bar. This is reasonable as 
Furosemide:Coripovidone 1:2 w/w processed by SAS at 100 bar is the only system 
containing part of the drug in the amorphous state, the most “activated” condition for an 
organic drug [293]. 
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4.11. Conclusion of SCF research application 
A new semi empirical equation able to predict the solubility of pharmaceutical compounds 
in supercritical carbon dioxide has been proposed. This approach provides useful 
information about the activity coefficient model, requiring only a dependence on CO2 
concentration. Moreover, it affords an explanation for a common and useful observation in 
the literature, in which the logarithm of the mole fraction of the solute in the fluid phase 
has an approximately linear dependence on the density of the SCF phase.  
It was considered the Abraham’s solvation theory as a valid tool for the evaluation of the 
interactions and compatibility between the drug-polymer and CO2- polymer giving helpful 
information for the supercritical impregnation processes.  
SAS technique is often preferred to process the drug particles, but careful attention must be 
paid to the parameters that influence the particle formations such as: type of organic 
solvent, CO2/drug solution ratio, operative pressure and temperature. The organic solvent 
is normally selected on the basis of the drug solubility, but sometimes this is not the right 
choice. The ternary system behavior is the key point of the process, and for the same drug 
it can be very different when the solvent is changed. For this reason, a method for the 
preliminary screening between different organic solvents and operative conditions is very 
useful. 
In this work a predictive method for the evaluation of the ternary behavior on the basis of 
binary information is applied. The results obtained for different systems are encouraging 
since they highlight the essential features of the behavior of these systems. Peng–Robinson 
EoS was used to represent solute–solvent-antisolvent systems and it was able to predict 
ternary behaviors using binary interaction parameters. Furthermore, was demonstrated that 
the used EoS is a valid tool to calculate, with the showed screw dislocation equation, the 
solute crystal growth along two axes for two pharmaceutical compounds like Vitamin B6 
and Piroxicam. The supersaturation ratio was directly related to the mean particle size and 
it was used to define the mixing conditions in the precipitation chamber and the drug yield 
in the considered ternary systems. The mechanism of crystallization undergoes a transition 
across ternary systems solubility curves, and it is expressed through changes in the surface 
energy, size, morphology and agglomeration of the particles.  
The obtained particles were physicochemically characterized in order to understand the 
influence of the SAS technique on the drug solid state and for this purposes Piroxicam, 
Quercetin and Furosemide were selected as model compounds. In all these cases, the SAS 
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technique allowed the formation of the most bioavailable particles favoring their 
dissolution kinetics. 
Supercritical Antisolvent technology, upon the processing of the single material was used 
to prepare solid dispersions of Furosemide with the polymeric carrier Crospovidone in the 
1:1 and 1:2 w/w ratios in order to improve its dissolution and solubility performances.  
It was proved how the supercritical antisolvent technology could be a versatile and 
interesting approach to prepare both micronized drug particles and solid dispersions. 
Furthermore, the accuracy of the proposed equations revealed their capacity to estimate the 
proposed experimental data of solute-SCO2 solubility behaviours, drug-SCO2-organic 
solvent precipitation and related crystal growth, and the in vitro-vivo dissolution profiles. 
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Appendix  
Pure components properties 
 
Table A: 0.1: Pure components characteristics: a DSC experimental data (SD ± 0.5 K), b calculated with the 
procedure described in section 4.6.5 (Lydersen’s group contribution method), c calculated from volume of the 
crystal cell. d calculated with Girolami’s method [257].  
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Binary interaction parameters kij and lij  
System  Temperature 
(K) 
kij(x10
2
) lij(x10
2
) Ref. 
CO2      
 Acetone 298 2.05 1.42 [294] 
  313 2.14 2.93 [294] 
 DCM 313 6.31 -1.20 [295] 
 DMSO 314 -0.43 -10.45 [295] 
 Ethyl acetate 313 4.16 10.52 [296] 
 EtOH 298 6.45 3.17 [294] 
  313 8.62 -0.39 [294] 
 MeOH 298 7.33 2.92 [297] 
  313 7.78 1.59 [297] 
 THF 298 0.70 0.07 [298] 
  313 0.08 0.19 [298] 
Table A: 0.2: CO2-organic solvent binary interaction parameters 
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